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ABSTRACT 
The role that glutathione S- transferases (GST) play in the protection of 
tumour cells from cytotoxic insult was investigated. The possibility that GSTs 
may be involved in a stress- response was also explored. 
Derived drug- resistant tumour cell lines as well as showing various 
changes commonly associated with drug resistance, also show overexpression 
of certain GSTs. In the majority of drug resistant tumour cell models however, 
the ability of the drugs against which resistance is seen to act as GST substrates 
has not been demonstrated. For this reason, the known GST substrate, 1- 
chloro-2,4- dinitrobenzene (CDNB) was used to generate a tumour cell line 
resistant to this compound. The resultant CDNB resistant lung tumour cell line 
(CDNBr) exhibited marked overexpression of both alpha and pi class GST 
subunits. This cell line was also resistant to cumene hydroperoxide, a substrate 
for alpha class GST. However, no resistance to any of the anticancer drugs 
studied, was observed. The results demonstrate that the GSTs can protect cells 
against cytotoxic insult from certain alkylating agents and hydroperoxides and it 
is possible that the GSTs are involved in some sort of chemical stress response. 
However, in the CDNB resistant lung tumour cell line, GSTs do not appear to 
provide protection against a broad spectrum of anticancer drugs. 
The role of the human class pi enzyme in the resistance of human 
leukaemia cells to antitumour agents was also investigated. The results of this 
show that in certain instances, the pi class enzyme may be involved in resistance 
mechanisms to a number of drugs including chlorambucil. This work however, 
highlighted the multifactoral nature of drug resistance. 
In conclusion, although the GSTs certainly appear to have the capacity 
to protect cells from cytotoxic compounds, it is evident that they are not the 
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1.1.0 RESISTANCE TO ANTICANCER DRUGS 
One in five people dies from cancer. Death is a result of metastases in two 
thirds of these cases and progression of the local disease in the remaining one third 
(Harris & Hickson, 1988). The major obstacle in the effective treatment of these 
cancers is the resistance of tumour cells to antineoplastic drugs. Resistance can either 
be intrinsic, exemplified by tumours that are refractory to treatment, or is acquired 
during chemotherapy regimens, exemplified by tumours that initially respond to 
anticancer drug therapy but which relapse subsequently and become unresponsive to 
treatment. 
Antitumour agents have varied mechanisms of action and cancer cells develop 
several ways of circumventing the toxic effects of drugs, which results in drug 
resistance. In order to improve treatment strategies, several approaches are being taken, 
the most important of which is the elucidation of the processes underlying the drug 
resistance phenomenon. 
Resistance to anticancer drugs can fall into two catergories. Cancer cells may be 
resistant to or develop resistance to just one particular agent, as in the case of the 
antimetabolite anticancer drugs such as methotrexate, discussed below. Alternatively, 
cancer cells are resistant to or develop resistance to a range of structurally and 
functionally unrelated drugs. This is termed cross -resistance and different tumour 
types display a range of cross -resistance patterns. Multidrug resistance (MDR) 
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describes the phenomenon whereby cells display cross -resistance patterns to a group 
of anticancer drugs that derive from natural products. This type of resistance is 
commonly associated with one particular resistance mechanism involving a membrane 
glycoprotein termed P- glycoprotein. This is dicussed in more detail in section 1.1.4. 
Mechanisms of resistance to other anticancer drugs not derived from natural products 
are less well understood. 
In establishing, more comprehensively, the mechanisms of resistance to 
antineoplastic agents, several therapeutic applications are envisaged. For example, if 
the proteins that confer resistance are identified, drug regimens may be developed to 
inhibit the activity of such proteins, thereby possibly overcoming the resistance. Novel 
anticancer drugs may also be developed that are not in the spectrum of agents 
commonly associated with drug resistance. Before discussing the factors involved in 
the drug resistance phenomenon that are already under investigation, the drugs used in 
current chemotherapy and their sites and mode of action will be reviewed. 
1.1.1 Sites and mechanisms of action of the 
anticancer drugs 
The drugs used in modern day chemotherapy regimens are classified as 
follows (Farmer, 1985): 
1. Alkylating agents 
2. Antimetabolites 
3. Vmca alkaloids 
4. Antimitotic antibiotics 
5. Miscellaneous compounds 
For several of the anticancer drugs, the mode of action and the biochemical 
basis of their toxicity is unknown and may occur via several mechanisms. For this 
reason it may not be possible to assign certain drugs using the above classification. 
However, until further information is available, it is a convenient way of categorising 
the drugs. 
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(a) The Alkylating Agents 
Examples of the drugs in this group are the nitrogen mustards, aziridines, 
dimethylsulphonates, nitrosoureas and the epoxides. The drugs have been designated 
alkylating agents because they all contain at least one alkyl moiety that is able to bond 
covalently to other molecules (Hirono, 1961; Connors, 1966). A simple representation 
of this reaction is shown below: 
RCH2 -X + Y >RCH2 -Y +X 
Alkylating agents in cancer chemotherapy, form covalent bonds with a number 
of biologically active macromolecules rendering them inactive. These macromolecules 
include DNA, RNA, proteins, amino acids and cell membrane constituents. The 
consequences of the covalent binding of alkylating agents to these molecules are DNA 
modification including formation of cross -links, inactivation of essential metabolic 
enzymes and membrane damage . 
The nitrogen alkylating agents include nitrogen mustard, cyclophosphamide, 
melphalan and chlorambucil (Fig. 1.1). These compounds contain two potentially 
active alkyl groups. 
Cyclophosphamide undergoes enzymatic hydroxylation in the liver, resulting in 
the formation of 4- hydroxycyclophosphamide which can spontaneously convert to 
aldophosphamide. Non -enzymatic cleavage of this latter molecule produces acrolein 
and phosphoramide mustard. The phosphoramide mustard, the aldophosphamide and 
the 4- hydroxycyclophosphamide are all toxic, but it is thought to be the phosphoramide 
mustard which is responsible for the antineoplastic effect of cyclophosphamide 
(Freidman et al, 1979; Sladek 1987). 
The nitrosourea alkylating agents are used widely in clinical practise. The 
three most important members of this group are BCNU, CCNU and methyl -CCNU. 
The alkylating activity of these drugs is thought to be their major cytotoxic action. In 
addition, their metabolites are able to inhibit the enzyme DNA polymerase and prevent 
the repair of DNA strand breaks and RNA synthesis (Gombar et al, 1981; Kohn 1977; 
Tewetal, 1981). 
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Figure 1.1 Examples of anticancer drugs in the group of 
compounds classed as alkylating agents. 
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(b) The Antimetabolites 
Before cells divide, nucleic acids, proteins and other cellular macromolecules 
are synthesised. Before this can occur, the precursor metabolites of the cellular 
constituents must also be synthesised. The antimetabolic neoplastic agents are very 
similar in structure to various precursor metabolites in nucleic acid biosynthesis 
pathways and are either incorporated into new nuclear material or combine with 
enzymes involved in precursor metabolism in an irreversible fashion, thus inhibiting 
their biological activity. As a result, either the new nuclear material will be unable to 
direct protein synthesis or enzyme inhibition will halt new nucleic acid biosynthesis. 
This breakdown in synthesis or functional integrity of these essential molecules will 
prevent further cell division. 
The drug methotrexate is a folic acid antagonist. Tetrahydrofolates, which are 
essential cofactors in the synthesis of both purine and pyrimidine bases are formed by 
the enzymatic reduction of folic acid. It is the enzyme dihydrofolate reductase which 
converts folic acid to tetrahydrofolic acid which then goes on to form a number of 
tetrahydrofolates. Methotrexate has an affinity for dihydrofolate reductase and binds to 
it irreversibly thus blocking purine and pyrimidine synthesis (Farmer , 1985 ). 
The antimetabolite 5- fluorouracil (Fig. 1.2) inhibits the enzyme thymidilate 
synthetase which catalyses the conversion of deoxyuridilic acid to thymidilic acid. This 
is an essential step in pyrimidine synthesis, and consequently, 5- fluorouracil prevents 
the formation of thymine and cytosine thereby arresting production of new DNA. This 
drug also affects RNA synthesis. Normal RNA contains the base uracil in place of 
thymine and as 5- fluorouracil is similar in structure to uracil, it becomes incorporated 
into RNA and halts protein transcription. It is not clear which of the two mechanisms 
detailed above is most important in the cytotoxic effect of this drug (Farmer ,1985). 
Another drug which is classed as an antimetabolite is cytosine arabinoside (Fig. 
1.2). This compound is an analogue of deoxycytidine and has a number of effects on 
DNA formation. It is known to inactivate DNA polymerase, thereby inhibiting both 
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Figure 1.2 Examples of anticancer drugs in the group of 
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DNA formation and repair, and is also directly incorporated into the DNA due to its 
structural similarity to deoxycytidine. This latter event has the effect of destabilising the 
DNA chain, making it more susceptible to degradation (Farmer 1985 ). 
(c) The vinca alkaloids. 
The vinca alkaloids are derived from the periwinkle plant, Vinca rosea . The 
three major drugs in this group are vincristine, vinblastine (Fig 1.2) and vindesine. All 
have a similar mechanism of action in that they bind to tubulin, the intracellular protein 
that polymerises to form microtubules. This causes mitosis to halt at the metaphase 
stage. Although this is probably the major cytotoxic effect,these drugs have also been 
shown to have a number of other properties including inhibition of thymidine 
incorporation into DNA and uracil incorporation into RNA. The drugs in this group are 
those found in the spectrum of compounds associated with the multidrug resistant 
phenotype (Johnson et al, 1963). 
(d) The Antimitotic Antibiotics 
These drugs include the anthracycline antibiotics, daunorubicin, doxorubicin 
(Fig 1.3) and epirubicin. These compounds are pigmented antibiotics produced by 
different strains of streptomyces. At least four potentially cytotoxic effects of these 
agents have been identified. 
Firstly, the molecular structures of these drugs are such that they can insert 
themselves between opposing DNA strands; this intercalation disturbs the various 
DNA functions. Secondly, it has also been shown that these drugs can bind to various 
membrane components leading to alterations in membrane fluidity and changes in the 
permeability to various ions. Thirdly, it is known that these agents produce free 
radicals due to redox cycling of the quinone moiety of their structure. These free 
radicals are highly reactive and modify DNA as well as other macromolecules. 
Fourthly, certain metabolites of the anthracycline antibiotics can also act as alkylating 
agents (Farmer , 1985 ). The relative importance of these different mechanisms to 
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Figure 1.3 Examples of anticancer drugs in the group of 
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the antitumour activity of the drugs is still unclear. 
Other non -anthracycline antibiotics are exemplified by drugs such as 
actinomycin D and mitomycin C (Fig 1.3). The former of these compounds is produced 
by the soil microorganism actinomyces. This drug is thought to intercalate with DNA 
and bind to guanine resulting in cessation of DNA, RNA and ultimately protein 
biosynthesis. 
The mechanism of action of mitomycin C is unclear. It is possible that it acts as 
an alkylating agent and forms cross -links with DNA. Alternatively, the drug generates 
free radicals. The net results are alkylation, DNA strand breakage and inhibition of 
DNA and RNA synthesis. 
(e) Miscellaneous Compounds 
The anticancer agents that are placed in this catergory include non -classical 
alkylating agents such as cisplatin and carboplatin. These two compounds carry a pair 
of chloride atoms which react in particular with the nitrogen atom at the N -7 position of 
guanine, in the DNA chain. The two chloride atoms are able to react with different 
guanines in the helical DNA molecule thereby forming both inter- and intra- strand 
linkages. 
Also included in this group of miscellaneous compounds are the 
anthracenedione drugs such as mitoxantrone, which cannot be described as alkylating 
agents, antimetabolites, vinca alkaloids or antimitotic antibiotics. They are derived 
from various chemical dyes and are chemically similar to doxorubicin. The mechanism 
of action of these compounds remains to be elucidated but mitoxantrone is known to 
intercalate with DNA causing strand breakage (Koeller & Eble, 1988). 
As demonstrated above, the sites and mechanisms of action of commonly used 
anticancer drugs are diverse and numerous. It would therefore perhaps be naive to 
think a single mechanism could account for resistance to all these compounds. Those 
mechanisms thought to be the most likely routes by which tumour cells acquire 
resistance or remain intrinsically resistant are discussed below. 
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1.1.2 Mechanisms of Resistance to the Antimetabolites 
The antimetabolites are not among those commonly associated with the 
multidrug resistant phenotype. As discussed earlier, the three main drugs in this group 
which are used clinically are methotrexate, which is predominantly used to treat chori- 
carcinoma, 5- fluorouracil, used mainly in the management of solid tumours, particular 
adenocarcinomas of the breast and gastrointestinal tract and cytosine arabinoside, which 
is used to treat leukaemia. The major problem with these drugs is the onset of 
resistance to the agent used. Cross -resistance to other anticancer drugs is not often 
seen. 
Resistance to methotrexate can arise by a variety of mechanisms. The enzyme 
dihydrofolate reductase, which is inhibited by methotrexate, can be overexpressed in 
tumour cells due to an amplification of the gene coding for this protein (Alt et al, 1978). 
Alternatively, resistance to methotrexate can occur due to mutations in the gene coding 
for dihydrofolate reductase (Simonsen & Levinson, 1983). It has also been suggested 
that mutations in the folate transport carrier, which is responsible for the uptake of 
methotrexate (Sirotnak, 1985) will also lead to resistance. Several of these mechanisms 
may be operational in a methotrexate resistant tumour population at any one time. 
Resistance to 5- fluorouracil may occur via a similar mechanism to that seen for 
methotrexate, in that mutations in the carrier system responsible for uptake of the drug 
(Wohlheuter et al, 1980) will result in resistance. Since 5- fluorouracil must first be 
activated in order to cause toxicity, loss of the enzyme activity responsible for the 
conversion of the drug to its active nucleotide, will also lead to resistance to the drug 
(Ardalan et al, 1980). Alterations in the structure of the target enzyme thymidilate 
synthetase may also confer resistance to 5- fluorouracil. 
1.1.3 Involvement of Topoisomerase II in Drug Resistance. 
DNA topoisomerases I and II are known to alter the topology of DNA during 
replication. DNA topoisomerase II is thought to act by knotting, unknotting, catenation 
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and decatenation of DNA and relaxation of supercoiled DNA (Gellert 1981; Wang 
1985). These topological rearrangements require one double strand of DNA to be 
passed through another double strand of DNA, which necessitates at some stage in the 
process, DNA strand breakage. The orientation of the DNA after this break has 
occurred is maintained by non -covalent bonds between the topoisomerase II enzyme 
and the DNA. 
The enzyme bridges strand breakages that have occurred in complementary 
strands of DNA. This intermediate in the topological rearrangement of the DNA is 
called the cleavable complex (Liu 1985; Ross 1985). Certain anticancer drugs are 
known to interact with topoisomerase II (e.g.vincristine and vinblastine) and freeze the 
topoisomerase II in covalent association with the DNA (i.e. augment the amount of 
cleavable complex formed).The exact mechanism of toxicity is unclear, but it is thought 
to be due to some property of the complex rather than loss of enzyme activity. 
The greater the level of expression of topoisomerase II, the more sensitive the 
cells are to drug- induced cytotoxicity. It is proposed that tumour cells may become 
resistant by failing to respond to the proposed toxic effects of the cleavable complex 
upon treatment with topoisomerase II -active drugs. The exact mechanism by which 
this occurs is unknown, but there are at least three possibilities : 
1. Insufficient enzyme so that cleavable complex 
formation is not possible. 
2. Presence of a mutant enzyme which is not 
stimulated by the drugs to form a fixed complex 
with the DNA. 
3. Regulation of cleavable complex formation. 
Whatever the mechanism, it is thought that resistance to this type of drug occurs 
due to reduced cleavable complex formation. In several cell lines resistant to 
topoisomerase II active drugs, there has been shown to be lower levels of cleavable 
complex and lower levels of topoisomerase II (Long et al, 1986; Bakic et al, 1986; 
Edwards et al, 1987). 
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1.1.4 P- glycoprotein 
The drugs usually associated with the multidrug resistant (MDR) phenotype are 
vinblastine, vincristine, etoposide (VP16), teniposide (VM -26), doxorubicin 
(adriamycin), daunorubicin, plicamycin (mithramycin) and actinomycin D. Although 
these drugs do not have common targets within tumour cells, they are all hydrophobic 
drugs derived from natural products (Safa et al, 1987). The alkylating agents and 
antimetabolites are not normally in the spectrum of drugs associated with MDR, 
although resistance to these drug classes also presents a considerable problem in cancer 
treatment. 
The development of in vitro cell lines established from in vivo tumours has 
aided the study of drug resistance. Many cell lines have now been described that 
exhibit the MDR phenotype. These have all been derived by sequential selection in an 
increasing concentration of a chosen anticancer drug and by definition display 
resistance to a range of other antineoplastic agents. Biedler & Riehm (1970) were the 
first workers to report that the MDR phenomenon encountered clinically, could be 
mimicked in vitro using cell culture models. 
In the 1970's Ling and co- workers derived a Chinese hamster ovary line 
resistant to colchicine (Juliano & Ling, 1976) and showed this cell line exhibited cross - 
resistance to a range of anticancer drugs. The resistant cell line was found to exhibit a 
decreased accumulation of drug. These workers showed that the decreased drug 
accumulation exhibited by the resistant cells was associated with the presence of a 
membrane glycoprotein of molecular weight 170,000 daltons, (Juliano & Ling, 1976; 
Bech- Hanson et al, 1976). This membrane glycoprotein has been termed P- 
glycoprotein and since its discovery much effort has been directed towards defining its 
role and contribution to the drug- resistant phenotype. Much of the available evidence 
shows a strong correlation between P- glycoprotein expression and the MDR 
phenotype. 
Several cDNA clones encoding P- glycoproteins have been isolated and 
sequenced from a variety of mammalian species (Chen et al, 1986; Gros et al, 1986.) 
Analysis of the DNA sequences of these clones has shown that the P- glycoprotein 
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genes can be divided into two classes on the basis of sequence homologies. These are 
MDR 1 and MDR 2. Of the two classes only the former can confer drug resistance. 
This has been demonstrated using gene transfection studies in which MDR 1 genes 
have been expressed in drug sensitive lines and resistance to the spectrum of drugs 
commonly associated with the MDR phenotype has been demonstrated (Gros et al, 
1986; Ueda et al, 1987; Croop et al, 1987; Pastan et al, 1988). 
How P- glycoprotein confers drug resistance to the wide spectrum of drugs 
commonly associated with drug resistance is not certain. The functional aspects of the 
protein that produce resistance will surely provide valuable insight to aid novel drug 
design. Much of the evidence now available suggests that P- glycoprotein functions as 
an energy dependent drug -efflux pump.This evidence is described below. 
Firstly, from gene sequence analysis it has been shown that P- glycoprotein 
shares homology with several bacterial transport proteins (Ueda et al, 1986). 
Haemolysin B, with which P- glycoprotein has been shown to share closest homology, 
is responsible for transporting alpha -haemolysin out of certain bacteria. However, 
homology with Mal K, which is part of the maltose transport system in Escherichia 
coli and His P which is part of the histidine permease system has also been noted 
(Gerlach et al, 1986),It has been suggested that this glycoprotein could possibly have 
arisen from tandem duplication of an ancestral gene, as it contains two regions 
homologous to the nucleotide binding domains on the energy transducing subunits of 
these bacterial transport proteins (Gottesman, 1988). Secondly, when MDR cell lines 
are grown in the presence of metabolic inhibitors such as 2- deoxyglucose and azide, 
which are known to deplete intracellular ATP, drug resistant cells can accumulate 
cytotoxic agents to levels approaching the parental sensitive line (Croop et al, 1988). 
When the inhibitors of ATP production are removed there is a rapid efflux of the 
cytotoxic agent out of the cell. 
Hammond and co- workers (Hammond et al, 1989) have more recently provided 
evidence showing that the MDR 1 gene product is responsible for the mechanisms 
controlling cellular drug levels in an ATP- dependent manner. In chinese hamster ovary 
(CHO) cells stably transfected with and overexpressing mouse MDR 1, a decrease in 
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[3H] vinblastine release was seen which was arrested when cellular ATP levels were 
reduced. 
Other workers using photoactivatable derivative of vinblastine has shown that 
P- glycoprotein is able to bind this drug (Cornwell et al, 1986). Although much of the 
data available suggest a strong correlation between P- glycoprotein and the MDR 
phenotype in vitro, there is information available which suggests that this is not the 
only mechanism involved in drug resistance. 
The binding constants of a variety of drugs with P- glycoprotein is estimated to 
be in the micromolar range (Cornwell et al, 1986), which is higher than the drug 
concentration range clinically achievable. This sort of information raises questions 
about the in vivo significance of P- glycoprotein as does the clinical data that has 
become available in recent years. 
Each in vitro model, although apparently showing overexpression of P- 
glycoprotein, displays a different pattern of cross -resistance (Moscow & Cowan, 
1988). Although several P- glycoprotein genes have been reported (Van der Bliek et al, 
1987; Gros et al, 1986) and there may be variation in expression of these genes, these 
two things taken together do not account for the diversity seen in cross -resistance 
patterns. Still more data that raises questions as to the importance of P- glycoproteins, 
is the fact that the degree of resistance in drug- resistant cell lines is not directly 
correlated with the intracellular drug accumulation (Louie et al, 1986; Sirotnak et al, 
1986). 
Mukhopadhyay & Kuo (1989), have looked at MDR 1 copy number and 
mRNA levels during the derivation of a vincristine resistant CHO cell line. They 
found high levels of MDR 1 in cells showing low levels of resistance when compared 
to the wild -type cell line. However, as resistance to vincristine increased, the P- 
glycoprotein levels did not, suggesting other mechanisms of resistance may be coming 
into operation in this model. 
Other in vitro models also support the presence of alternative resistance 
mechanisms. McGrath & Center, (1987) derived an adriamycin resistant human 
leukaemia cell line (HL6O) that exhibits the MDR phenotype but shows no detectable 
levels of P- glycoprotein. Proteins conferring resistance in this cell line may be different 
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from those previously described (Beck et al, 1987; Fergusson et al, 1988). Other cell 
lines displaying resistance to various anticancer drugs without expression of P- 
glycoprotein have also been reported (Danks et al, 1987). 
The in vivo patterns of resistance to anticancer drugs frequently differ from 
those observed in drug resistant tissue culture cell line models. Sometimes in addition 
to resistance towards the typical drugs that are associated with MDR, resistance 
towards alkylating agents and antimetabolites is also noted. Recent clinical evidence on 
MDR 1 expression in human tumour samples has yielded information suggesting great 
diversity of P- glycoprotein expression in different tumours (Bell et al, 1985; Gerlach et 
al, 1987; Ma et al, 1987). The picture generated by these workers about the role of P- 
glycoprotein in the patient, is far from clear -cut. 
Essentially, P- glycoprotein is expressed in some tumours refractory to 
chemotherapy but not in others which are equally refractory. There seems to be little 
correlation between P- glycoprotein expression in tumours analysed before or after 
treatment, this being so particularly in the case of certain lung tumours (Lai et al, 1989). 
Recently, in a large study, P- glycoprotein expression in over 400 tumour samples of 
diverse origin were analysed (Goldstein et al, 1989). This study indicated that there 
was a consistent association of MDR 1 expression in several intrinsically resistant 
cancers and also increased expression of the MDR 1 gene in certain cancers with 
acquired drug resistance. Absence of detectable P- glycoprotein in other intrinsically 
resistant tumours suggested the occurrence of other resistance mechanisms. 
1.2.0 THE GLUTATHIONE S- TRANSFERASES 
Although it is clear from the preceding section that resistance to anticancer drugs 
may be attributable to several known mechanisms, it is clear that other important 
mechanisms still remain to be fully elucidated. It has been proposed that the glutathione 
S- transferases may have the ability to detoxify alkylating anticancer drugs since they are 
known to catalyse the conjugation of xenobiotic electrophiles to glutathione. The GSTs 
may also bind non -covalently to drugs and carcinogens thus also inactivating them via 
this route (Hayes & Wolf, 1988). 
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The GSTs were initially discovered simultaneously by Combes & Stakelum 
(1961) and Booth et al (1961) who were studying, respectively, the metabolism of 
bromosulphophthalein and 1,2- dichloro -4- nitrobenzene in rat liver. These enzymes are 
multifunctional and because of their diverse activities they have enjoyed various names. 
Owing to their ability to bind non -substrate ligands such as bilirubin (Levi et al, 1969) 
GSTs have also been called `ligandins' (Litwack et al, 1971). 
GSTs have subsequently been shown to be ubiquitous in nature, being found in 
many organisms ranging from bacteria to man. In the three mammalian species studied 
in the greatest detail, man, rat and mouse, the complexity of this enzyme system has 
become evident. The different enzymes in these species have been shown to be 
encoded by multiple genes which are subject to complex regulation. 
All GSTs so far discovered can catalyse the formation of a thioether 
bondbetween reduced glutathione and a large number of reactive electrophiles. In 
addition to this function, certain enzymes also have peroxidase activity. One other 
cellular function that certain GSTs perform, is binding to non -substrate ligands which 
may aid excretion of certain compounds from the body. The large spectrum of 
electrophilic compounds, many of them potentially harmful, with which the GSTs can 
interact is achieved through the range of isoenzymes present in cells. Each particular 
isoenzyme has its own particular range of substrate specificities. 
The literature concerning the glutathione S- transferases (GSTs) is extensive and 
somewhat confusing. This confusion stems from the fact that the relationship between 
the multiple forms isolated from different species has not always been clearly defined. 
With the development of molecular biology and protein sequencing techniques, it has 
now become clear that the cytosolic GSTs from mouse, rat and man can be grouped 
into three classes or families, which have been named alpha, mu and pi (Mannervik, 
1985; Mannervik et al, 1985). In addition, a microsomal protein has also been 
identified (Morgenstern et al, 1980). 
This grouping is based on several parameters. Firstly, sequence data at both the 
DNA and protein level has revealed strong homology between isoenzymes within a 
class isolated from the three different species (Mannervik & Danielson, 1988). 
Secondly, studies using GST substrates have shown that these enzymes can be divided 
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into the three groups on the basis of their substrate specificities ( Jakoby, 1978; 
Chasseaud, 1979). This classification system also applies when various inhibitors of 
the enzymes are used (Mannervik & Danielson, 1988; Boyer, 1986 ; Boyer, 1989). 
Thirdly, using immunochemical techniques such as Western blotting (Hayes & Mantle, 
1986; Hayes et al, 1987 a ;b), antibodies raised against a purified protein isolated from 
one of the three groups can be shown to cross -react only with other proteins within the 
same group. 
The most extensively studied GST isoenzymes are those isolated from the rat 
and although this thesis will concentrate on human GSTs, it will be necessary to make 
frequent reference to the rat counterparts. All cytosolic GSTs so far isolated consist of 
homo or hetero dimeric combinations of various GST subunits. 
1.2.1 GST Isolation Procedures 
The development of affinity matrices has simplified the purification of the GSTs 
in rat, mouse and man. The two most commonly used affinity gels are S- 
hexylglutathione- Sepharose affinity matrices (Mannervik & Guthenberg, 1981) and 
glutathione -Sepharose matrices (Simons & Vander Jagt, 1977; Vander Jagt et al, 1985). 
The pools of GST activity isolated by the above methods can be resolved into the 
individual isoenzymes using other chromatographic techniques such as 
chromatofocusing, ion exchange and hydroxyapatite columns. Alternatively, subunits 
can be resolved by reverse phase high pressure liquid chromatography (Ostlund 
Farrants et al, 1987). 
The S- hexylglutathione -Sepharose affinity matrix has been the most commonly 
used technique. In rat, mouse and man there is an ordered elution of the subunits from 
chromatography columns. This may reflect the conservation of activities of the 
different subunits between the species and is likely to be mediated by the GSH- binding 
site in that different forms from the same class will show different affinities for the 
glutathione affinity matrix (Hayes, 1988). 
Using the techniques outlined above, multiple GST forms have been isolated 
(Reddy et al, 1983; Guthenberg et al, 1985; Stockman et al, 1985; McCusker and 
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Mantle, 1987; Warholm et al, 1986; Hayes & Mantle, 1986; Hayes, 1986; Hayes et al, 
1987 a;b.) and the methodologies are applicable to the GSTs from many species. 
However, it is becoming evident that in rat there are a significant number of GSTs 
which remain to be purified. This is also likely to be the case for other species (Hussey 
et al, 1990). Care should be taken in interpreting the results from different laboratories. 
Claims of new GST forms should stand up to rigorous scrutiny and it is highly 
desirable that molecular evidence for the existence of novel forms of GST should be 
presented. 
1.2.2 Classification 
Tables 1.1 to 1.3 show how the rat, mouse and human cytosolic GSTs have 
been assigned to the alpha, mu and pi classes. As already stated, this has been based 
on substrate specificities, immunological analysis and sequence data. The latter of 
these techniques have provided the most informative data about the molecular 
relationship between the GST forms. 
The primary structures from both protein sequence and DNA sequence data for 
different GSTs has been compared for the three species (Mannervik & Danielson, 
1988). There was shown to be close homology between enzymes within a class when 
the amino acid sequences were aligned. These data have lead to speculation that the 
,GSTs evolved into separate classes before the divergence of the mammalian species. 
1.2.3 GST Nomenclature 
(a) Rat cytosolic GST nomenclature 
Jakoby and co- workers (Habig et al, 1974a; Habig et al, 1976; Jakoby et al, 
1976) originally isolated six forms from rat liver, all with a neutral or basic isoelectric 
point. They were named alphabetically E, D, C, B, A and AA, on the basis of their 
elution order from a carboxy -methylcellulose ion -exchange matrix. Each enzyme was 
found to possess overlapping substrate specificity. 
Subsequently, Mannervik and his co- workers isolated six major GST forms 
from rat liver (Mannervik & Jensson, 1982) and showed these dimeric proteins to 
comprise homo- and hetero- dimeric combinations of four separate subunits, each 
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GSTs from rat liver have been isolated independently by other groups (Sheehan 
& Mantle, 1984; Hayes, 1986; Hayes et al, 1987 a;b; Hayes & Mantle, 1986) and these 
have been given nomencltures based on their mobility on SDS -PAGE (Bass et a1,1977) 
called Ya, Yb, Yc etc. A more recent system of nomenclature has been based on 
Arabic numerals. Table 1.2 shows the different subunits isolated to date and compares 
the Ya, Yb etc., nomenclature with the Arabic numeral system. 
(i) Rat Class Alpha 
To date five class alpha GSTs have been isolated from various rat tissue. These 
are: YaYa (1 -1), YcYc (2 -2), YaYc (1 -2) (Hayes et al , 1981; Hayes 1988), YkYk (8- 
8) (Hayes, 1986) and Y1Yc (10 -2) (Scott & Kirsch, 1987; Hayes 1988). The tissue 
distribution of these different forms may reflect the function of the specific tissue and 
the range of electrophilic compounds with which a particular tissue may come into 
contact. 
(ii) Rat Class Mu 
This class seems to contain the most isoenzyme forms and to date the following 
isoenzymes have been discovered in different rat tissues: Yb1Yb1 (3 -3), Yb2Yb2 (4 -4), 
Yb1Yb2 (3 -4), Yb1Yn1 (3 -6), Yb2Yn1 (4 -6), Yn 1Ynl (6 -6) Yn1Yn2 (6 -9), Yn2Yn2 (9- 
9) and YoYo (11 -11) (Hayes, 1988; Kispert et al, 1989). 
(iii). Rat Class Pi 
To date only one subunit in this group has been isolated and this was from rat 
placenta. This is subunit YfYf (7 -7) and is sometimes also referred to as YpYp 
(Kitahara et al, 1984). 
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1.2.3 (b) Mouse Cytosolic GST Nomenclature 
GSTs isolated from the mouse have also been named using Arabic numerals and 
classified using the same criteria for substrate specificity, amino acid sequence and 
immunological properties as GST from rat and man. 
The subunits isolated to date are not as extensive as for rat or man and are 
shown in Table 1.3. Although the subunit designations Ya, Yb and Yf have been used 
to describe the equivalent polypeptides in rat and mouse (McLellan & Hayes 1987) the 
numerical classification system used for mouse is independent of that used for rat. This 
may lead to confusion since mouse enzyme 3 -3 is not equivalent to rat 3 -3 (Mannervik 
& Danielson, 1988). 
1.2.3 (c) Human Cytosolic GST Nomenclature 
The human GSTs on which the rest of this thesis will concentrate, have been 
shown to consist of a variety of forms that can be isolated from a range of human 
tissues. Again the literature concerning the human GSTs is diverse and the 
nomenclature somewhat confusing owing to the independent isolation of identical 
forms by different research groups and a subsequent independent naming system by 
individual groups. The system used today is shown in Table 1.1. 
(i). Human Class Alpha 
Kamisaka et al, (1975), isolated five GST forms of basic pH from human liver 
cytosol, originally termed a, ß, y, S, e in order of increasing isoelectric points. It was 
subsequently difficult to correlate these enzyme forms with other basic forms isolated 
by other workers. As a result of the confusion as to their true identity, the forms 
isolated by Kamisaka and his colleagues have sometimes been referred to as the (a -e) 
(Mannervik & Danielson, 1988). 
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Later work has shown the human cytosolic GSTs from the class alpha family to 
comprise of two homodimers and a heterodimer formed by two different subunits B 1 
and B2 (Stockman et al, 1985; 1987; Hayes et al, 1990). It has been proposed that 
B 1B 1, B 1B2 and B 2B2 correspond to the GST e, S and y isolated by Kamisaka and co- 
workers (Stockman et al, 1985; 1987). 
Recently a GST isolated from human skin has also been assigned to this class 
(Del Boccio et al, 1987) and termed 9.9. It has not been reported in any other tissue to 
date. 
(ii). Human Class Mu 
The human enzymes in this group have pI values of about 4.5 -6.5 and were 
initially referred to as the neutral GST group. A more rational classification based on 
the aforementioned criteria, has shown there to be at least three subunits in this class 
these being subunits p., cp, and Nr (Stockman & Hayes 1987; Hayes 1989). Recently, 
data has been presented showing that at least three forms of class mu enzymes are 
present in human skeletal muscle (Hussey, et al, 1990). 
It is not known whether enzymes in this group all exist as homodimers or 
whether they can also form heterodimers. Heterodimers consisting of p. and yr subunits 
have been demonstrated in vitro (Hayes 1989). There is now one report in the literature 
of a . -i i heterodimer being present in human liver (Van Omenn et al, 1989). 
(iii). Human Class Pi 
To date, it appears that there is only one enzyme form that can be assigned to the 
class pi group (Guthenberg & Mannervik, 1979). This was originally isolated from 
placenta but has been observed in a variety of other tissues. Although another class pi 
GST form has never been isolated it is noteworthy that fatty acid ethyl ester synthetase 
from human myocardium has been reported to be highly homologous, but not identical 
to the placental pi GST (Bora et al, 1989). 
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1.2.4 Polymorphic Expression of Human Cytosolic 
GSTs 
There is marked polymorphic expression of the GST enzymes. The response 
of an individual's tissues to cytotoxic insult is likely to be determined by the drug 
detoxification capacity of that tissue. Since many of the reactions catalysed by the 
GSTs serve to detoxify reactive metabolic intermediates, it may be speculated that the 
lack of certain GST isoenzymes may predispose an individual to carcinogenesis since 
certain carcinogens may not be detoxified efficiently. 
The multiplicity of GST forms is indicative of a multigene family. To date, at 
least three loci have been defined that code for members of the three cytosolic classes 
(Board 1981; Strange et al, 1985). As yet it is not clear how many genes there are in 
each family but it is thought that the multiple isoenzymes arise to some extent from 
allelic variance. 
(a) GST 1 Locus 
GST 1 locus encodes members of the human class mu enzymes . This locus has 
so far been shown to consist of three common alleles. 
GST 1 type 1 and GST 1 type 2 both encode similar protein products, the 
former coding for the it subunit, the latter coding for the t subunit. GST 1 type 0 
encodes no protein product since it appears to have resulted from a gene deletion. One 
of the proteins encoded by the GST 1 locus has been shown to be polymorphic in man. 
40% of the human population fail to synthesise the .t homodimers (Seidegard et al, 
1986). Seidegard et al (1990) have shown this to be due to a deletion in the mu gene. 
Evidence has also been presented that individuals nulled for GST 11 are more 
susceptible to lung cancer if they smoke (Seidegard et al, 1986). 
It seems likely, in the light of recent data (Hussey et al, 1990), that multiple 
forms of the human mu -class GST family exist. The fact that human mu -class genes 
have mapped to both chromosomes 1 (De Jong ems, 1988) and 3 (Islam et al, 1989) is 
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in itself interesting and suggests the presence of more than one locus which could 
account for the multiplicity of class -mu proteins. 
(b) GST 2 Locus 
This locus codes for the class alpha proteins and has been shown so far to 
contain at least two closely linked genes referred to as GST 2 type 1 and GST 2 type 2. 
The former has been shown to code for GST B1B1 and the latter for B2B2. Recent 
work has compared fifty percent of the protein sequence of the human B1 and B2 
subunits (Hayes et al, 1990) with cDNAs for class alpha proteins, isolated from human 
liver. This work has shown that these two subunits are 96% homologous but show 
differences at amino acid residues 88, 110, 111, 112, 116, 124 and 127, indicating that 
they are indeed different gene products and that their expression is therefore unlikely to 
be coordinately regulated. The GST 2 locus has been shown to map to chromosome 6 
(Board & Webb, 1987). 
The expression of subunits from these genes has been shown to be variable in 
man (Hussey et al, 1986; Singh et al, 1987). The basis of the inter -individual 
differences in the expression of B1 and B2 has yet to be discovered. 
(c) GST 3 Locus 
So far the available data has shown that this locus encodes a single gene 
(Cowell et al, 1988; Morrow et al, 1989) which is expressed in most tissues so far 
analysed. This locus is found on chromosome 11 (Laisney et al, 1983). The 
polymorphic expression of the gene product is open to question. 
(d) Relationship of Gene Loci to Protein Products 
The relationship of the gene loci to the actual protein product is not obvious. 
Although GST loci 1,2 and 3 are now known to contain genes coding proteins in the 
mu, alpha and pi classes, there are still other gene loci whose genes and subsequent 
protein products are still difficult to classify. For example the GST -4 locus encodes a 
near neutral enzyme and has close homology with GST 1 (Board et al, 1988).The 
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GST -5 locus encodes a protein product found in brain which is also closely 
homologous to GST 1. 
The progress at the genetic level has been slower than that at the protein level. 
The genetic information available at present makes it impossible to say how many genes 
there are per family and what their actual protein products are. It is clear that more 
work is needed in this area to complement the work at the protein level with molecular 
data. 
1.2.5 Tissue Distribution of Human Cytosolic GSTs 
In man these enzymes have been most extensively studied in liver (Stockman et 
al, 1985; 1987; Boyer & Kenney 1985; Singh et al, 1985; Hussey et al, 1986; Soma tt 
al, 1986; Tu & Quian 1987; Singh et al, 1987; Board & Pierce 1987). Interest in the 
tissue distribution of human cytosolic GSTs is fuelled by the fact that this may be a 
determinant of resistance or sensitivity of a given tissue to certain drugs and 
carcinogens. 
Because the GSTs have been shown to have a wide range of substrate 
specificities (see Section 1.2.7), it would be expected that organs involved in 
detoxification processes may possess more GST activity and perhaps a wider range of 
GST isoenzymes than organs which are not involved with drug metabolism. 
It has proved difficult to generalise about the GST content of various human 
tissues since expression of some of the isoenzymes shows a marked polymorphism. 
However, whilst comments about the expression of specific subunits is unwise, a few 
generalisations about the distribution of the three classes of GST in different human 
organs can be made and there is an increasing body of literature concerning this subject. 
(a) Human Class pi GST 
This enzyme has a wide tissue distribution and although levels of expression 
may vary in the different tissues. The pi class enzyme has been detected in lung, 
bladder, breast (Ketterer 1988), kidney ( Sherman et al, 1983; Tateoka et al, 1987; 
Singh et al, 1987; Pemble et al, 1987), erythrocytes, platelets, thyroid, heart, spleen 
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(Koskelo 1983; Di Ilio et al, 1986; Tateoka et al, 1987), and at low levels in liver 
(Mannervik, 1985; Hussey et al, 1986). 
Peters et al (1989) have looked at human intestinal GST 7T and found little 
variation in this enzyme level from proximal to distal sections of the small intestine. 
These workers reported GST IT to be present in large amounts in the normal mucosa of 
small and large intestine. Kodate et al (1986) have looked at mRNA levels of IC in 
normal human colon and found there to be high expression. Moscow and co- workers 
(Moscow et al, 1989) have carried out a comparative study on 7C mRNA levels in 
various normal human tissues.They found the level of expression is heterogeneous, 
the highest levels being seen in lung, oesophagus and placenta and the lowest levels 
being detectable in liver. The low levels of expression found in liver by these workers 
is in keeping with the results of other research groups. 
(b) Human GST Class alpha 
Of all tissues examined, this enzyme class is expressed predominantly in human 
liver (Stockman et al, 1985). The subunits detected so far in human liver have been B 
1 
and B2 either as GST B1B1, B 1B2 or B2B2. These isoenzymes have also been 
detected in human adrenal, ovary and testis tissue (Sherman et al, 1983; Corrigal & 
Kirsch, 1988). They have also been found in kidney (Di Ilio et al, 1987). Another 
GST form isolated from human skin (9.9) is also thought to belong to the class alpha 
enzyme group (Del Boccio et al, 1987). However, with the possible exception of 
cardiac muscle this isoenzyme has not been recorded in any other human tissue (Di flio 
et al, 1986). 
(c) Human GST Class mu 
The tissue studied in the greatest detail with respect to these enzymes, is again 
the liver. The subunits found to date in this tissue are la (Warholm et al, 1983), yr 
(Hayes et al, 1987) and (Stockman & Hayes, 1987) and as already stated, there is 
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polymorphic expression of both yr andµ (Van Ommen, 1989; Seidegard et al, 1986). 
Of other tissues examined, the 11 homodimer has been found in human mononuclear 
leukocytes (Seidegard et al, 1987). Of the three human cytosolic classes, the class 
mu is the least well characterised in terms of tissue distribution. It remains to be seen 
whether there is a marked tissue specific expression of enzymes in this class. Recent 
evidence (Hussey et al, 1990) has revealed the presence of several class mu enzymes in 
human muscle tissue termed N1, N2 and N3. The primary structure of N1 has shown it 
to be homologous to the .t subunit. It remains to be seen whether the N2 and N3 
subunits have homologues in other human tissues. 
It is apparent that more work needs to be done in this area in terms of 
identification of the particular subunits expressed in human tissues. As well as this, the 
role of these isoenzymes in each particular tissue needs to be established. It is 
important to know the catalytic functions of each subunit in order to assign specific 
physiological roles to the different isoenzymes within a given tissue. 
1.2.6 GSTs as Intracellular Transport Proteins 
The binding of GSTs to non -substrate ligands, such as bilirubin, led to their 
earlier name of ligandin (Levi et al, 1969; Litwack et al, 1971). They have 
subsequently been shown to bind a range of compounds including steroids and bile 
acids. A number of other non -physiological inhibitors are also able to bind to GST and 
some of them have been used, along with other criteria, to assign the GSTs into the 
alpha, mu and pi classes. This has been possible because isoenzymes within a group 
have distinct affinities for these compounds How non - substrate ligands exert their 
inhibitory effect on enzyme function is unknown. It has been suggested that the 
substrates may bind at the active site or at an alternative specific binding site (Boyer, 
1989). The physiological role of this phenomenon has been an area of active research 
for many years (Wolkoff et al, 1979; Tipping & Ketterer 1981). It has been suggested 
that the GSTs may play a role in the transport of non -polar or alipathic molecules by 
binding to them and rendering them more soluble (Husby et al, 1981; Senjo et al, 
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1985). More recently, a non -histone binding protein isolated from rat was found to be 
a class mu enzyme (Bennett et al, 1986). 
There have also been suggestions that GSTs may function as steroid binding 
proteins. Experiments with dexamethasone 21- methane- sulphonate have shown that 
class mu GST isolated from rat nuclei is able to bind to this compound (Homma & 
Listowsky, 1985). Due to the binding capabilities of the GSTs it is feasible that they 
may bind harmful chemical species and aid their excretion before the reactive chemicals 
can cause cellular damage. 
1.2.7 Reactions Catalysed by the GSTs 
The GSTs have a broad range of substrate specificities owing in part to the 
existence of multiple isoenzymes. More is known about the exogenous substrates since 
it is these that have been used diagnostically in classifying the GSTs. However, many 
of the diagnostic substrates are not encountered in vivo and so have little biological 
significance (see Table 1.4 ). 
(a) Exogenous Substrates 
Many exogenous substrates for GST such as herbicides, pesticides and 
pollutants from combustion of organic material, are widely encountered in the 
environment. Many of these compounds have been shown to have carcinogenic 
properties and so it is desirable that if they are ingested they be detoxified and removed 
from the body. Conjugation of toxic xenobiotics with glutathione (catalysed by the 
GSTs) represents a major detoxification pathway, the final product of detoxification 
being mercapturic acid, which is excreted ( Gibson & Skett, 1986) . 
Environmental pollutants such as 1- nitropyrene -4,5 -oxide and 1- nitropyrene -9, 
10 -oxide are known substrates for GSTs. The actual GST isoenzymes responsible for 
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A well known carcinogen which is the product of microsomal oxidation of 
benzopyrene is benzo[a]pyrene- 7,8 -dio1- 9,10 -oxide (BPDE). This has been shown to 
be a substrate for all the GST isoenzymes so far tested but particularly for the Yb2 
subunit and the class pi transferase (Nemoto et al, 1975). Alpha class GSTs have been 
shown to have low activities with this substrate (Robertson & Jernstrom, 1986). 
A compound which has been shown to be a powerful hepatocarcinogen in rat is 
a metabolite of the mould toxin aflatoxin B1 (AFB1). Kensler et al, (1986) have shown 
that induction of a Ya subunit in rat by the antioxidant ethoxyquin, results in increased 
detoxification of AFB 1 -8,9- oxide, the carcinogenic metabolite of AFB1. Although 
there is as yet no direct evidence that the conjugation of glutathione to AFB1 -8, 9 -oxide 
is carried out enzymatically, the fact that induction of a Ya subunit leads to increased 
biliary excretion of an AFB1 - GSH conjugate and that there is decreased DNA 
damage, implicates the Ya subunit in the detoxification process. 
A wide range of compounds have been shown to induce GSTs in the rat 
(Talalay et al, 1988). The inducers include antioxidants, like butylated hydroxyanisole 
and also ethoxyquin, barbiturates, epoxides, such as trans - stilbene oxide, aromatic 
hydrocarbons (Igarashi et al, 1987) and N,N- dimethyl- 4- aminoazobenzene (Listowsky 
et al, 1988). In the rat it is predominately Ya (subunit 1) Yb1 (subunit 3) and Yb2 
(subunit 4) that are induced by these compounds. The induced isoenzymes act to 
detoxify reactive electrophilic forms of carcinogens. 
Recent work by Talalay et al (1988) has highlighted the fact that all the GST 
inducers are Michael reaction acceptors. It remains to be resolved whether all GST 
inducers are also themselves substrates for the enzymes. It is possible that the 
requirement for an inducer to serve as a substrate for GST is an intrinsic aspect of the 
induction mechanism. 
One other important consequence of the detoxification reactions catalysed by the 
GST, apart from the removal of harmful exogenous carcinogenic products from the 
body, is that of resistance to anti -cancer drugs. Although at present there is little 
evidence that many of the commonly used anticancer drugs are potential GST 
substrates, there is a large body of circumstantial evidence showing that certain GST 
isoenzymes are elevated in cell lines resistant to a range of anti -cancer agents (see 
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Section 1.3). 
However, there is now evidence that two of the drugs used in chemotherapy at 
least, are indeed substrates for certain GSTs. Dulik et al (1986) have shown that a 
melphalan -glutathione conjugate is formed due to enzymatic catalysis by both 
microsomal and cytosolic GSTs . 
More recently Smith et al (1989) have shown that a rat class mu enzyme is 
effective in the inactivation of BCNU through a denitrosation reaction. In addition to 
this, over expression of this mu class enzyme in rat brain tumour cells resistant to 
BCNU was reported. 
(b) Endogenous Substrates 
One physiological function of the GSTs that has already been discussed is the 
transport of compounds in the body. As already stated, many of the known GST 
substrates are of little biological importance. However, many harmful compounds are 
produced as a result of normal metabolism and are known to be substrates for the 
different GST classes. For example, certain products of lipid peroxidation such as 
cholesterol -a -oxide have known mutagenic properties (Meyer and Ketterer, 1982) and 
have been shown to be particularly good substrates for the alpha class, rat Ya subunit. 
Breakdown of arachidonate and linoleate yield the lipid peroxides arachnidonate 
hydroperoxide and lineoleate hydroperoxide. These two compounds have activities 
with the class alpha GSTs that are comparable to the diagnostic substrate cumene 
hydroperoxide. 
Other major breakdown products of peroxidative degradation of 
polyunsaturated fatty acids are alkenes such as 4- hydroxynon -2 -enal (Alin et al, 1985). 
In a study by Danielson et al (1987), a series of 4- hydroxyalkenals ranging from 4- 
hydroxypentenal to 4- hydroxypentadecanal were used as substrates for rat enzymes 
from the three different classes. The rat alpha class enzyme YkYk (8 -8) was most 
active with the whole range of hydroxyenals. 
More recently it has been shown that the products of DNA peroxidation, DNA 
hydroperoxides, are excellent substrates for the class mu enzymes (Tan et al, 1988). 
These workers isolated a subunit from rat liver nuclei, termed subunit 5 * -5* since it is 
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unlike any subunit so far isolated. GST 5 * -5* showed the highest activity towards 
DNA hydroperoxides. These workers discussed a possible role for GSTs in repair of 
damaged DNA. 
1.2.8. Regulation of the GSTs 
As already mentioned, the tissue distribution of the GSTs has consequences for 
detoxification of potentially harmful compounds. It is now known that as well as the 
intrinsic composition of isoenzymes, cells also have the potential to transcriptionally 
activate genes coding for certain GSTs in response to a range of harmful compounds. 
This may have consequences for cytotoxic insult by, for example, carcinogens or 
anticancer agents which are highly toxic molecules. 
In recent years there has been much interest in the regulation of the GSTs 
(Satoh, 1989; Pickett & Lu, 1989). Much of the work has been carried out using rat 
models and care must be taken in drawing parallels between rat and man. Although 
GSTs within a class share close sequence homology between species, the regulatory 
mechanisms may be very different. Since most of the available data relates to the rat 
system, frequent reference will be made to this. The situation in man will be reviewed 
where possible. 
Structure and Regulation of the Class Alpha GSTs 
Structure 
The structural and regulatory analysis of this class of GST has come 
predominantly from cDNAs encoding the rat Ya and Yc subunits (Rothkopf et al, 1986; 
Tu & Quian, 1987). It is becoming clear that the alpha class gene family in rat and 
probably also in man is very complex. Sequence analysis of the cDNAs for Ya and Yc 
have revealed them to be 75% homologous in the coding region. However, homology 
in the 5' and 3' untranslated region is low (Rothkopf et al, 1986). Rothkopf et al 
(1986) have used cDNAs coding for Ya (pGTB 38) and Yc (pGTB 2) to probe 
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Southern blots of rat genomic DNA. They showed the presence of at least 5 Ya genes 
and 2 Yc genes. 
This group also isolated three unique genomic fragments from a rat genomic 
library using a rat Ya cDNA clone (pGTB38) as a probe, also indicating the presence of 
multiple genes in this family. The protein products encoded by these genes remain to 
be elucidated. 
Analysis of the nucleotide sequence of these genomic fragments has shown the 
similarities and differences that exist between them. Comparison of the amino acid 
sequences encoded by the Ya genomic fragments and equivalent sequences from Yc 
structural genes has revealed there to be high overall homology in all but exon 3, of the 
genes (Picket & Lu, 1989). Exon 3 of the Ya genomic fragment shares only a 35% 
homology with the equivalent Yc amino acid sequence. By contrast, exons 2 and 4 of 
Ya show 86% and 91% homology with exons 2 and 4 of the Yc subunit. It may be the 
case that conserved regions in a protein impart similar functional aspects such as 
glutathione binding domains, while the regions of low homology confer other 
properties that give each isoenzyme their individual properties such as substrate 
specificities. 
Although Rothkopf et al (1986) have isolated three unique genomic fragments 
from a rat genomic library and Southern blot analysis has revealed the presence of at 
least 5 Ya and 2 Yc genes, the precise number of functional genes is unknown. To 
date, no investigators have characterised a Yc structural gene and all the information 
regarding homologies has come from cDNA and amino acid sequence data. More data 
is needed regarding the number and structural characteristics of different genes coding 
for the Ya, Yc and other class alpha subunits contained within rat genomes. 
With regard to the situation in man, cDNAs encoding proteins of this class have 
been cloned and characterised (Tu & Quian, 1986; Rhoads et al, 1987; Board & Webb, 
1987). The human cDNA sequences are 80% homologous with rat liver Ya and Yc 
cDNAs and the predicted amino acid sequence shows a 75% identity between rat and 
man. The two cDNA clones pGTH1 (Tu & Quian, 1986) and pGTH2 (Rhoads et al, 
1987) have been shown to encode B1 and B2 subunits respectively (Hayes et al, 1990). 
The sequences for B1 and B2 although 96% homologous, differ in 9 amino acids 
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indicating they are the products of two different genes. These structural genes have yet 
to be isolated and characterised. 
(ii) Regulation 
The rat liver Ya subunit has been shown to be induced by various xenobiotics 
such as 3- methylcholanthrene and phenobarbital (Telakowski- Hopkins et al, 1988). 
The observed increase in enzyme activity has been shown to be due to an increase in 
translational activity of the Ya mRNA (Pickett et al, 1982a;1982b; Pickett et al, 1984). 
Work by Ding & Pickett (1985) showed that members of the Ya gene family are 
transcriptionally activated in rat liver. Subsequently, Telakowski- Hopkins et al (1988) 
have investigated the mechanisms responsible for this induction. These workers fused 
various lengths of the 5' flanking region of a rat Ya structural gene to a gene encoding 
chloramphenical acetyltransferase (CAT) and looked for inducibility of CAT activity by 
various planar aromatic compounds, such as B- naphthoflavone. 
The following features were noted and lead to the proposed mechanism of 
regulation shown in Fig. 1.4 (Pickett, 1987). Firstly, two regulatory sequences were 
discovered, one which is required for maximal basal expression and the other which is 
responsible for inducibility by planar aromatic compounds such as B- naphthoflavone 
and 3- methylcholanthrene. Secondly, this second regulatory element is only responsive 
in cells that have a functional dioxin receptor. 
The mechanism proposed in Fig. 1.4 is as follows: A polycyclic aromatic 
hydrocarbon binds to the dioxin receptor forming a complex. This ligand- receptor 
complex is then translocated to the nucleus where is causes transcriptional activation of 
the Ya gene by interacting with the regulatory element responsive to polycyclic aromatic 
hydrocarbons. It could alternatively be the case that the ligand- dioxin receptor complex 
activates a transacting gene coding for a regulatory protein which in turn regulates 
expression of the Ya gene by interacting with the regulatory element responsive to 
polycyclic aromatic hydrocarbons. 
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Figure 1.4 Proposed models of rat Ya glutathione S- transferase 
gene expression regulation by polycyclic aromatic hydrocarbons. 
There are two proposed mechanisms. (1) A polycyclic hydrocarbon (1) binds to the 
dioxin receptor (R) forming a complex. This ligand- receptor complex (1 -R) is then 
translocated to the nucleus where it causes transcriptional activation of the Ya gene by 
reacting with the regulatory element responsive to polycyclic aromatic hydrocarbons. It is 
proposed that the same mechanism is responsible for P450 induction. (2) Alternatively, the 
ligand- receptor complex (1 -R) activates a gene coding for a regulatory protein (Y) which in 
turn regulates expression of the Ya gene by interacting with the regulatory element 
































To date, it has not been possible to distinguish between the two possibilities. So 
far, structural features such as those discussed above for rat Ya have not been described 
for the human alpha class genes and information of this nature is eagerly awaited. 
Regulation of the class alpha genes in the mouse has been addressed (McLellan 
et al, 1989). It has been shown that a mouse liver alpha class subunit which is not 
normally detectable in liver, is induced by both butylated hydroxyanisole (BHA) and 13- 
naphthoflavone. At the genetic level, Daniel et al (1987), using a mouse Ya subunit 
linked to a CAT gene, have also shown the presence of two regulatory elements. The 
situation is the same as in rat, in that one of the regulatory elements is responsible for 
basal expression and one is responsible for inducible expression by compounds such as 
3- methylcholanthrene and ß- naphthoflavone. Again, the inducible receptor is only 
active in the presence of a functional dioxin receptor. 
(b) Structure and Regulation of the Class Pi GSTs 
(i) Structure 
Full length genomic clones for both the rat and human pi class GST have been 
isolated ( Suguoka, et al ,1985; Okuda et al, 1987; Muramatsu et al, 1987; Sakai et al, 
1988). Suguoka et al (1985) have isolated the rat YfYf (GST -P) gene from a phage 
library which they probed with a rat cDNA isolated from a 2- acetylaminofluorene 
induced rat hepatocellular carcinoma. The rat YfYf gene has been demonstrated to be 
3000 base pairs long and consists of 7 exons and 6 introns. These workers also linked 
the 5' end of the rat YfYf gene to the gene for CAT to allow the investigation of the 
regulatory DNA sequences in this region. Using this technique, two enhancing 
elements were found 2500 and 61 base pairs upstream from the translation initiation 
site. Both enhancers contained a 12- 0- tetradecanoyl -phorbol -B- acetate (TPA) 
responsive element (TRE). Mechanisms for altered gene expression by TPA have been 
proposed (Nishizuka, 1984; Chiu et al, 1987). This is speculated to involve a signal 
transduction cascade mechanism triggered by protein kinase C. During this mechanism 
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specific transacting factors are modified so causing alterations in the expression of the 
genes with which these factors are active. 
A silencing element was also found 400 base pairs upstream from the 
translation initiation site (CAP site) of the Yf gene. It has been proposed that this may 
act as some sort of negative regulatory element (Muramatsu et al, 1989). This may 
function to suppress the expression of YfYf in normal liver cells. 
The structure of the human 7t gene has also been analysed (Cowell et al 1988). 
The human GST it gene was isolated from a cosmid library constructed with genomic 
DNA prepared from the acute lymphocytic leukaemia cell line HPB -ALL and the CAT 
assay was used in order to investigate structures involved in the regulation of this gene. 
As with the rat sequence, a THE consensus sequence was noted in the promoter region. 
However, in contrast to the rat sequence in the 2.2 to 2.5 kilobase upstream region of 
the human gene, no enhancer sequences were found, only repetitive elements (Cowell 
et al, 1989). This work indicates that enhancer sequences if present, must be located 
further than 6kb upstream of the promoter or in a downstream position. 
(ii) Regulation 
It has been postulated that regulation of the rat liver Yf gene during chemical 
carcinogenesis takes place by de- repression rather than a transcriptional activation of the 
gene. Whatever the mechanism, certain factors have been shown to be involved in the 
expression of the rat Yf gene. Several workers (Power et al, 1987; Li et al, 1988) have 
shown that both TPA and ras- oncogene expression can increase steady state levels of 
rat Yf mRNA. The actual mechanism by which this occurs has not yet been elucidated. 
However, it has been suggested (Cowell et al, 1988) that ras may act through the 
TRE's of several cellular genes leading to the concomitant induction of various other 
gene products. This is highly relevant to the tumour specific induction of YfYf seen in 
rat liver carcinogenesis models, since ras is overexpressed in many tumours. 
(c) Structure and Regulation of the Class Mu GSTs 
(i) Structure 
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Again, most of the work in this area has been carried out using the rat model 
(Ding et al, 1985; Ding et al, 1986; Lai et al, 1986; Lai & Tu, 1986; Abramovitz & 
Listowsky 1987). To date, at least three rat mu class cDNA clones have been isolated 
and characterised. They have been referred to as Yb 1, Yb2 and Yb3 and are about 80% 
homologous at the amino acid and nucleotide sequence level in the coding region. The 
5' and 3' untranslated regions, however, are divergent. Lai et al, (1986) have carried 
out Southern blot analysis of rat genomic DNA which indicates the presence of multiple 
Yb genes. 
Three structural genes have been characterised (Tu et al, 1987; Lai et al, 1988) 
and have been shown to code for the mu class subunits Yb 1, Yb2 and a Yb4, the latter 
of which has not yet been shown to be expressed in rat tissue. A rat Yb3 subunit has 
been shown to be expressed in rat brain using a cDNA for this subunit to detect mRNA 
levels, but the structural gene encoding this has not been isolated. The sequence 
analysis of the genomic clones Yb 1, Yb2 and Yb4 has revealed them to consist of 8 
exons separated by 7 introns and containing approximately 5000 base pairs. The 
nucleotide sequences of exons 3, 4 and 6 are highly conserved and it has been 
suggested that evolution of these genes occurred due to gene conversion (Lai et al, 
1988). 
(ii) Regulation 
Like the rat class alpha subunits Ya and Yc, the class mu subunits Yb1 and Yb2 
have also been shown to be elevated by compounds such as phenobarbital and 3- 
methylcholanthrene (Pickett et al, 1982a; 1982b). This elevation can also be attributed 
to transcriptional activation of the genes coding for the subunits (Ding & Pickett, 
1985). However, the mechanisms by which various xenobiotics cause transcriptional 
activation of the mu class GST genes remains to be elucidated. 
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1.2.9 Future Prospects. 
It is evident from the preceding sections that there are a range of GST 
isoenzymes in rat and man whose functions are varied. It is also clear that further 
molecular characterization of these enzymes is required in order to relate the genes to 
the protein products. 
With the advent of site -directed mutagenesis techniques, more information 
should become available on the structure /function relationships of the GSTs. 
Furthermore, the regulation of gene expression and identification of the transacting 
factors involved will provide more information about the role of GSTs in processes 
such as carcinogenesis and drug resistance. 
1.3.0 THE ROLE OF THE GLUTATHIONE S- 
TRANSFERASES IN DRUG RESISTANCE 
Introduction 
As discussed in Section 1.1, the major cause of treatment failure in cancer 
chemotherapy is the onset of clinical drug resistance to a range of structurally and 
functionally dissimilar compounds. It is becoming evident that this phenomenon is 
multifactoral in nature. The role of the glutathione S- transferases in this process is not 
clear at present but a large body of circumstantial evidence is emerging indicating that 
GSTs are involved in drug resistance. 
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1.3.1. Analysis of GST Expression in Human Tumour 
Samples 
Although much of the work carried out on drug resistant cell lines has yielded 
valuable information, relevance of GST expression to the clinical situation must also be 
assessed. To this end several investigators have analysed the GST content in various 
human tumours. The over expression of a number of different GST isoenzymes has 
been noted in a variety of different tumour types. 
The work in human tumour samples has been carried out primarily at the 
protein level, using enzyme assays and immunological techniques and at the RNA 
level, using both northern and slot blot analysis. Work by Shea et al (1988) involved 
measurement of GST activity in 24 human tumour samples, including six colon 
adenocarcinomas, three renal carcinomas, two melanomas and six breast 
adenocarcinomas. Purification of the GSTs from the cytosols of these tumours revealed 
that 70% of the overall GST activity could be attributed to the IC subunit. 
High levels of the rat class pi subunit Yf are seen in rat hepatic nodules 
resulting from exposure to carcinogens and it has been postulated that this leads to 
resistance to other cytotoxic compounds. Therefore, high levels of GST pi may 
predispose cells in a tumour population to resistance to anticancer drugs. 
Other workers have also showed that the GST isoenzyme content in certain 
tumour tissues is altered in relation to normal tissue from the same organ and 
individual. Di Ilio et al (1987) have studied GST isoenzyme content in human renal 
carcinomas. Paired tumour and non -tumour tissue from the same patient were 
analysed. The overall GST activity, measured using CDNB as a diagnostic substrate, 
was reduced in the tumour samples. However, analysis of the GST isoenzyme profile 
using double immunodiffusion techniques, revealed an overall increase in the 7C subunit 
content but an overall decrease in the class alpha subunits in tumour versus normal 
tissue, leading to an overall decrease in total GST activity. 
Other work by this group on lung tumours (Di Ilio et al, 1988) has shown GST 
activity is increased in tumour tissue relative to normal surrounding tissue. Analysis of 
the isoenzyme profile revealed the increase in GST activity could be attributed to the 
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class it subunit. 
In another study (Soma et al, 1986) it was also found that the GST it enzyme is 
overexpressed in human hepatic tumours. These workers have suggested that GST 7c 
can serve as a hepatic tumour marker. This has also been suggested by other workers. 
High levels of GST it were also detected in human malignant melanoma 
(Mannervik et al, 1987). However, in this study, only two samples were analysed and 
fibroblasts and naevus samples were used as a normal comparison. 
A more comprehensive study of GST it expression in human tumours has been 
carried out by Moscow et al (1989) who not only looked at a wide variety of tumours 
but also compared GST it mRNA with P- glycoprotein expression. A total of 170 
specimens were analysed and both normal and malignant tissues were compared. In 
normal tissue, it mRNA levels were low in liver and high in lung, oesophagus and 
placenta in agreement with other workers. In the tumour samples GST it mRNA levels 
were found to be low in lymphoma and breast cancer and high in lung and head and 
neck cancers. In most of the paired tumour and non -tumour specimens, GST was 
found to be overexpressed in the former. This is particularly true for the colonic 
carcinomas which is in agreement with Kodate et al (1986) and the stomach samples in 
which is in agreement with Tsutsume et al (1987). 
One criticism that can be made of much of the work carried out in this area is 
that GST overexpression is rarely correlated with drug treatment status, disease status 
or clinical outcome. Preliminary results (Moscow et al, 1989) indicate that GST it may 
be elevated during initial treatment with chemotherapeutic agents since in two patients 
with relapsed acute lymphoblastic leukaemia, GST it mRNA levels were elevated after 
treatment, compared to levels detectable before treatment. 
Comparison of normal versus tumour tissue is desirable as is the analysis of 
the actual GST isoenzymes expressed in samples. Correlation of the GST data with 
other drug resistance markers, as well as several clinical factors, is also required if the 
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relevance of GSTs to the drug resistant phenotype is to be ascertained. 
1.3.2. GST Content of Derived Drug Resistant Cell Lines 
As with most of the work concerning P- glycoprotein expression, much of the 
work on the involvement of GSTs in drug resistance has come from work using cell 
lines made resistant in vitro to certain anticancer drugs. Although informative, obvious 
extrapolations to the clinical situation cannot be made based on results from these cell 
line models. Several approaches have been taken in order to study in vitro the role of 
the GSTs in drug resistance: 
(1) Selection of a resistant cell line and examination of cross -resistance 
patterns and various biochemical changes. 
(2) Transfection of genes known to code for factors implicated in drug 
resistance into cells and examination of cross -resistance patterns. 
(3) Use of inhibitors of resistance factors to analyse whether drug resistance 
patterns can be reversed. 
Table 1.5 shows drug resistance models where GST involvement has been implicated. 
The work in this area is reviewed below. Many drug resistance tumour cell 
lines have been established from a number of mammalian species. It is possible that 
mammalian cells from different species may respond differently to treatment with 
antitumour agents and that expression of the different isoenzymes among species may 
be subject to different control mechanisms. 
The first reports that a protein of molecular weight of about 25,000 daltons was 
present in a derived drug resistant line and not in the parent line appeared in the early 
1980's (Myers & Biedler, 1981; Beck, 1983). This protein was not identified and it is 
therefore unclear whether this protein represents a GST subunit or not. Since then 
many reports have appeared in the literature showing that GST activity is elevated in 
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In a large number of cases, however, overall GST activity has been used as a 
measure of overexpression. This may sometimes be misleading as has been shown by 
Di Ilio et al (1987), who reported that in renal carcinomas the it subunit was up- 
regulated while the class alpha subunits were down regulated, leading to an overall 
decrease in total GST activity. Changes in individual isoenzyme content may have 
greater implications for drug resistance than a change in total GST activity. 
This has been shown to be the case for a rat brain tumour cell line resistant to 
BCNU termed 9L (parent line) and 9L -2 (BCNU resistant line). Smith et al (1989) 
found that although the overall GST activity of 9L -2 had decreased by about 50 %, there 
was an increase in a class mu enzyme and a decrease in the class pi enzyme. It was 
suggested that this up- regulation in the class mu enzyme was contributing to BCNU 
resistance. Further evidence for this hypothesis came from the use of GST inhibitors to 
sensitise the 9L -2 cells to BCNU. 
Others, working on a rat mammary carcinoma cell line resistant to chlorambucil 
(Wang & Tew 1985; Buller et al, 1987; Clapper & Tew, 1989) have shown 
overexpression of an alpha class subunit in the resistant subline. There was a 4 -fold 
increase in GST activity detected in the resistant line (WR) and it was shown that 
during selection with chlorambucil, increasing the concentration of the drug led to an 
concomitant rise in GST activity up to a maximum of 4 -fold. As with all of these 
generated models, the authors were unable to say whether the overexpression of the 
class alpha subunit had occurred by selection of a subpopulation of cells or by an 
induction mechanism due to drug treatment. 
Further to the work illustrating over- expression of certain cytosolic GSTs, the 
subcellular fractions of the chlorambucil resistant line were also analysed. The 
microsomal fraction was subjected to S- hexyl -glutathione affinity purification. Two 
proteins of molecular weight 25.7 and 29.0 kilodaltons were isolated from WR and 
antisera raised against total liver cytosolic GST cross -reacted with these proteins. The 
29kD protein was not found in the chlorambucil sensitive parent line and was 
immunologically distinct from the known 14kD microsomal GST. These workers 
suggested that a novel microsomal GST was present in WR and that this may be 
contributing to resistance to chlorambucil. However, it is possible that the 29kd protein 
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identified in the microsomal fraction of WR represents contamination by a cytosolic 
GST. 
The pi class enzymes have also been implicated in drug resistance as well as 
members of the other two GST classes discussed above. Gupta et al (1989) have 
derived human plasma lines resistant to melphalan. Upon injection of these lines into 
mice, plasmacytomas were formed. The GSTs were purified from these 
plasmacytomas and subjected to western blot analysis. A moderate overexpression of 
the pi class enzyme was seen. The functional characteristics of the overexpressed class 
pi enzyme were found to differ to those recorded for the class pi enzyme in rat, mouse 
and man. Whether these workers have isolated a novel class pi enzyme remains to be 
established. 
Other rodent models have been examined where overexpression of more than 
one class of GST isoenzyme is reported (Robson et al, 1986; Robson et al, 1987; 
Singh et al, 1989), In a Chinese hamster ovary cell line 20 -fold resistant to 
chlorambucil (CHO -CHLr ) but showing little cross -resistance to other drugs except 
mechlorethamine and melphalan, a cytosolic protein of molecular weight 25kd was 
found to be overexpressed (Robson et al, 1986). Upon further analysis, this resistant 
line was found to have reduced levels of DNA cross -links but an apparent unchanged 
DNA repair capacity. The CHO -CHLr showed a 3 -fold increase in overall GST 
activity, provided by a 2 -fold increase in the class pi enzyme and a 5 -fold increase in 
class alpha enzyme activity (Robson et al, 1987). The overexpressed enzymes were 
purified from the cytosolic fraction of the CHO -CHLr and subjected to western blot 
analysis (Lewis et al, 1988). There was seen to be a 40 -fold overexpression of a class 
alpha subunit that cross -reacted with anti -rat Yc antisera. A pi class subunit and 
another class alpha (Ya) were also shown to be overexpressed. The mechanisms of 
overexpression of the class alpha subunits were examined. Northern blot analysis 
revealed significantly higher levels of the mRNA coding for these subunits and 
Southern blot analysis revealed a 4- to 8 -fold increase in gene copy number of the class 
alpha subunits in the CHO -CHLr cell line. 
Concomitant increases in class alpha and class pi subunits have been reported in 
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a murine leukaemic cell line P388, resistant to adriamycin (Sing et al, 1989). These 
workers however, did not use immunological techniques to analyse the overexpressed 
subunits but employed the diagnostic substrates cumene hydroperoxide and ethacrynic 
acid. These workers suggested that the class alpha GST may contribute to resistance 
by enhancing free -radical detoxification, since the generation of oxyradicals by the 
redox cycling of the quinone moiety of adriamycin is believed to contribute to the 
antitumour activity of this drug. This view is also supported by other workers (Kramer 
et al, 1988). 
Other groups also working on derived adriamycin resistant cell lines have 
found increases in GST activity, up to 45 -fold (Batist et al, 1986). These workers 
were investigating the human breast tumour cell line, MCF 7 which expresses 
intrinsically low GST activity. The adriamycin resistant subline MCF 7 /ADR, 
however, has been shown to express a class pi enzyme which is not seen in the parent 
line. The class pi enzyme was purified from MCF 7 /ADRr and subjected to further 
analysis. 
Batist and co- workers (1986) reported that this anionic GST, which is 
homologous to the class pi subunit overexpressed in rat preneoplastic modules, also 
had high levels of intrinsic peroxidase activity. This finding has not been reproduced 
by others and this raises the question of the purity of the GST these workers isolated. 
A cDNA clone of this anionic GST has subsequently been isolated (Moscow et al, 
1989) and the nucleotide sequence in the protein coding region is essentially identical 
to the sequence reported by Kano et al (1987). 
Much of the work discussed above has detailed one type of change that may 
have occurred in a drug resistant cell line. However, the emerging picture from the 
clinical data is that drug resistance is a multifactoral process involving P- glycoprotein 
expression, DNA repair and topoisomerase II. Factors may of course predominate 
depending on the model studied. 
In a murine lymphoblast line resistant to hydrolysed benzoquinone mustard 
(Begleiter et al, 1988) several factors associated with drug resistance were analysed. 
Drug uptake was found to be lower in the resistant cell line. Of the enzymes analysed, 
superoxide dismutase, catalase, glutathione peroxidase, glutathione S- transferase and 
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DT- diaphorase were all increased. The individual GST isoenzyme changes were not 
investigated. These overexpressed enzymes may contribute to resistance by 
inactivating free radicals formed by action of the drug. 
Deffie et al (1988) studied an adriamycin resistant murine leukaemic cell line 
and showed there to be no difference in drug efflux, indicating that an active drug 
extrusion pump was not operational. However, there was an increase (2 -fold) in P- 
glycoprotein expression as detected by northern and western blot analysis. Total GST 
activity was estimated to be increased by 1.44 -fold and the levels of class pi mRNA and 
protein was shown to be elevated. 
As well as the multifactoral nature of drug resistance, another aspect of this 
phenomenon that needs to be addressed is the relevance of these in vitro models to the 
in vivo situation. In an attempt to study this, a number of workers have generated cell 
lines from surgically removed tumours in order to investigate whether the characteristic 
drug resistance of tumours is also evident in the derived cell lines and if so, what 
factors may be involved (Carmichael et al, 1988). 
Non -small cell and small cell lung tumour cell lines were established from 
patients with the corresponding disease (Carmichael et a1,1988 ). The chemosensitivity 
patterns of these cell lines to a variety of anticancer drugs were similar to those 
observed clinically. Certain drug detoxification enzymes were analysed, including 
GST. The the non -small cell lines demonstrated an overall increase in GST activity of 
about 2.5 -fold when compared to the small cell lines. This correlates with the patterns 
of drug resistance seen in the two clinical tumour types, in that small cell lung cancer is 
usually drug sensitive upon presentation but develops resistance in response to 
treatment whereas non -small cell lung cancer is refractory to treatment and so 
intrinsically resistant (Bergsagel & Feld, 1986; Ruckdeschel et al, 1986). In this study, 
there was no correlation with treated and non -treated patients. The individual GST 
isoenzyme profiles were not examined, and as mentioned previously a measurement of 
overall GST activity may mask individual isoenzyme changes (Di Ilio et al, 1987). 
A review of some of the major work in this field would not be complete without 
reference to work on derived drug resistant cell lines where GST overexpression is not 
noted. Bellamy et al (1989) showed that in a human myeloma cell line resistant to 
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adriamycin, no overall difference in GST activity was seen. Using a cDNA for the it 
subunit no increase in mRNA levels was noted. Using cumeme hydroperoxide as a 
diagnostic substrate, no increase in the class alpha enzyme activity was observed. 
However, these workers offered no explanation as to the possible mechanisms of 
resistance operational in this cell line. 
Work by Yusa et al (1988) showed that a colchicine resistant MCF 7 cell line 
exhibited a 70 -fold increase in overall GST activity. A subline that reverted to being 
colchicine sensitive, however, still showed the overexpression of GST activity. The it 
subunit was shown to be responsible for the increased GST activity in the resistant and 
revertant line. These results prompted the authors to conclude that GSTs are not 
associated with the development of drug resistance. However, in order to analyse the 
role of GSTs in drug resistance, all the available data needs to be considered. 
The two major criticisms that arise from the work reviewed above are as 
follows. Firstly, in every case it is impossible to say whether or not the GSTs confer 
resistance or are overexpressed non -specifically as a result of the many changes that are 
presumed to occur during the resistance phenomenon. Secondly, there are few reports 
of anticancer drug -glutathione conjugates formed as a result of GST catalysis and little 
available evidence as yet that different anticancer drugs can act as GST substrates. 
In order to answer the question as to whether GSTs can actually confer 
resistance, several workers have cloned GSTs into various vectors and used these to 
transfect different cell lines (Manoharan et al, 1987; Black et al, 1990). 
Puchalski et al (1989) transfected mouse cells with expressions vectors that 
contained either Ya, Yb 1 or it subunits and which were driven by the a collagen 
promoter. The transfected cells were then subjected to colony forming assays in order 
to assess the sensitivity of wild type and transfected cells to a variety of anticancer 
drugs. The cell lines expressing Ya were 1.5, 2.5 and 2.9 -fold resistant to 
chlorambucil. 
Other workers have cloned cDNAs for human B 1 and it subunits into the yeast 
expression vector pMA56 and expressed these in S. cerevisiae (Black et al, 1990). 
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The sensitivity of the wild type and transfected strains to a variety of drugs were tested. 
Both subunits appear to afford protection against chlorambucil and adriamycin. In 
addition to this, the B1 subunit afforded protection against CDNB and cumene 
hydroperoxide. This work suggests that the GSTs do indeed have the ability to confer 
drug resistance and has implications for the drug resistant cell line models reviewed 
earlier. That is, it is possible that the GST may be responsible, or partially responsible, 
for the drug resistance seen in these cell lines. However, as already highlighted in 
Section 1.1., it is probable that more than one factor is involved in the multidrug 
resistant phenotype and the relative importance of the GST in this phenomenon needs to 
be assessed. The question as to whether anticancer drugs can act as substrates for the 
GSTs has also been addressed. Dulik et al (1986) have isolated melphalan- glutathione 
conjugates and have demonstrated that adduct formation is catalysed by both 
microsomal and cytosolic GSTs. However, few workers with drug resistant cell line 
models have shown that drug -glutathione conjugates can be isolated from these drug 
resistant cell lines. 
1.3.3 CONCLUSION 
As can be seen, drug resistance to a wide range of anticancer drugs can arise by 
a variety of different mechanisms. The relative role of the GSTs in this phenomenon 
needs clarification. Since these enzymes have been shown to fulfill a number of 
different and varied functions, it is quite feasible that they could detoxify certain 
anticancer drugs so reducing their cellular concentration and hence their harmful 
cytotoxic effects. Further data regarding the ability of the different isoenzymes to 




1.4.0 OBJECTIVES OF THE STUDY 
The major aim of this project is to study the role of the glutathione S- 
transferases in resistance to cytotoxic compounds. In order to do this , known GST 
substrates will be used to generate resistant tumour cell lines. Whether directed 
overexpression of GST subunits can be achieved, using such a model, will be 
investigated. The cross -resistance patterns of these models to cytotoxic compounds and 
anticancer drugs will be analysed in order to ascertain whether resistance to structurally 
and functionally distinct compounds can be achieved potentially through only one 
mechanism, in this case GST catalysed detoxification. 
A secondary aim of this project is to investigate whether the treatment of cells 
with cytotoxic compounds can elicit a stress response and if so, whether certain GSTs 
may function as stress response proteins. 
The expression of the pi class GST in clinical leukaemia samples will also be 




MATERIALS AND METHODS 
2.1.0 CELL CULTURE 
2.1.1 Growing and Routine Maintenance of Human Tumour Cell Lines 
All cell lines used during this work were taken from laboratory stocks of the lines 
that had been stored in liquid nitrogen until required. The cell lines used were MCF 7, 
PE04, NCI H322 and HT29 which were human breast carcinoma, ovarian adenocarcinoma, 
lung carcinoma and colonic carcinoma respectively. The cell lines were all grown in RPMI 
1640 media which was supplemented with 10% (v /v) foetal calf serum, streptomycin 
(100µg /m1) and penicillin (100 IU /ml). Insulin (2.5mg /ml) was also supplemented to the 
media in which the PEO4 cell line was grown. 
The cell lines were cultured at 37 °C in an atmosphere of 5% CO2 at 100% humidity. 
Before commencing experiments with the various cell lines, frozen stocks at one particular 
passage were obtained for each line. 
Cells were cultured for no more than eight passages. After eight passages, the cells 
were discarded and fresh cryopreserved cells from the frozen stocks were utilised. This was 
to avoid, as far as possible, phenotypic and genotypic changes that have been shown to 
occur in cells over prolonged periods of time in culture. 
To cryopreserve cells at the same passage, 50 to 100 x 106 cells /ml were aliquoted 
into 2m1 of freezing mix which consisted of 90% (v /v) newborn calf serum and 10% (v /v) 
dimethyl sulphoxide. Cells were first frozen at -70 °C for 24 hours and then transferred to 
liquid nitrogen. When these cryopreserved cells were required, they were thawed rapidly in 
a water bath at 37 °C, washed twice in the appropriate medium to remove the dimethyl 
sulphoxide and transferred to a 1 x 25 cm2 flask (Nunc) in 5 -10 ml of the appropriate 
media. 
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The cells were allowed to settle overnight and refed with fresh medium the next day 
to remove any cell debris. Cultures of cells were fed every 2 -3 days with the appropriate 
medium and sub -cultured (passaged) as necessary. This involved harvesting the cells(section 
2.1.5) with sterile 0.1% (w /v) trypsin and 0.001% (w /v) versene (EDTA) mixed in a ratio of 
1:1 and dividing the resultant cell suspension into equal volumes before seeding it into new 
flasks. 
This procedure was to maintain cells in logarithmic growth and avoid the cells 
becoming over confluent. Each time this procedure was carried out, one passage was added 
to the passage at the start of the culture. 
2.1.2 Mycoplasma Testing 
Periodic assays for mycoplasma were carried out routinely by the MRC Clinical and 
Population Cytogenetics Unit, Western General Hospital, Edinburgh and were always found 
to be negative. The assays involved growth of mycoplasma on defined agar plates and also 
a fluorescence test. 
2.1.3 Derivation of an Ethacrynic Acid Resistant MCF 7 Cell Line 
8 x 75 cm2 flasks (Nunc) were seeded with 107 cells. Four flasks were maintained 
as described in Section 2.1.1. The other four flasks were dosed with ethacrynic acid at 
concentrations of 41.M, 1011M, 25µM and 5011M. The cells were observed and 
photographed daily and dosed every two days. The derivation process is shown in Fig. 3.05 
(chapter 3). 
Cells were dosed by tipping off the media containing ethacrynic acid, in which the 
cells were growing, and washing the cells three times with PBS (140mM NaCI; 2.7M KC1; 
8mM sodium phosphate, pH 7.4). 20m1 of fresh medium containing the appropriate 
concentration of ethacrynic acid made from a stock solution was then added. The stock 
solution of ethacrynic acid was freshly prepared every time the cells were dosed. 
The stock solution was made by weighing out the appropriate amount of ethacrynic 
acid on a Mettler A E 160 electronic balance, dissolving this in dimethyl sulphoxide and 
diluting this into serum free medium. This was then filter sterilised using a sterile 10 ml 
syringe (Becton Dickson) and a 0.221.IM filter (Millipore) before adding to the culture 
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medium. 
To give a final ethacrynic acid concentration of 25µM, 0.5mis of a 10-31ví stock 
solution of ethacrynic acid was added to 19.5 ml of culture medium. It was cells dosed at 
this ethacrynic acid concentration that were used in the derivation of a drug resistant subline 
since other drug concentrations either had no observable effects on cells (5 and 10µM) or 
killed 100% of the cells (50µM). 
MCF 7 cells were cultured in the presence of ethacrynic acid for about two months. 
Dosing cells at 25RM of ethacrynic acid also meant that dimethyl sulphoxide was present in 
the culture medium at a concentration of 0.025% (v /v). To rule out any changes that may 
have resulted from this, control cells were also cultured in the presence of 0.025% (v /v) 
dimethyl sulphoxide. 
2.1.4 Derivation of a CDNB resistant NCI H322 Cell Line 
8 x 75cm2 flasks (Nunc) were seeded with 107 NCI H322 cells. Four flasks were 
maintained as described in Section 2.1.1. The other four flasks were dosed with CDNB at a 
concentration of 10µM or 25µM. The higher dose of CDNB proved to be toxic at this stage 
of the derivation process so cells dosed at 10µM were used to derive a resistant cell line. 
There was a stepwise increase in the concentration of CDNB up to a maximum of 
251.IM over an eight month period. This is represented in Figure 3.05 (chapter 3). 
With each increase in CDNB concentration there was a certain amount of cell death. 
However, at each stage small colonies of cells remained which eventually became confluent 
even in the presence of the CDNB. Frozen stocks of cells were obtained at every stage of 
the derivation process. 
Cells were dosed every two days. This was done by tipping off the media 
containing CDNB, in which the cells were cultured and washing the cells three times with 
PBS. 20m1 of fresh media containing the appropriate dose of CDNB made from a stock 
solution of CDNB was then added. The stock solution of CDNB was freshly prepared each 
time the cells were dosed. The stock solution of CDNB was made by weighing the 
appropriate amount of CDNB on a Mettler A C 160 electronic balance and dissolving this in 
dimethyl sulphoxide. This was then diluted in serum free media and filter sterilised using a 
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10m1 syringe (Becton Dickson) and a 0.22µM filter (Millipore) before adding to the 
medium. 
For example, to give a final CDNB concentration of 25µM, 0.5mls of a 10-3M stock 
solution was added to 19.5m1 of culture medium. Dosing cells at this concentration of 
CDNB also meant that dimethyl sulphoxide was present in the culturç medium at a 
concentration of 0.025% (v /v). To rule out changes that may have resulted from this, 
control cells were also dosed with 0.025% (v /v) of dimethyl sulphoxide. 
After eight months, resistance to CDNB was analysed using the MTT assay (Section 
2.1.6). At this stage of the derivation process, some cells were maintained in the presence 
of CDNB and some were maintained in the absence of CDNB. 
2.1.5 Harvesting and Counting of Viable Cells 
Cells were harvested with 0.1% (w /v) trypsin and 0.001% (w /v) versene (EDTA) in 
a ratio of 1:1. The media was tipped off the cells which were then washed three times in 
PBS. The trypsin /versene mix was added in a sufficient volume to just cover the cells and 
the flask was incubated at 37° until cells were seen to begin lifting off. The flask was shaken 
gently and the resultant cell suspension was washed three times with medium before 
suspending the cells in 10 mis of culture medium 
The number of viable cells was assessed using a hemocytometer (Scientific 
Furnishings). l00µ1 of cell suspension was mixed with 100111 of 0.5% (w /v) nigrosin. 
l0111 of this suspension was loaded onto a pre -prepared hemocytometer and the cells were 
observed under phase contrast microscopy. Any dark blue cells were non -viable since 
viable cells do not take up the nigrosin dye. Viable cells were counted and the concentration 
of cells per ml was calculated. 
2.1.6 Assessment of Cell Sensitivity to Cytotoxic Compounds using 
the MTT Assay 
Cells were harvested and counted as described in Section 2.1.5. A suspension of 
2.8 x 104 cells was then prepared by adding the appropriate volume of cells to an 
appropriate volume of medium. 0.18 ml of this 2.8 x 104 cells /ml suspension was added to 
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all wells of a 96 -well plate (Costar) apart from the wells on the perimeter of the plate. 
2O0111 of medium only was added to the wells on the perimeter of the plate. 
The final number of cells in each well was 5 x 103 cells per well. The plates were 
then incubated overnight at 37 °C, 5% Coe and 100% humidity to permit cell attachment. 
The following day the appropriate drug dilutions were prepared and 0.02m1 of each drug 
concentration was added to three consecutive wells of the plate to allow triplicate 
determinations of cell viability at each drug concentration. Six wells were left free of drug 
for determination of 100% cell viability and if drugs had been dissolved in dimethyl 
sulphoxide then the appropriate concentration of DMSO was added to six wells and this 
was used to assess 100% cell viability. The drug was left on the cells for 5 days after which 
time 50111 of MTT (2mg/m1) was added to each well and the plate left for four hours. After 
this time, the liquid was carefully aspirated from each well taking care not to disturb the 
crystals that had formed. 
50111 of DMSO was added to the wells to dissolve the crystals and the absorbance of 
the resultant solution was determined at 540nm using a 2550 EIA reader (Biorad 
Laboratories). Rows AI to HI were used to zero the machine and the values recorded for 
the wells with no drug or an appropriate concentration of DMSO, were used as a measure of 
100% cell viability. Percentage viability of cells dosed with different drug concentrations 
was calculated relative to the value for 100% cell viability. Mean and standard deviation 
were calculated for triplicate determinations of cell viability. The LD50 for a particular drug 
was calculated from the plot of cell viability vs. drug concentration. 
2.2.0 PREPARATION OF CELLULAR FRACTIONS 
2.2.1. Preparation of Cell Cytosol Samples 
Cultures of subconfluent cells were harvested from 75cm2 flasks (Nunc) with 0.1% 
(w /v) trypsin and 0.001% (w /v) versene (EDTA) mixed in a 1:1 ratio. The cells were 
washed three times in medium and resuspended in 250µ1 of sterile distilled water. Cell 
viability was determined to be greater than 95% as assessed by nigrosin dye exclusion. This 
cell suspension was subjected to three 5- second pulses from an MSE Soniprep 150 at 
maximal power in order to lyse the cells. Each sample was cooled for 30 seconds at 0° 
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between each burst from the sonicator. 250µ1 of KC1 phosphate (40mM KPO4, 4.6% 
(w /v) KC1, 0.4mM EDTA, pH 7.7) was added to each sample before spinning at 13,000 
rpm (Eppendorf 5414 centrifuge). The supernatant was decanted leaving behind the pellet. 
Both fractions were stored at -70 °C. 
2.2.2 Preparation of Cell Membrane Fractions 
The pellet resulting from the procedure described in Section 2.2.1 was used as a 
crude membrane preparation. 
2.2.3 Preparation of Cell Nuclei Fractions 
The method described below was followed (A. Bartoszek, personnal 
communication). This method was loosely based on the method of Taylor et al, 1979 except that 
ficoll was used instead of sucrose to create a gradient. Cells from a 175cm2 flask (Nunc) 
were harvested with 0.1% (w /v) trypsin and 0.001% (w /v) versene, mixed in a ratio of 1:1. 
The cells were pelleted, then suspended in 1.5ml of buffer H and homogenised gently in a 
glass homogeniser with fifteen strokes of the plunger. The homogenate was transferred to 
an eppendorf and spun at 13,000 rpm for 5 minutes (Eppendorf 5414 centrifuge). The 
pellet that was formed was mixed with 0.5ml of buffer H. This was then mixed with 1.5ml 
of 20% ficoll (w /v) in buffer H and layered onto 4m1 of 20% ficoll (w /v) in buffer H. The 
nuclei were spun through the ficoll at 4° for 15 minutes at a speed of 5,000 rpm in a 
Sorvall RT 6000 (DuPont). 
The supernatant was gently aspirated off, taking care not to disturb the pellet. The 
pellet was rinsed with buffer H and suspended in l00111 of PBS. 1 -2.t1 of the nuclei 
suspension were loaded onto a prepared hemocytometer to verify the presence of intact 
nuclei. The nuclei were stored at -70 °C. 
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Buffer H 
10mM NaH2PO4; pH 8.0 
2mM Mg C12 
2mM DTT 
1mM EDTA 
2.3.0 Protein Estimation 
The method of Lowry et al (1951) was used to determine the protein content of the 
samples. Bovine serum albumin fraction IV was used as a standard and the following 
reagents were used to carry out the assay: 
A) 70mM NaCO3 10 H2O: 40mM NaOH 
B) 40mM CuSO4 5H2O 
C) 71mM NaK tartrate 
D) Stock Folin Ciocalteau reagent diluted 1:1 (v /v) with distilled water 
E) Alkaline copper solution which was made up fresh by adding 0.5ml of both 
solutions B and C and making the volume up to 50mis with solution A. 
The following technique was used for cytosol, crude membrane and nuclei 
preparations. The samples were diluted 1:200 (v /v) with 0.1 m NaOH to give a final 
volume of lml. 5m1 of solution E was added to the samples which were then vortexed and 
left for 10 minutes. 
1ml of solution D was then added, the samples vortexed again and left for 45 
minutes. Standard solutions of bovine serum albumin at 0, 25, 50, 80, 100, 120, 150 and 
200 .tg/ml were also treated in exactly the same way. 
The absorbance of the standard solution was measured at 600nm on a Schimadzu 
UV 160 spectrophotometer and a standard curve generated. The amount of protein in each 
sample was then measured and determined at 600 nm. 
A new standard curve was constructed each time a protein determination was carried 
out. Occasionally sample volume or protein concentration was low and so a microassay was 
used to assess the protein concentration of such samples. The above method was carried out 
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but the volume of samples and reagents used was reduced by a factor of 5 and the samples 
were diluted 1: 50. 
Standard protein concentrations were carried out in duplicate and sample protein 
determinations were carried out in triplicate. 
2 . 4 . 0 SDS Polyacrylamide Gel Electrophoresis 
The method used by Hayes et al (1979) based on the discontinuous buffer system 
developed by Laemelli (1970) was closely followed. A gel sandwich was prepared by 
inserting clean spacers between two clean plates of dimensions ( 12cm x 12cm ) and ( 12cm 
x 14cm) and inserting the sandwich formed between two clamps from the Biorad Protean 1 
apparatus (Biorad Laboratories, UK). This was then positioned on the base of the apparatus 
so that the glass plate sandwich was sealed on three sides ready for casting the gel. This 
was performed as follows: 
Firstly, the separating gel consisting of 14.8 mis of a solution containing 0.32% 
(w /v) N,N'- methylene bisacrylamide and 30% (w /v) acrylamide, 9.25 mis of stacking gel 
buffer (1.5m tris HC1, 0.5% [w /v]; SDS, pH 8.8) and 11.0 mls of distilled water, was 
prepared. This solution was mixed thoroughly and 2mls of a 1% (w /v) solution of 
ammonium persulphate followed by 20µ1 of N,N,N,N' -tetramethylene diamine (TEMED) 
was added in order to polymerise the gel. The gel solution was quickly mixed, poured to a 
height of 12 cm into the glass plate sandwich, overlayed with distilled water and left for 30 
minutes to allow polymerisation to occur. The overlay was then tipped off and a clean 15, 
20 or 25 track comb was inserted between the two glass plates. 
The stacking gel was then cast. This consisted of 1.5 mis of the acrylamide/bis- 
acrylamide solution used for the separating gel, 2.5 mis of stacking gel buffer (0.5M tris 
HC1, 0.5% [w /v] SDS, pH 6.8) and 5.7 mis of distilled water. This solution was mixed 
before adding 0.3 mls of 1% ammonium persulphate and 10111 TEMED. The stacking gel 
was then cast taking care to avoid formation of bubbles. The gel was left for 30 minutes to 
allow polymerisation to occur and then the comb was gently removed. 
The gel was then slotted onto the upper reservoir of the Biorad Protean 1 kit which 
also contained the cooling system. 1 litre of electrode buffer (0.52M tris, 0.53M glycine, 
35mM SDS, pH 7.3) diluted 1:10 (v /v) with distilled water, was added to the lower 
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reservoir. The upper reservoir was filled with electrode buffer diluted 1:10 with distilled 
water and the wells of the stacking gel were flushed to remove any debris. 
The protein samples were prepared by diluting them with distilled water and adding 
boiling mix (10% (v /v) stacking gel buffer, 2% (w /v) SDS, 5% (v /v) [3- mercaptoethanol, 
10% (v /v) glycerol and 0.005% (w /v) bromophenol blue) at a ratio of 1:1 to give a final 
protein concentration of 1 mg/ml. Samples treated in this way were heated to 100 °C for 5 
minutes prior to loading in order to denature and solubilise the proteins. The samples were 
loaded with a Hamilton syringe (Hamilton, Bonadoz, Switzerland). Standard purified GST 
proteins were treated in the same way as the samples. 
The upper reservoir was inserted into the tank containing the lower reservoir. The 
cooling system was switched on to provide a steady flow of cold water and the lid of the 
apparatus containing the electrodes was positioned. The current was maintained at 20mA 
per gel as the dye front ran to the bottom of the stacking gel and was increased to 30mA per 
gel as the dye front ran to 1cm above the bottom of the separating gel. 
If it was necessary to visualise the protein pattern after electrophoresis, the gels were 
removed from the glass plates by prising the plates apart. The stacking gel was removed 
and the separating gel was immersed in 0.25% (w /v) solution of Coomasie Brilliant Blue R 
in water /methanol /acetic acid solution in a ratio of 5:50:7 by volume and left for 1 hour. To 
destain the gel, it was transferred to a water /methanol/acetic acid solution in a ratio of 88:5:7 
by volume. After several changes of destain solution, the protein pattern was viewed on a 
light box. 
2.5.0 Western Blotting 
Western blotting was carried out according to the method of Towbin et al (1979) and 
modified according to Adams et al (1985). The method of SDS/PAGE as described in 
Section 2.4.0 was used to resolve the polypeptides in the samples under analysis. The gels 
were treated as follows. 
After removal of the stacking gel, the separating gel was trimmed by cutting along 
the dye front. If more than one gel was being analysed, small incisions were made at the 
bottom right or left hand corners of the gel to permit identification of the different gels. 
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The transblot cassette was pre- soaked in the electroblotting buffer (20mM Nat 
HPO4, 20% [v /v] methanol). The gel was orientated in the apparatus so that it was placed 
on top of a piece of 0.45 µM nitrocellulose which had been cut to the same size as the gel. 
This was sandwiched between two pieces of scotchbrite pad. The pad was placed into the 
transblot tank with the nitrocellulose nearest the anode. The tank was filled with 
electroblotting buffer and the gel blotted overnight at 0.25A. 
After transfer, the transblot kit was disassembled and the nitrocellulose removed. 
The nitrocellulose was washed for two 10 minute periods in TBST (50mM tris/HC1, pH 
7.9, 0.15M NaCl, 0.05% [v /v] Tween 20) before blocking in 3% (w /v) low fat milk in 
TBST, for one hour. 
After this procedure, the nitrocellulose filters were given four 10 minute washes in 
TBST before incubating with the specific GST antisera. The antisera was diluted 1:500 
(v /v) in TBST. 
Filters were given four 15 minute washes in TBST and then incubated for one hour 
in goat anti -rabbit IgG antibody conjugated to horseraddish peroxidase (Scottish Antibody 
Production Unit, Glasgow, Scotland) diluted 1:1000 (v /v) in TBST. Following four 15 
minute washes in TBST, the filters were incubated at room temperature in 200 mis TBS 
containing 0-1 M 4- chloro -l- naphthol and 8 µl of 30% (v /v) hydrogen peroxide, in order to 
visualise the bands. 
Subsequent to this, the filters were washed in distilled water before incubating them 
in 50 mis of TBST containing 0.19mBq 125I protein A for 1 hour. The filters were washed 
in several changes of TBST until the counts on the filter approached background levels as 
ascertained using a Geiger counter. After blotting dry, the filters were autoradiographed for 
differing time periods using Kodak Xar5 film. 
2.6.0 Isolation and analysis of nucleic acids 
2.6.1 Isolation of DNA 
1 x 175cm2 flasks (Nunc) of cell lines were harvested for DNA isolation using the 
method described in Section 2.1.5. The cells were washed three times in PBS and then 
suspended in 5 mis of lysis buffer (0.5% [w /v] SDS, 150mM NaC1, 10mM tris HC1, 10mM 
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EDTA, pH 7.5). The cells were shaken well and RNAse at a concentration of 10 .tl /m1 was 
added from a stock (10mg/m1) solution. 
This solution was incubated for 1 hour at 37 °C before adding pronase at a 
concentration of 50 tl /ml from a stock 5mg/m1 solution and incubating for a further 4 hours 
at 37 °C. At this stage 5m1 of TE (10mM Tris, 1mM EDTA, pH 8.0) buffered phenol was 
added and the solution shaken vigorously for 2 minutes before spinning at 3000 rpm in a 
Sorvall RT 6000 (Du Pont) at 4 °C for 10 minutes. The aqueous layer was removed and an 
equal volume of TE buffered phenol /chloroform mixture in a v/v ratio of 1:1 was added to it. 
The mixture was shaken and spun as above and the aqueous phase removed and extracted 
with chloroform. 
The aqueous phase formed after this last extraction was mixed with a half volume of 
7.5 M ammonium acetate and 2 volumes of absolute alcohol. The DNA was allowed to 
precipitate overnight at 4 °C and then spooled out using a pasteur pipette. It was air dried 
before dissolving in distilled water. 
2.6.2 Isolation of RNA 
The method according to Birboim (1988 ) was carried out on 175cm2 flasks (Nunc) 
of confluent cells. In order to minimise degradation of RNA by contaminating nucleases, 
plastic and glassware used for the procedure described below was treated with distilled 
water containing 0.1% DEPC for 12 hours before autoclaving the glassware and using the 
plastic. 
The media was removed and the cells washed with cold PBS before 5 ml of RES 
was added. The flask was swirled gently for 2 minutes until the monolayer of cells lifted 
off. The resultant lysate was transferred to a falcon tube and sonicated at low power on an 
MSE Soniprep 150 for 5 -10 seconds before adding 450.tí of pronase (1mg/m1 stock) and 
incubating at 50 °C for 30 minutes. 
The mixture was then cooled to room temperature and 500 µl of 2M sodium 
acetate and 17.5 ml of ethanol at -20 °C were added. The mixture was left for 20 minutes 
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at -20 °C before spinning at 10,000 rpm for 10 minutes in a Sorvall RC -5B (Du Pont) at 
0 °C. The pellet that was formed was dissolved in RES and extracted with chloroform. The 
aqueous phase was precipitated by incubating it with 15 pl of 2M acetic acid and 1 ml 
LiCl/ethanol overnight at 0 °C before spinning at 13,00 rpm (eppendorf 5414 centrifuge) for 




0.25% SDS (w /v) 
0.02% Sodium citrate 
25.0mM CDTA 
Final pH 6.8. 
LiCI /ethanol 
3 volumes 5m LiC1 
2 volumes ethanol 
CCS 
1mM Sodium citrate 
1mM CDTA 
0.1% (w /v) SDS 
pH 6.8 
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2.6.3 Spectrophotometric Quantification of DNA and RNA 
DNA and RNA concentrations were measured spectrophotometrically at 260 and 280 
nm. Concentrations of nucleic acid given below correspond to a change of 1 absorbance 
unit. 
1 absorbance unit at 260nm = 50mg/m1 for double stranded DNA 
= 40mg/m1 for single stranded DNA and RNA. 
The ratio between absorbance at 260 and 280 nm provides an estimate of the purity 
of the preparation. For a pure DNA preparation the OD260/OD280 ratio should be 1.8, and 
for RNA and the ratio should be 2.0. 
2.6.4 Southern Blot Analysis 
The DNA isolated by the method described in Section 2.7.0 was restricted using the 
endonucleases EcoRI, BamHI, HindlII and PstI. 10 µg of DNA was restricted in a total 
volume of 50 µl. To the appropriate volume of DNA was added 3 µl of the required 
restriction enzyme, 51.1.1 of the appropriate buffer, 5 p.1 of BSA (10mg/m1), 1 Ill of RNAse 
(10mg /m1), 2 tl of spermidine (5mM) and a volume of sterile distilled water to make the 
final volume 50 µl. This mixture was incubated overnight at 37 °C. 
Before preparation of the gel for Southern blotting, a mini gel was prepared to 
analyse cut and uncut DNA. This was to check the quality and loadings of the DNA and 
verify that DNA had been digested, where applicable. To do this, the procedure described 
below was scaled down and after gel electrophoresis, the gel was stained with ethidium 
bromide for 30 minutes, destained with water and visualised using a short wavelength trans - 
illuminator. 
For Southern blot analysis, a horizontal 1% (w /v) agarose gel in 1 x TAE buffer 
(0.4m Tris pH 8.2, 0.2m Sodium acetate, 10mM EDTA) was prepared (dimensions 20cm x 
25.0cm x 0.5 cm). Prior to electrophoresis, 21.1l of loading dye was added to digested DNA 
samples. 
Human liver DNA was loaded alongside human cell line DNA to act as a control. 
Using the BRL horizontal electrophoresis model 41, the DNA samples were electrophoresed 
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at 45V for 15 -20 hours or until the dye front was 5cm from the edge of the gel. The gel 
equipment was disassembled and the gel denatured in denaturing solution (0.5M NaOH, 
1.5M NaC1) and neutralised in neutralising solution (2M NaC1, 1m tris HC1, pH 5.5) for 45 
minutes and 1 hour respectively. 
The DNA was transferred to hybond paper by capilliary action in 10 x SSC (1.5 M 
NaC1, 0.15M tri- sodium citrate) as described by Southern (1975). The filter was then baked 
at 80 °C for 2 hours in a vacuum oven to fix the DNA. The gel was checked after this proces 
in order to confirm the successful transfer of the DNA. To do this the gel was stained in 
ethidium bromide for 1 hour, washed with water and viewed using a short wavelength 
transilluminator. 
The hybond filter was prehybridised at 65 °C for 4 -6 hours in pre -hybridisation mix 
in a heat - sealed plastic bag. A small incision was made in one of the top corners of the bag 
containing the filter and the prehybridisation mixture was removed. Hybridisation mixture 
at 65 °C was then added, taking care not to trap any bubbles. The bag was sealed once again 
and incubated for a further hour at 65&C. The probe, which had been radiolabelled as 
described in Section 2.6.7 was denatured by heating to 100 °C for 5 minutes and added to 
the bag. The bag was then sealed and the filter and probe allowed to hybridise for 16 -24 
hours at 65 °C. 
Following this, the filter was washed for 15 minutes in 2 x SSC (0.3M NaCl, 
0.03M tri- sodium citrate), 0.1% (w /v) SDS and 0.1% (w /v) NaPPi, followed by a further 
3 x 20 minute washes to remove the unbound probe. The filters were rinsed in 2 x SSC 
(0.3M NaC1, 0.03M tri- sodium citrate), air dried, wrapped in saranwrap and 
autoradiographed using Kodak XarS film. 
Pre -Hybridisation Mix 
5 x SSC 
4 x Denhardts 
10% (w /v) dextran sulphate 
0.1% (w /v) SDS 
0.1% (w /v)NaPPi 
50 µg herring sperm DNA 
Loading Dye 
0.4% bromophenol blue (w /v) 
0.4% xylene cyamol (w /v) 








5 x SSC 
4 x Denhardts solution 
10% (w /v) dextran sulphate 
0.1% SDS 
0.1% Na PPi 
2.6.5 Northern Blot Analysis 
For northern blot analysis, a horizontal 1.5% agarose gel in MOPS buffer (0.2M 
MOPS, 501aM NaOAc, 10mM EDTA, pH 7.0 ) containing 18% formaldehyde solution from 
a stock formaldehyde solution of 40% (v /v) was prepared. RNA samples were prepared by 
adding 3 volumes of sample buffer to the volume of RNA required to give a final 
concentration of 15 µg of RNA and heating to 50 °C for 30 minutes. 
The loading dye was added at a one -tenth volume prior to loading. The RNA 
samples were electrophoresed at 45V for 15 -20 hours or until the dye front was 5cm from 
the edge of the gel, in MOPS buffer, using a BRL horizontal electrophoresis model 41 
(BRL). 
The RNA was transferred by capilliary action in 10 x SSC (1.5M NaCI, 0.15 tri - 
sodium citrate) to hybond paper as described by Southern (1975). The hybond filter was 
rinsed in 2 x SSC (0.3M NaC1, 0.03 M tri- sodium citrate) and allowed to air dry before 
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irradiating it with U.V. from a short wavelength transilluminator for 2.5 minutes. The filter 
was then baked for an hour at 80 °C. 
In order to probe the filter, it was incubated for 4 -6 hours in a sealed bag with pre - 
hybridisation mix at 68 °C. The prehybridisation mixture was removed and hybridisation 
mixture added. The filter was incubated for a further hour at 68 °C before adding the probe 
which was denatured just before adding to the filter, by heating to 100 °C for 5 minutes. 
The hybridisation was allowed to proceed overnight. Following this, the filter was washed 
for 15 minutes in 2 x SSC (0.3M NaC1, 0.03M tri- sodium citrate) and for 2 x 30 minute 
periods in 2 x SSC (0.3M NaC1, 0.03M tri- sodium citrate) containing 0.1% (w /v) SDS and 
0.1% (w /v) NaPPi. The filter was air dried, wrapped in saranwrap and autoradiographed 
using a Kodak XarS film. 
Prehybridisation Mix 
6 x SSC 
2 x Denhardts 
0.1% (w /v) SDS 
0.1% Na PPi 
50 µg herring sperm DNA 
Sample buffer 
0.1M MOPS 




6 x SSC 
2 x Denhardts 
0.1% (w /v) dextran sulphate 
0.1% (w /v) SDS 
0.1% (w /v) Na PPi 
Loading dye 
0.4% bromophenol blue (w /v) 
0.4% xylene cyanol (w /v) 
50 % glycerol (v /v) 
1 mM EDTA 
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2.6.6 RNA slot blot analysis 
RNA was extracted by lysis in guanidine thiocyanate and centrifugation in a 
caesium chloride gradient(Maniatis et al, 1982). Duplicate slot blots were made with five 
doubling dilutions of total RNA (1014 to 0.62514) onto Hybond. The filters were prepared 
and probed with a full length GST pi cDNA (Kano et al, 1987) as described in sec tion 
2.6.5. Quntification of RNA was carried out by hybridisation with a human B (PHA 4.1) 
probe (Khalili et al, 1983). The blots were finally washed with 2x SSC (0.3M NaCI; 
0.03M ti- sodium citrate) containing 0.1% (w /v) SDS at 65 °C Kodak Xar film exposed at 
-70 °C for 1 -5 days was used for autoradiography. Relative levels of GST pi expression 
was determined by densitometry. 
2.6.7 Radiolabelling of cDNA probes 
Purified cDNA inserts contained within low melting point agarose were "oligo- 
labelled" according to the technique of Feinberg and Vogelstein (1983). Labelling was 
performed overnight at room temperature and 90 ng of DNA in a total volume of 3011l was 
used. The necessary solutions and constituents of the labelling reaction are as follows: 
Radiolabelling reaction mixture 
OLB 3µl 
BSA (1mg/m1) 2111 
Klenow enzyme 1 unit 
32PdCTP 5011Ci 
The procedure for labelling the probe is outlined below. 90ng of the cDNA to be labelled, 
contained in low melting point agarose, was heated to 100 °C for 3 minutes. As the DNA 
was cooling 3 111 of OLB was added. The mixture was cooled to room temperature, 
whereupon 2 111 of BSA, 19 .t1 of dH2O and 50 11Ci 32P dCTP were added. Finally the 
Klenow was added and the reaction left to proceed at room temperature overnight. 
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The amount of radioactivity incorporated into DNA was estimated by DEAE- 
cellulose paper chromatography in 0.3 M ammonium formate, pH 8.0. To do this, 1 1.1,1 of 
the labelling reaction was applied to a strip of DEAE cellulose and the chromatograph was 
run for approximately 30 minutes before air drying and autoradiographing for 30 minutes 
using Kodak Xar5 film. Probes that incorporated 50 -100% of the radioactive nucleotides 
were used for northern and Southern blotting. 
This was assessed by analysing the autoradiograph. Labelled probe remained at the 
origin while unincorporated nucleotides ran close to the solvent front. 
OLB 
OLB is a complex buffer consisting of solutions A, B and C which are mixed in the 
ratio 2:5:1 respectively. This stock solutions A, B and C can be stored for up to 3 months 
at -20 °C. 
Solution A 
625m1 of 2M tris HC1, pH 8.0 + 25 ml of 5m MgC12 + 350 ml of dH2O + 18 ml of 
mercaptoethanol + 5 ml of dATP, dGTP and dTTP (each tri- phosphate is dissolved in 3mM 
Tris/HC1, 0.2mM EDTA [pH 7.0] to give a concentration of 0.1M). 
Solution B 
2M HEPES titrated to pH 6.6 with NaOH. This solution is stored at 4 °C. 
Solution C 
Hexadeoxyribonucleotides suspended in 3mM Tris/HC1, 0.2mM EDTA (pH 7.0) to 
give a concentration of 90 O.D. units /ml. This is stored at -20 °C. 
2.7.0 Immunohistochemistry on fixed cell lines 
The tumour cell lines under investigation were cultured on 6cm diameter tissue 
culture petri- dishes (Nunc). Cells were plated at a density of 106 cells and incubated for 36 
hours to allow cells to adhere and be in the log stage of growth when they were fixed. 
Cells were fixed with a 50:50 (v /v) solution of methanol and acetone by first 
washing the cells three times with cold PBS and then pouring 2m1 of cold fixing solution 
onto the cells. The fixing solution was left on the cells for 2 minutes after which time it was 
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poured away. The plates were allowed to air dry before freezing them at -40 °C. 
When required, the fixed cells were thawed in such a way as to avoid fracturing of 
cells. To do this, 2 mis of fixing solution, that had been cooled on dry ice for 30 minutes, 
was poured onto the cells as soon as they were taken out of the freezer. This was left on the 
cells for 10 minutes before pouring away and allowing the plates of fixed cells to air dry. 
Sera containing antibody against the antigen under investigation was serially diluted 
in PBS containing 10% FCS. A grid was marked on the underside of the plate and 1 ill of 
each antibody dilution was spotted onto a square on the grid. This was incubated in a 
humid atmosphere for 2 hours at room temperature before washing the plates five times with 
PBS. 
Following this, the plates were incubated for 1 hour in a humid environment at room 
temperature with a 1:200 (v /v) solution of antirabbit IgG antibody conjugated to horseradish 
peroxidase (Scottish Antibody Product Unit, Glasgow, Scotland) diluted with PBS 
containing 10% FCS (w /v). (If antibodies had been raised in mouse then the cells on the 
plates were incubated with antimouse IgG antibody conjugated to horseradish peroxidase 
[Scottish Antibody Product Unit, Glasgow, Scotland]). 
Plates were again washed 5 times with PBS before adding the substrate 
diaminobenzene at a concentration of lmg/ml in PBS to which hydrogen peroxide, at a 
1:5000 (v /v) dilution was added immediately before developing the plates. 
This was left for 20 minutes to allow the colour to develop. The substrate was 
washed off with distilled water and the stained cells viewed and photographed. The controls 
used in this type of analysis were pre- immune serum from the animal in which the 
antibodies under investigations had been raised. 
2.8.0 GST activity determination 
Enzyme assays were either performed automatically using a Cobas Fara centrifugal 
analyser or were determined by a manual method on a Schimadzu MPS 200 
spectrophotometer. The method used was essentially the same as that described by Habig et 
al (1984b) where i,chloro -2,4- dinitrobenzene was used as a substrate and using the Cobas 
Fara, the assays were normally performed in triplicate. 
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Assays were performed in 100mM sodium phosphate buffer pH 6.5. Samples were 
pre- incubated with GSH prior to initiation of the reaction by addition of CDNB. Final 
concentrations of GSH and CDNB were 2mM and 1mM respectively. 
The conjugation of CDNB with GSH was measured by recording the absorbance of 
the reaction mixture at 340nm. A series of absorbance readings were taken. The first was 
taken 10 seconds after the reaction had been started and the other 7 at 5 second intervals 
thereafter. The enzyme activities measured were given as µmoles of product formed/min/mg 
protein. 
The non -enzymatic conjugation of CDNB with GSH was subtracted from the 
enzymatic conjugation. Using the Cobas Fara, linear regression analysis was performed 
using the manufacturers kinetic rate programme for the GST assay. A preprogrammed 
conversion factor was used and data from the CDNB assay was presented as change in 
absorbance (AA) /min /ml. The extinction co- efficient of 38 allowed conversion of these 
units to µmoles /min/mg protein. 
Using the manual method, the reaction was carried out in 100mM sodium phosphate 
buffer, pH 6.5 and the final concentrations of GSH and CDNB were 2mM and 1mM 
respectively. The non -enzymatic conjugation of CDNB to GSH was recorded at 340nm 
before the sample was added to the test cuvette. The enzymatic conjugation of CDNB to 
GSH was then recorded at 340nm. The change in absorbance (AA) was calculated per 
minute and converted to µmoles using the extinction coefficient of 38. The units of enzyme 
activity were given as µmoles of product formed /min/mg protein. 
2.9.0 Reverse phase HPLC and subsequent Western blot analysis of 
cell line cytosols 
The levels of B1 and B2 subunits were investigated using reverse hplc analysis 
according to the method of Ostlund Farrants et al (1987) followed by western blot analysis 
according to the method described in Section 2.5.0. A Waters reverse phase HPLC (Model 
510) machine was used. The column (Waters p.- Bondapak C -18 reverse phase column 
0.3cm x30cm) was washed through with 70% acetonitrile 
Two solvent mixtures ( A and B) were then attached to the equipment. (A) 
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consisted of 200 mis of acetonitrile, 300 mis of distilled water and 0.5 ml of trifluoroacetate. 
(B) consisted of 350m1s of acetonitrile, 150 mis of distilled water and 0.5 ml of 
trifluoroacetate. Both solutions were filtered prior to use. 
The equipment was then programmed to give the required mix of solutions A and B 
in order to create a gradient which washed through the column,Before switching in the 
gradient, a mixture of purified B 
1 
and B 2 subunits was applied to the column. The preset 
fraction collector and pen recorder were then switched on at the same time as the solvent 
flow which created the gradient. 
The absorbance of the protein eluted from the column, was measured at 280 nm. 
After analysis of the purified B 1 and B2 subunits, the column was washed through for 2 
hours with 70% acetonitrile -Cell cytosol containing 500 .tg of protein was then loaded onto 
the column. Trifluoracetate diluted 1:10 (v /v) was added to the cytosol before addition to the 
column, at a ratio of 1:3 (v /v) trifluoracetate to cytosol. The cytosol was eluted from the 
column as described for the B 
1 
and B2 subunits. 
Cell cytosol protein samples eluting in the same range of fraction numbers as B1 and 
B2 subunits were collected. The above procedure was repeated for the cytosol from several 
cell lines. Purified B 
1 
and B2 subunits were always used to calibrate the system prior to 
adding sample cytosol. 
The samples were prepared for western blot analysis as follows: The isolated 
fractions were freeze dried before adding 40 µl of a 1:10 (v /v) dilution of buffer (1.5 m 
Tris/HC1, 0.5% (w /v) SDS, pH 8.8) and 20 pl of boiling mix (10% [v /v] stacking gel 
buffer, 2% (w /v) SDS, 5% (v /v) ß- mercaptoethanol, 10% (v /v) glycerol and 0.005% (w /v) 
bromophenol blue). 
SDS polyacrylamide gel electrophoresis (Section 2.4.0) and western blot analysis 
(Section 2.5.0) were then carried out and the blots probed with an anti human B1 antibodies. 
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LIST OF SUPPLIERS 
The chemicals and equipment used were obtained from the following 
sources: 
Amersham Internatonal,Amersham, Buckinghamshire, U.K. 
P32CTP; dATP; dGTP; d1 11'; Hexadeoxyribonucleotides; 125I protein A; Hybond 
Anderman & Co Ltd., Kingston- Upon- Thames, Surrey. 
Nitrocellulose. 
Becton -Dickson, Cowly, Oxfordshire, U.K. 
Sterile syringes. 
B.D.H. Chemicals Ltd., Thonliebanh, Glasgow. 
EDTA; Hydrogen peroxide; Chloroform; Ammonium acetate; Ammonium formate; 
Acetone; Methanol; NaCI; KC1; NaH2PO3; KPO4LiC1; MgC12; NaCO3NaOH; 
CuSO4NaK tartrate; LiCI; Sodium citrate; Sodium tri- citrate; Sodium acetate; 
Biorad Laboratories, Watford, Hertfordshire. 
Ammonium persulphate; 4- chloro-l- napthol; Tween 20. 
B.R.L., Uxbridge, Middlesex, U.K. 
EcoRl; BamHl; Hindu l 1; Pstl; Costar serile 96 -well tissue culture plates; Formamide; 
Phenol (redistilled nucleic acid grade); Urea; Klenow; RNase; Pronase; Spermidine; 
Herring sperm DNA; Denhardts. 
Fisons, Loughborough, U.K. 
Mercaptoethanol. 
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GIBCO, Ltd., Paisley, Scotland. 
Foetal calf serum; RPMI 1640 media; Nunc sterile tissue culture flasks and plates 
Steptomycin; Penicillin; New born calf serum; Sterile Falcon tubes; Trypsin. 
Koch Light Laboratories, Colinbrook, Berkshire, U.K. 
Cumene hydroperoxide. 
Kodak Ltd., Kirby, Liverpool. U.K. 
Kodak Xar film. 
May and Baker, Dagenam, Kent, U.K. 
Absolute alcohol; Acetic Acid. 
Millipore (U.K.) Ltd., Harrow, Middlesex. U.K. 
Ultrafiltration membranes (0.4511M) ; Sterile syringe filters (0.2211M) 
Oxoid, Basingstoke, Hampshire, U.K. 
Phosphate buffered saline tablets. 
Pharmacia,Milton Keynes.U.K. 
Ficoll; Dextran sulphate 
Raeburn Chemicals Ltd., Walkerburn, Peebleshire, Scotland. 
Acetonitrile. 
Scientific Furnishings Ltd.,Macclesfield, Chesire, U.K. 
Hemocytometers. 
Sigma Chemical Co., Poole, Dorset, U.K. 
Insulin; Dimethyl sulphoxide; CDNB; Ethacrynic acid; nigrosin; MTT; BSA; 
Acrylamide; Bisacrylamide; Ethidium bromide; GSH; Folin Ciocalteau; DTT; Tris- 
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HC1; SDS; TEMED; Glycine; Agarose; Low melting point agarose; NaPPi; Xylene 
cyanol; HEPES; PVP; DEPC; MOPS; Formaldehyde; Glycerol; Coomasie brilliant 
blue R; CDTA; Glycerol; Diaminobenzene. 
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CHAPTER 3 
THE ROLE OF THE GLUTATHIONE S- 
TRANSFERASES IN RESISTANCE TO 
CYTOTOXIC COMPOUNDS 
3.1.0 INTRODUCTION 
Intrinsic and acquired drug resistance are of central importance in clinical oncology. 
The term intrinsic, or de novo, resistance is used to describe the situation where a cellular 
population which has not been exposed previously to any chemotherapeutic agent, can 
tolerate a particular drug at concentrations that are toxic to other cellular populations. In 
such cases the resistant population is thought to possess certain inherent "features" that 
allows it to survive drug concentrations that are cytotoxic to other cells. It is thought that 
the causal factors of intrinsic drug resistance, in a large number of cases, have evolved as a 
result of selection pressures that are totally unrelated to the drug to which tolerance is 
observed. Unfortunately, the cellular mechanisms and factors that bestow this resistance 
are, to a large degree, unknown. 
By contrast to intrinsic drug resistance, acquired resistance describes the process 
whereby a resistant cell population emerges from one which had initially been sensitive to 
the drug in question and is a direct result of exposure to the particular compound. In cancer 
chemotherapy, the major problem with acquired drug resistance is that as well as resistance 
to the compound to which the cellular population was initially exposed, resistance to a range 
of structurally and functionally unrelated drugs is often encountered. 
Factors that may account for this clinical observation have become apparent in the 
last few years and it has been found that they are often absent from a cellular population or 
present at low levels, before the cells are challenged with the drug. It has also emerged that 
several mechanisms may operate simultaneously and which mechanism is responsible for 
resistance is likely to depend on the nature of the drug to which cells were initially exposed. 
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In recent years there have been a growing number of reports that the glutathione S- 
transferases (GSTs) are involved in the process of drug resistance. However, in the 
majority of cases it has not been ascertained whether the reported overexpression of GSTs is 
a cause or an effect of drug resistance. In addition, only two of the antitumour agents 
commonly associated with the drug resistance have actually been shown to be substrates for 
the GST isoenzymes. One further criticism that can be made of the work in this area, is that 
although there are a growing number of reports that there is an increase in overall GST 
activity in several drug resistant cell lines, the identity of the GST subunits that are 
overexpressed is seldom investigated. 
In an attempt to clarify the role of the GSTs in both intrinsic and acquired drug 
resistance several tumour cell line models have been analysed in the work presented below. 
3.2.0 RESULTS AND DISCUSSION 
3.2.1 Intrinsic Resistance of Human Tumour Cell Lines to 
Alkylating Agents. 
In order to study the potential role the GST may play in clinically encountered 
intrinsic drug resistance, cytosolic fractions from four human tumour cell lines were 
prepared according to the Materials and Methods (Section 2.2.1). These cell lines were 
PE04, HT29, MCF7 and NC1H322 which had originally been derived from human ovarian 
colonic, breast and lung tumours respectively. The cytosolic fractions from these cells were 
subjected to western blot analysis according to the Materials and Methods (Section 2.5.0), 
and the blots were probed with antibodies that had been raised to purified human GST from 
the three cytosolic classes. The results are shown in Figure 3.01. 
From this analysis, it is evident that of the four cell lines, MCF7 expresses the 
lowest levels of GST. In this cell line there is no detectable class alpha, mu or pi 
expression. These results are comparable to those obtained by other investigators working 
on this cell line (Batist et ai 1986). These workers estimated the low overall GST activity of 
this cell line to be 3.6 nmol/min/mg. 
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Figure 3.01 GST subunit expression in the cytosol of four 
human tumour cell lines. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 and 
prepared as described in Section 2.2.1 
251,ig of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against purified subunits from the three known human 
cytosolic GST classes: alpha (B 1); mu (µ) and pi (it); Stds = Standard (purified protein); 
N = NCI H322; P = PE04; M = MCF -7 and H = HT29. 
ftleá.l.1111P, 41111 .m 
Class alpha 
Class mu 
41110 Class pi 
Stds N P M H 
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The other three cell lines, HT29, NCIH322 and PEO4 all express relatively high 
levels of the class pi enzyme. Of the three human cytosolic GST classes, the class pi 
subunit has been shown to have the widest distribution in different tumour cell lines (Batist 
et al, 1986; Deffie et al, 1988; Gupta et al, 1989). The significance of this is unknown, 
although it has been suggested that in tumour tissue, surgically removed from patients, the 
class pi subunit is elevated compared to normal surrounding tissue (Soma et al , 1986; Di 
Ilio et al, 1987; Moscow et al, 1989; Howie et al, 1990). Since most tumour cell lines are 
established from surgically- removed malignant tissue, it may not be surprising that 
overexpression of the pi subunit is commonly encountered in tumour cell lines. It is also 
interesting that high levels of the class pi subunit are observed in tumour types usually 
classed as being intrinsically resistant to chemotherapeutic agents, for example, colonic 
tumour tissue (Kodate et al, 1986; Moscow et al, 1989). 
Relatively little class alpha or mu subunit expression is detectable in any of the four 
cell lines analysed, although there is a low level of expression of the class alpha subunit(s) 
in the NCIH322 cell line (Figure 3.01). 
The four cell lines analysed in Figure 3.01 were studied with respect to their 
sensitivity to several toxic compounds. The MIT assay was used to test the sensitivity of 
PEO4, MCF7, HT29 and NCIH322 to 1- chloro -2,4- dinitrobenzene, ethacrynic acid and 
chlorambucil, TheMTT assay uses the fact that the dehydrogenase enzymes in the 
mitochondria of live but not dead cells can metabolise the compound [3-(4,5 - 
dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide], (MTT) to its tetrazolium salt. The 
latter product is blue and is used to assess the percentage of live cells by means of 
colorimetry (Carmichael,et al, 1987). Only HT29 and MCF7 were compared graphically to 
avoid confusion (Figs 3.02 to 3.04). These two cell lines were chosen since they 
exemplified cell lines with high and low GST content respectively. As can be seen, MCF7 
is more sensitive to the effects of CDNB, CHP and chlorambucil compared to HT29 as 
judged by the LD50 for these compounds; the LD50 is a measure of the dose of drug which 
is lethal to 50% of the cells. 
Although this evidence is very circumstantial, it does perhaps suggest that the 
intrinsic drug detoxification capacity, as exemplified in this work by GSTs, may determine 
















Fig.3.02 Sensitivity of HT29 and MCF7 human tumour lines 
to chlorambucil. 
MTT assays were carried out as described in the Materials and Methods. 
The values shown are the mean of triplcate determinations. 
L.D.50 = 3811M 
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Fig. 3.03 Sensitivities of HT29 and MCF7 human tumour 
cell lines to CDNB. 
MTT assays were carried out as described in the Materials and Methods. 
The values shown are the mean of triplicate determinations. 
L.D.50 MCF7 = 6.01.tM CDNB 
L.D.50 HT29 = 21.511M CDNB 
Fig.3.04 
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Sensitivities of HT29 and MCF7 human tumour 
cell lines to ethacrynic acid. 
MTT assays were carried out as described in the Materials and 
Methods. The values shown are the mean of triplicate 
determinations. 
L.D.50 MCF7 = 10µM ethacrynic acid 
L.D.50 HT29 = 30µM ethacrynic acid 
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detoxification capacity of a cell changes as a result of the carcinogenesis process. 
It has already been shown that preneoplastic foci in rat liver, which can be induced 
by various carcinogens including 2- acetylaminofluorene and 3- methyl -4- dimethylamine 
azobenzene, overexpress certain drug detoxification enzymes (Farber, 1984;Cowan et al,, 
1986;Carr, 1987). These include GST, glucuronyiansferases, DT- diaphorase and epoxide 
hydrolase. 
Although the results presented in Figures 3.01 to 3.04 may suggest a role for GSTs 
in the intrinsic drug resistant process, it is also necessary to inspect other factors thought to 
be involved in resistance. Other workers have analysed the P- glycoprotein contents of 
various tumour types in order to assess whether those types commonly classed as being 
intrinsically resistant, and so refractory to treatment, express higher levels of this protein 
than other tumour types usually classed as being responsive to treatment (Goldstein et al, 
1989). 
The picture to emerge from analyses of this nature is far from clear cut. However, in 
general it appears that tumour types that are particularly refractory to treatment express 
higher levels of P- glycoprotein than their more treatable counterparts. For example, colonic 
tumour tissue has been investigated by several workers (Moscow et al, 1989; Goldstein et 
11, 1989) and the majority of tumours analysed were seen to express high levels of mdr 1 
mRNA. However, the data presented by these workers also showed that some intrinsically 
resistant colonic tumours seem to express very low levels of P- glycoprotein which leads to 
speculation that other resistance mechanisms are operational in these cases. 
GSTs have also been analysed with respect to their expression in different tumour 
types. Again, the results are not at all clear cut. There does however seem to be a pattern 
emerging that the more intrinsically resistant tumours such as lung and colon express higher 
GST levels (Kodate et al, 1986; Moscow et al, 1989). 
3.2.2 Acquired Resistance of Human Tumour Cell Lines 
From the work on the four different cell -lines that has been detailed above, MCF7 
and NCIH322 were chosen as parent cell lines from which drug resistant variants would be 
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derived in order to study acquired drug resistance. Since much of the work described in the 
literature has failed to show that the drugs used to derive resistant cell lines can actually act 
as GST substrates, in this work, known GST substrates were used to derive resistant cell 
lines. 
(i) Selection of an MCF7 Subline Resistant to Ethacrynic Acid 
The MCF7 cell line has been used by various workers to create variant sublines 
resistant to several compounds ( Batist et al, 1986; Wheelan et al, 1990). From work of this 
nature, the MCF7 cell line appeared to be a reasonable choice because drug resistant lines 
have been successfully achieved in the past. The MCF7 cell line also seemed a very suitable 
model in which to study GSTs since the parent line had been shown to possess low levels of 
these enzymes. It had also been shown that the class pi enzyme at least, could be induced in 
this cell line (Batist et al, 1986). 
The derivation of an ethacrynic acid resistant MCF7 variant is detailed in Figure 
3.05. Unfortunately after this derivation had been in process for four months, the 
ethacrynic acid - treated cell line became contaminated with a yeast infection. The progress 
with this cell line had been so slow that only limited frozen stocks had been obtained. 
However, a minimum number of cells had been harvested which enabled a cytosolic fraction 
to be prepared. 
A western blot was carried out on the cell line and the results are shown in Figure 
3.06. As can be seen, there has been an elevation of the human mu subunit. This result is 
perhaps surprising since ethacrynic acid is a substrate for certain class alpha and pi enzymes. 
It is difficult to offer an explanation for this result due to lack of other available information. 
There are at present no published results showing that mu can be elevated in MCF7 in 
response to any of the chemicals that have been used to derive drug resistant variants. 
Recently, however, there has been a report that a class mu subunit is elevated in a rat 
gliosarcoma cell line made resistant to BCNU (Smith et al, 1989). In rat preneoplastic foci 
it has also been noted that rat class mu proteins can be elevated and it has been postulated 
that elevation is observed as a result of challenge by carcinogenic compounds (Cowan 1986; 
Carr 1987; Beer & Pitot 1987). 






















































































































































































Figure 3.06 Class mu subunit expression in the cytosols of 
wild type and ethacrynic acid resistant MCF -7 cells. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and prepared as described in Section 2.2.1 
25µg of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against a human class mu subunit (.t); Stds = 
Standard (purified protein); WT = wild type MCF -7; EAr = ethacrynic acid resistant 
MCF -7. 
Stds. WT EAr 
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that in the model described above, induction of the mu class subunit has occurred in order 
to fulfil a non -enzymic function. It has previously been shown (Yamada & Kaplowitz 1980) 
that hepatic class mu enzymes can bind ethacrynic acid covalently. In the model generated 
during this work, resistance to ethacrynic acid may have occurred as a result of increased 
drug binding resulting from the overexpressed class mu subunit. 
It is not possible to state the fold resistance exhibited by the MCF7 variant cell line to 
ethacrynic acid, since it was not possible to carry out an MTT assay on this cell line. The 
only available information on resistance is that 100% of the wild type cells were killed when 
subjected to the same concentrations of ethacrynic acid that the variant cell line could tolerate 
(ie. 251..t.m ethacrynic acid). 
(ii) Selection of an NCI H322 Cell Line Resistant to CDNB 
As previously mentioned the NCI H322 cell line was also chosen as a parent line 
from which to derive a variant,resistant to known GST substrates. NCI H322 is a human 
lung tumour cell line derived from an adenocarcinoma of the lung and is very similar to 
Clara cells in the features it possesses (Carmichael et al, 1988). The GST concentration of 
this cell line is comparable to the concentrations observed in preparations of human lung 
(Mukhtar et al 1981). 
This cell line was chosen for several reasons. Firstly, it was derived from a human 
tumour type which, as described in the Introduction is one that initially responds well to 
chemotherapy regimens but which often is associated with relapse as a consequence of 
emerging drug resistant populations (ie. acquired drug resistance). Secondly, the drug 
detoxification capacity of this cell line has already been examined since it has been used 
previously to study the cytotoxic effects of a number of compounds (Falzon et al 1986; 
Weibel et al, 1986). Thirdly, the parent cell line expresses class pi and, to a much lesser 
extent alpha class subunits (see Figure 3.01), showing that it possesses the transcriptional 
factors required for the expression of these two classes of enzyme. 
CDNB, which is a general substrate for all three cytosolic GST classes was used to 
derive a resistant variant. The derivation process is outlined in Figure 3.05. Progress with 
this human lung tumour cell line proved to more successful than with the MCF7 line. After 
eight months of continual culture in the presence of an incrementally increasing 
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concentration of CDNB, a cell line was derived that exhibited 2 -2.5 fold resistance to this 
compound compared to the parent line, as ascertained by the MTT assay (Figure 3.07). 
Cells were frozen down at various stages of the derivation process to safeguard 
against contamination. At the 8 month stage of derivation, the CDNB resistant line, termed 
CDNBr was cultured in the absence of CDNB. The phenotype was found to be stable and 
the observed changes which are described below were also stable in the absence of CDNB 
for at least 3 months (see Figures 3.14 and 3.15). 
The stability of the phenotype is discussed in more detail in Section 3.2.5. Since 
frozen stocks of the CDNBr cell line were available, analysis was only done on cells that 
had been in culture for no longer than 3 months. After this time, fresh cells were cultured 
from the frozen stocks. 
Figure 3.08 shows the microscopic appearance of both the wild type and CDNB 
resistant (CDNBr) cell lines. The cells of the resistant population display a more spiked 
morphology than the sensitive parental cells but the reason for this is unknown. However, 
there has been a report that cells treated with a tumour promoting compound show a change 
in their appearance similar to those reported in this thesis (Kitijama et al,, 1988). 
The underlying mechanisms responsible for these changes are unknown. It is also 
unknown whether these changes have any role in the resistance these cells exhibit to CDNB. 
It may be that the cytotoxic effects of the drug have caused alterations in membrane or 
cytoskeletal structure, which may in some way allow the cells to resist concentrations of 
CDNB that would normally be toxic. 
3.2.3. Expression of the Human Cytosolic GST in the 
CDNB Resistant NCIH322 Cells. 
Initially the overall GST activity was analysed according to the method of Habig et 
al, (1974b) using CDNB as a diagnostic substrate. A marked increase in activity towards 
CDNB was observed in the resistant subline (Figure 3.09). The parent cell line had an 
overall GST activity of 28± 10 units and the CDNBr line had an overall GST activity of 
375 +30 units. Other workers have reported increases in GST activity in many drug - 
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Fig.3.07 Sensitivity of wild type (W /T) and CDNB resistant 
(CDNBr) cell lines to CDNB. 
MTT assays were carried out as described in the 
Materials and Methods. The values shown are the 
mean of triplicate determinations. 
L.D.50 WT = 5.5µM CDNB. 
L.D.50 CDNBr = 12.011M CDNB. 
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Figure 3.08 Microscopic appearance of wild type and CDNB 
resistant NCI H322 cells. 
Cells were viewed at a x 200 magnification and photographed. 
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Fig 3.09. Overall Gst activity in WT and CDNB'. 
Cells were harvested and cell cytosol fractions prepared as 
described in the Materials andMethods (sections 2.1.5 and 2.2.1). 
GST activity was assessed using CDNB as a substrate according 
to the Materials and Methods (section 2.8.0 ) 
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increases in the GST activity which have been observed in these studies is between 1.5 
and 5.0 -fold, with the notable exception of the adriamycin resistant MCF 7 cell line 
( Batist et al, 1986) where GST activity was found to be elevated 15 to 45 -fold. In the 
CDNBr cell line developed in this thesis, the elevation in GST activity towards CDNB 
is the order of 15 -fold. 
The changes in expression of the individual GST subunits were then investigated in 
the CDNBr line. GST subunit expression as well as being analysed in the cytosolic fraction 
was analysed in both cell membrane and nuclei preparations. In order to study the cytosolic 
fraction, both WT and CDNBr cytosols were subjected to western blot analysis and probed 
with antibodies raised against purified human GST subunits from the three cytosolic classes 
(Figure 3.10). The blots demonstrate a marked overexpression of both human class pi and 
alpha subunits. No evidence for class mu expression in either the wild type or CDNBr cell 
lines was observed. 
The reason for absence of the mu class GST is unclear but it may be that the 
NCI H322 cell line was derived from an individual who was nulled for the mu subunit. It 
has already been shown that 45% of the human population are nulled for the mu subunit 
and it has been proposed that individuals with the null phenotype are more susceptible to 
lung cancer if they smoke (Seidegard et al, 1986). 
Since CDNB is a general substrate for all classes of cytosolic GST (Table 1.4) , the 
overexpression of alpha and pi class subunits strongly indicates that, in this model, the 
overexpressed proteins are conferring resistance to CDNB. Although it is impossible to rule 
out other factors that may be conferring resistance, this information taken together with the 
results of Black et al (1990) are strong evidence in favour of this proposal. In the work by 
Black et al (1990) human cDNAs encoding ir and B1 subunits were cloned into vectors 
and when expressed in yeast cells were found to confer resistance to CDNB, cumene 
hydroperoxide, chlorambucil and adriamycin. 
In the increasing number of drug resistant models reported in the literature where 
various GST subunits are overexpressed (see Table 1.5), it has been suggested that the 
GST may contribute to resistance by detoxifying drugs through catalysing the conjugation 
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Figure 3.10 GST subunit expression in the cytosol of wild 
type and CDNB resistant NCI H322 cells. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and prepared as described Section 2.2.1 
25µg of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against subnits from the three known human cytosolic 
GST classes: alpha (B1); mu (.t) and pi (it). 
Stds = Standards (purified protein); WT = wild type NCI H322 cells; CDNBr = CDNB 
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of the drug with GSH (Hayes & Wolf, 1988). However, more supportive evidence for this 
would come from studies showing that the drugs in question are indeed GST substrates. 
Dulik et al, (1986) have isolated melphalan -glutathione conjugates whose formation was 
shown to be catalysed by certain GSTs, although the identities of the GST subunits 
responsible for catalysis were not established. 
Smith et al (1989) have examined the role of GSTs in resistance to 1,3- bis(2- 
chloroethyl)-4- nitrosourea (BCNU). These workers derived a rat brain tumour line resistant 
to BCNU and when this cell line was analysed, elevated mu class GST activity was 
observed. Using a range of cytosolic GSTs they also showed that the rat class mu proteins 
were by far the best catalysts of BCNU denitrosation reactions, leading the authors to 
speculate that class mu overexpression was at least partially responsible for the observed 
resistance to BCNU. 
Further and more comprehensive evidence that GSTs play a causal role in resistance 
to certain anticancer drugs would come from purifying and characterising the GSTs that are 
overexpressed in resistant cell lines. It would then be necessary to show that the GSTs in 
cell lines resistant to antitumour agents are capable of catalysing detoxification reactions 
involving the drug to which resistance is seen. Information of this nature is eagerly awaited. 
3.2.4 Analysis of Alpha Class Subunit Expression in 
CDNB Resistant NCI H322 Cells 
The western blot analysis presented in Figure 3.10 demonstrates a marked 
overexpression of both human class pi and alpha subunits. However, it is not possible to 
discriminate between the alpha class B 
1 
and B2 GST subunits by western blotting. The data 
presented in Figure 3.10 do not indicate whether B1 or B2 or indeed both are elevated in the 
CDNBr cells. 
In order to clarify the situation with respect to B1 and B2 expression, whole cell 
cytosols of both WT and CDNBr cell lines were subjected to reverse phase HPLC analysis 
according to the method of Ostlund - Farrants et al (1987), since B1 and B2 alpha class 
subunits can be resolved by this technique (Hayes et al, 1990). The results are shown in 
Figure 3.11. 
Purified human B 1 and B 2 subunits were initially applied to the µ- Bondapak HPLC 
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Figure 3.11 Purification of B1 and B2 subunits from wild 
type (WT) and CDNB resistant (CDNB')) cell lines. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and prepared as described in Section 2.2.1 The cytosolic fractions were subjected to HPLC 
analysis as described in Section 2.9.0. The purified protein fractions were subjected to 
SDS/PAGE, transferred to nitrocellulose and probed with specific antibodies to the human 
B subunit. 
89 and 98 = Fraction numbers giving highest absorbance reading at 280 nm during 
collection of fractions. 
(89) 
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column to establish the retention times of those subunits. Immediately following calibration, 
whole cell cytosol from the WT cell line was applied to the column and subsequently eluted. 
The fraction numbers corresponding to those in which B and B2 had been eluted were 
collected. The column was washed, the procedure repeated for the standard B and B2 
proteins, the column was washed again and the procedure was then repeated for whole cell 
CDNBr cytosol. 
The protein concentration of WT and CDNBr cytosols loaded onto the column were 
equivalent. The fractions that had been collected for both WT and CDNBr lines were 
analysed by western blotting. As can be seen from Figure 3.11, both B and B2 are 
overexpressed in the resistant cells. The WT cell line contains slightly more B2 subunit 
(approximately 2 -fold) as judged by the intensity of the immunoreactive bands. However, 
in the CDNB r cell line, the reverse is true in that there seems to be slightly more B than B2 
subunit overexpression 
These data indicate that B is elevated in the CDNB r line to a greater extent than B 2. 
If time had permitted, quantitative data regarding B1 and B2 overexpression could have been 
obtained using the R.I.A. technique developed by Hayes et al (1983); this technique also 
differentiates between B and B2 subunits. 
The results shown in Figures 3.10 and 3.11 raise the question of which factors 
govern the regulation of the B1 and B2 subunits. It has already been shown that these two 
proteins, although 96% homologous, are the products of two different genes (Hayes et al, 
1990). It may be that their regulation by certain regulatory factors in certain instances, is 
tightly linked and that factors leading to elevation in one subunit also lead to elevation in the 
other. 
3.2.5. Stability of GST overexpression in the CDNB Resistant Cells. 
The stability of overexpression of the B1, B2 and 7C subunits was investigated and 
correlated with the stability of the CDNB resistant phenotype. During the derivation of the 
CDNBr cell line, once resistance to CDNB had reached about 2 -2.5 -fold a further increase 
in resistance proved to be unattainable. At this stage CDNB was removed from the cells and 
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this cell line was termed CDNBr. The analyses described above were carried out on these 
CDNBr cells. Some cells however were maintained in the presence of CDNB.This cell line 
is termed CDNBr(2) for convenience. 
The GST profile of WT, CDNBr and CDNBr(2) was analysed one month after the 
CDNB had been removed from CDNBr but maintained on CDNBr(2). The results are 
shown in Figure 3.13. In the CDNBr(2) cell line it was found that the expression of the 
class alpha GST had reverted back to the levels seen in the WT cell line despite the fact this 
cell line was grown in the presence of CDNB. 
However in CDNBr, after the initial eight month derivation process in the presence 
of CDNB, the class alpha protein expression remained elevated for at least three months in 
the absence of CDNB ( Figs 3.14 and 3.15 ). The class pi subunit remained elevated in 
both CDNBr and CDNBr(2) irrespective of whether the cell line was grown in the presence 
or absence of the drug. 
In terms of the stability of overexpression of the GST subunits, it would seem 
that It overexpression is stable whether or not CDNB is present. The class alpha GST 
overexpression, however, does not seem to be stable if the CDNB resistant cell line is 
grown for a prolonged period of time in the presence of CDNB. If CDNB is removed after 
the maximum resistance to the drug is obtained, the B 1 and B2 subunits remain elevated for 
at least 3 months (Figs. 3.14 and 3.15 ). 
The relationship of the change in GST subunit expression in CDNBr and CDNBr(2) 
to CDNB resistance in these two cell lines was analysed using the MIT assay. The results 
are shown in Figures 3.16 and 3.17. 
It is apparent from these cytotoxicity assays that resistance to CDNB is not 
maintained in the CDNBr(2) cell line. One conclusion that could be drawn from these data, 
is that it is the overexpression of the B 1 and B2 subunit which is responsible for the 
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Figure 3.13 Stability of alpha and pi class subunit 
overexpression in cells grown in the presence or absence of 
CDNB, one month after maximum resistance to CDNB had been 
observed. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and prepared as described in Section 2.2.1 
2514 of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against subunits from two known human cytosolic 
GST classes: alpha (B1); and pi (it); Stds = Standard (purified protein); WT = wild type 
NCI H322 cells. CDNBr = CDNB resistant NCI H322 cells (cultured in the absence of 
CDNB, after the initial 8 month derivation period). CDNBr (2) = CDNB resistant NCI 
H322 cells (cultured in the presence of CDNB after the initial 8 month derivation period. 
Class pi 
Class alpha 
Stds. WT CDNBrCDNBr 
(2) 
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Figure 3.14 Stability of class alpha and pi subunit 
overexpression in the CDNBr cell line during length of time in 
culture. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and prepared as described in Section 2.2.1 
251.1.g of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against known subunits from human alpha and pi 
class cytosolic GST. Alpha (B1); pi (ir); Stds. = Standard (purified protein); WT = Wild 
type NCI H322 cells; A to J = CDNB resistant cell line following removal of CDNB. 
Time (in days) after CDNB had been removed following the 8 month derivation procedure 
of CDNBr: 
A = 1 day B = 10 days C = 19 days D =25 days 
E = 31 days F = 35 days G = 35 days H = 39 days 
I = 39 days J = 42 days. 
Class alpha 
Class pi 
Std. WT A B C D E F G H I J WT 
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Figure 3.15 Stability of the class alpha and pi subunit 
overexpression in the CDNBr line during length of time in 
culture. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and prepared as described in Section 2.2.1 
25µg of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against known subunits from human alpha and pi 
class cytosolic GST. Alpha (B1); pi (it); Stds = Standards (purified protein); WT = wild 
type NCI H322 cells; 1 to 5 = CDNB resistant cell line following removal of CDNB. 
Time (in months) after CDNB removed, following the 8 month derivation procedure of 
CDNBr: 
1 = 1 month 2 = 1.5 months 3 = 2 months 4 = 2.5 months 
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Fig. 3.16 Sensitivity of wild type (WT) and CDNB resistant (CDNBr) 
cell lines to CDNB. 
MTT assays were carried out as described in the Materials and Methods. 
The values shown are the mean of triplicate determinations. 
% surv. = Percentage survival. 
L.D50 WT = 8.0 µM CDNB. 
L.D.50 CDNBr = 14.0 µM CDNB. 
--a- % surv WT -*- %surv CDNBr(2) 
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Fig. 3.17 Sensitivity of wild type (WT) and CDNBr(2) cell lines to 
CDNB. 
MTT assays were carried out as described in the Materials and Methods. 
The values shown are the mean of triplicate determinations. 
% surv. = Percentage survival. 
L.D.50 WT = 8.0µM CDNB. 
L.D. 50 CDNBr (2) = 9.0µM CDNB. 
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observed CDNB resistance in the CDNBr cell line. 
However if these class alpha proteins alone could confer resistance to CDNB, this 
raises questions as to why the class pi subunits is elevated in the CDNBr cell line. It may be 
that while the class alpha subunits provide specific protection from CDNB cytotoxicity 
through an increase in detoxification of this compound, the class pi subunit is involved in a 
more generalised stress response. The involvement of GSTs in the stress response 
phenomenon is discussed in more detail in Chapter 5. 
The sensitivity of CDNBr and CDNBr(2) to cumene hydroperoxide was also 
analysed using the MIT assay (Figures 3.18 and 3.19). These analyses indicate that both 
CDNBr and CDNBr(2) are resistant to CHP (the resistance of CDNBr to CHP is discussed 
in more detail in section 3.2.8). However, from these results it would seem that the class 
alpha subunits overexpressed in the CDNBr cell line are only partially responsible for the 
resistance of this line to cumene hydroperoxide (CHP) since the CDNBr(2) cell line, which 
no longer overexpresses B1 and B2, is still resistant to cumene hydroperoxide. It is evident 
from the LD50 of CDNB r and CDNBr(2) that the latter cell line is slightly more sensitive to 
CHP in that the LD50 of CDNBr(2) is 66µM CHP and the LD50 of CDNBr is 82.51.M CHP 
compared to the WT cell line. 
This result could be explained by the fact that resistance to CHP may be conferred by 
both the class alpha and pi GST subunits. However, the class pi subunit has been shown 
to exhibit little activity towards hydroperoxides and so the results shown in Figures 3.13 
and 3.19 taken together, would seem contradictory to this. One explanation for these results 
could be that the class pi overexpression does not confer resistance to CHP by means of 
detoxifying this compound, but rather by detoxification of harmful compounds that may be 
formed due to the action of CHP in the cell. 
Whatever the mechanism, the results in Figure 3.13 and 3.19 do suggest that class pi 
120 -cr- % surv. WT -*- % surv. CDNBr 
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Fig. 3.18 Sensitivity of wild type (WT) and CDNB resistant (CDNBr ) 
cell lines to cumene hydroperoxide. 
MIT assays were carried out as described in the Materials and Methods. 
The values shown are the mean of triplicate determinations. 
% surv. = Percentage survival. 
L.D.50 WT = 37.5 µM CHP. 
L.D. 50 CDNBr = 82.51.tM CHP. 
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Fig. 3.19. Sensitivity of wild type (WT) and CDNBr (2) cell lines to 
to cumene hydroperoxide. 
MIT assays were carried out as described in the Materials and Methods. 
The values shown are the mean of triplicate determinatons. 
% surv. = Percentage survival. 
L.D.50 WT = 37.511M Cl-íP. 
L.D.50 CDNBr (2) = 6611M CHP. 
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overexpression alone can provide some degree of protection against CHP. The results of 
Figures 3.13 and 3.18 taken together suggest that protection against CHP is enhanced if 
class alpha subunits are concomitantly overexpressed with the class pi subunit. 
The results seen here with prolonged culture in the presence of CDNB (Figure 3.13) 
raises several interesting questions as to the actual mechanism of regulation of the B 
1 
and B2 
subunits. As previously discussed these proteins are the products of two different genes 
( Tu & Quian, 1986; Rhoads et al, 1987; Hayes, et al, 1990). 
From the work presented here it would seem that the control of their expression may 
be tightly linked. How prolonged exposure to CDNB could cause levels of the B1 and B2 
subunits to return to those seen in the WT cell line is intriguing. Since it is not known how 
the protein levels were elevated in the first instance, it is not possible to say what mechanism 
is responsible for their levels returning to those seen in wild type cells. 
One possibility is that during prolonged culture in the presence of CDNB, which has 
already been shown to be mutagenic to prokaryotes and so could possibly have the same 
effect on eukaryotes, some regulatory factor common to both B 1 and B2 becomes mutated. 
This may in turn cause the levels of B 1 and B2 to return to those seen in the wild type cell 
line. Alternatively DNA sequences on the B 
1 
and B2 genes that respond to the regulatory 
factors may themselves become mutated. This would possibly mean that the B1 and B2 
genes would not longer respond to the regulatory factors and so the genes would be down 
regulated. 
The stability of class alpha and pi subunit overexpression during the length of 
time of culture of CDNBr was also analysed (Figures 3.16 and 3.17). It is obvious from 
this analysis that overexpression of both alpha and pi class subunits is stable for at least 
three months in the CDNBr cell line, that is, at least three months after the CDNB has been 
removed once maximum resistance to CDNB is obtained. As mentioned earlier in this 
chapter, the CDNBr cell line was never cultured for longer than three months before the 
original frozen stocks were returned to and fresh cells were cultured. 
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3.2.6 Expression of Microsomal GST in CDNB Resistant 
Cells 
GST expression in both nuclear and microsomal fractions was also analysed. The 
microsomal fraction was in fact a crude membrane extract ( Materials and Methods, Section 
2.2.2). The pellet obtained during the preparation of cytosolic fractions from cell lines was 
used in western blotting experiments to investigate the expression of the human microsomal 
GST in both WT and CDNBr lines (Figure 3.20). Expression of the microsomal protein 
was observed in both wild type and CDNBr cell lines but there was no significant difference 
in the level of expression in either WT or CDNBr lines. The Mr of the membrane -bound 
protein that cross -reacted with the anti -microsomal GST antibody is 14 000 and is distinct 
from the Mr of the cytosolic enzymes, which range from 24 800 - 27 500 Daltons (Hayes & 
Mantle, 1986). The expression of the microsomal GST in tumour samples and tumour cell 
lines is not well documented and so its relevance to drug resistance is unknown. 
Recently Clapper & Tew et al (1989) have reported that a rat mammary tumour cell 
line resistant to chlorambucil expresses a "novel" microsomal GST which is not expressed 
in the parent cell line. The microsomal GST these authors report as novel is not recognised 
by antibodies to the human rat microsomal enzyme. However, this "novel" GST has the 
same Mr as the cytosolic enzymes and it is recognised by antibodies raised against certain 
rat cytosolic GST subunits. It is feasible that the microsomal fraction prepared in this work 
is contaminated with cytosolic proteins and that the GST being recognised in the microsomal 
fraction is a cytosolic enzyme. For this reason more information is required before the 
protein seen in the microsomal fraction of the chlorambucil- resistant rat mammary cell line 
can be defined as novel. 
3.2.7 Expression of the Human GST subunits in the nuclei of 
CDNB treated cells 
Nuclei were isolated from both WT, CDNBr and CDNBr (2) NCIH322 cells 
(Materials and Methods, section 2.2.3). After the final stage of the isolation procedure, the 
nuclei fraction was examined microscopically under high power to verify the presence of 
nuclei. This fraction was then subjected to western blot analysis and the nuclei preparations 
109 
Figure 3.20 The expression of the human microsomal GST in 
the membrane fraction of WT and CDNBr cell lines. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5 
and a membrane fraction prepared according to Section 2.2.2 
2514 and 50 p.g of soluble protein (as shown below) was subjected to SDS/PAGE, 
transferred to nitrocellulose and probed with specific antibodies raised to the human 
microsomal GST. 
WT = wild type NCI H322 cells. 
CDNBr = CDNB resistant NCI H322 cells. 
69K 
46K 
WT CDNBr WT CDNBr 
25µg 25µg 50µg 50µg 
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probed with antibodies to human class alpha, mu and pi cytosolic enzymes (Figure 3.21). 
Only the class pi GST was detectable in the nuclei fraction and there was an apparent 
increase in the expression of this protein in the nuclei of the CDNBr (2) line. The 
significance of this observation is not known. However, it is possible that the elevation of 
this subunit in the nuclei is a response to the harmful effects of CDNB. 
CDNB is a known sulphydryl agent and as such is capable of damaging proteins and 
so disrupting DNA replication. CDNB has been shown to have mutagenic effects on 
Salmonella typhimurium when subjected to the Ames test (Kerklaan et al, 1987). It is 
unknown whether this compound can cause DNA damage in eukaryotic cells but it is likely. 
CDNB may have various sites of toxicity causing damage to both DNA and proteins. 
If this compound does have genotoxic effects, it is possible that the apparent elevation in the 
pi subunit in the nuclei of CDNBr (2) cells may have occurred in response to DNA damage. 
Recent evidence (Tan et al, 1988; Meyer et al 1989) has shown that certain GST 
isolated from rat liver nuclei have high activity towards DNA peroxides. Although these 
workers failed to demcnstrate the presence of class pi enzymes in the nuclei they isolated, 
they used rat liver, ° which does not express pi class GST as an enzyme source. The 
subunits Tan et al (19E8) isolated from rat liver nuclei were 1 and 2 (class alpha), 3 and 4 
(class mu) and a subunit homologous but not identical to subunit 5, termed 5 *. 
In the work presented in Figure 3.21 class alpha and mu enzymes were not detected 
in the nuclei from either WT or CDNBr cells. In a study of the response of NCI H322 
cells to heat shock, an elevation of the mu class GST subunit was observed in the nuclei 
fraction of these cells (A. Hall - Personal Communication). 
Until the exact mechanism of toxicity of CDNB has been accurately ascertained, it is 
difficult to state the reason for the overexpression of pi class GST in the nuclei of the 
CDNBr (2) cell line. It may be that GST subunits overexpressed in nuclei, in this case the 
class pi enzyme, are involved in some sort of stress response. This could also possibly 
account for the observed overexpression of the mu subunit in cells challenged with elevated 
temperatures (A. Hall - Personal Communication). The role of the GST in a stress response 
is discussed in more detail in Chapter 5. 
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Figure 3.21 Expression of human GST classes in nuclei 
isolated from WT, CDNBr and CDNBr(2) cell lines. 
Cells were harvested from confluent tissue culture flasks as described in Section 2.1.5. 
and a nuclei fraction prepared according to Section 2.2.3 
5014 of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against subunits from the three known human 
cytosolic GST classes. Alpha (B1); pi (ic) and mu (.t). Stds = Standards (purified protein); 
WT = wild type NCI H322 cells; CDNBr = CDNB resistant NCI H322 cells (cultured in the 
absence of CDNB, after the initial 8 month derivation period). 
CDNBr(2) = CDNB resistant NCI H322 cells (cultured in the presence of CDNB after the 
initial 8 month derivation period) 
Class alpha 
Class mu 
"" Class pi 
Stds. WT CDNBrCDNBr 
(2) 
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The purity of the nuclei fraction isolated in this work is of importance since 
anomalous results have been obtained by some workers using different types of nuclei 
isolation proceduresmcCuskeret a1,1989It is possible that proteins from the cytosol may have 
been co- isolated with the nuclei so that what is possibly seen in Figure 3.21 is cytosolic 
GST contamination. 
3.2.8 Cross Resistance Patterns of the CDNB resistant cells 
The cross resistance of the CDNBr to other toxic compounds was also examined. 
The results from the analysis using cumene hydroperoxide are shown in Figure 3.22. As 
can be seen, CDNB r is approximately 2.5 -fold resistant to cumene hydroperoxide compared 
to the wild type line as ascertained from the LD50's. 
Cumene hydroperoxide is an organic hydroperoxide and a diagnostic substrate for 
both selenium- dependent and selenium- independent glutathione peroxidase. It is a highly 
toxic compound since it acts as a peroxidising agent. Lipid peroxidation is a complex chain 
reaction which can cause detrimental effects to cellular membranes and releases toxic 
breakdown products which may then go on to damage other important cellular 
macromolecules (Slater 1984; Ketterer et al, 1987). 
Examples of some breakdown products of lipid metabolism are compounds such as 
lineoleate hydroperoxide and arachidonate hydroperoxide. These substances have also been 
shown to be good substrates for the class alpha GSTs (Tan et al, 1984; Ketterer et al, 1987) 
and it is postulated that detoxification of lipid peroxides by GST is one mechanism of 
protection from potential cellular damage by the peroxides (Ketterer et al, 1987). This 
hypothesis is supported by the evidence from experiments carried out with cumene 
hydroperoxide during this project. 
It has been shown in the work presented in this thesis that the class alpha GST 
subunits (B1 and B2) are overexpressed in the CDNBr cell line (see Figures 3.10 and 3.11) 
and that as well as exhibiting resistance to CDNB, this cell line is also resistant to cumene 
hydroperoxide (Figure 3.22). Supportive evidence that the class alpha subunits 
overexpressed in the CDNBr line protect against the damaging effects of cumene 
hydroperoxide comes from the work of Black et al (1990) in which the B1 subunit was 
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Fig. 3.22 Sensitivity of wild type (WT) and CDNB resistant 
(CDNBr) cell lines to cumene hydroperoxide. 
MIT assays were carried out as described in the 
Materials and Methods. The values shown are the 
mean of triplicate determinations. 
L.D.50 WT = 30.0µM CHP. 
L.D.50 CDNBr = 82.511M CHP. 
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was examined. It was found that the yeast strain expressing the B 1 subunit was, by 
comparison to the wild type strain, resistant to cumene hydroperoxide. 
It is likely that cumene hydroperoxide and 1- chloro -2,4- dinitrobenzene cause their 
toxic effects through distinct mechanisms. Specifically, cumene hydroperoxide leads to lipid 
peroxidation whereas CDNB forms covalent bonds with proteins through reactions with 
sulphydryl groups and can also potentially cause DNA damage. However, it has been 
shown in this work, albeit indirectly, that tumour cells may exhibit resistance to compounds 
with different structures and different modes of toxicity through a single mechanism. In this 
case, it is postulated that resistance to both CDNB and cumene hydroperoxide has arisen as 
a result of elevated GST activity. The work by Black et al (1990), which is of a more direct 
nature, supports this hypothesis. 
The situation regarding the CDNB r cell line may be analogous to that seen in other 
mammalian tumour cell lines resistant to a range of toxic anticancer agents. However, in 
these drug resistant models the structures and mechanisms of lethality of the antitumour 
drugs are more diverse than those of the compounds discussed above. As stated in the 
Introduction, the routes by which tumour cells exhibit resistance to these anticancer agents is 
the subject of continuing intensive research but the emerging picture is that no one 
mechanism is solely responsible for all instances of resistance to a single drug. It is 
becoming evident that resistance is multifactoral. It is possible that the GSTs due to their 
broad substrate specificities may be an important factor in the resistance process to several 
classes of drugs. 
In this piece of work it was assumed that if the GST play a causal role in drug 
resistance, then theoretically the CDNBr cell line, which overexpresses both class alpha and 
pi subunits, would exhibit cross resistance to some of the anticancer agents commonly 
associated with this process. 
The results of cytotoxicity assays using a range of antitumour drugs are shown in 
Figures 3.23 to 3.26. It is evident that in this CDNBr model, the overexpressed GST 
subunits are not conferring resistance to the drugs analysed. Although initially discouraging 
and seemingly contradictory to certain results obtained by other workers (Manoharan et al, 
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Fig. 3.23 Sensitivity of wild type (WT) and CDNB resistant 
(CDNBr) cell lines to adriamycin. 
MTT assays were carried out as described in the Materials 
and Methods. The values shown are the mean of triplicate 
determinations. 
















Fig 3.24 Sensitivity of wild type (WT) and CDNB resistant (CDNBr) 
cell lines to melphalan. 
MIT assays were carried out as described in the Materials 
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Sensitivity of wild type(WT) and CDNB resistant 
(CDNBr) to chlorambucil. 
MTT assays were carried out as described in the Materials 
and Methods. The values shown are the mean of triplicate 
determinations. 
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Fig 3.26 Sensitivity of wild type (WT) and CDNB resistant 
(CDNBr) cell lines to mitoxantrone. 
MTT assays were carried out as described in the Materials 
and Methods. The values shown are the mean of triplicate 
determinations. 
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the multifactoral nature of drug resistance, other necessary proteins were not co- induced 
with the GSTs in this particular cell line. Unfortunately, it was outwith the scope of this 
project to investigate other cellular factors thought to be involved in the drug resistance. 
Another possibility which again is in disagreement with Black et al (1990) and 
Puchalski et al (1989) is that in many of the drug resistant models generated (see Table 1.5), 
the observed increase in GST activity seen in drug resistant variants relative to parent lines, 
is incidental. Although increased GST activity may not be the direct cause of resistance in 
many of the models generated to date, the number of workers reporting this kind of finding 
tends to suggest that these enzymes do have an important role to play in the resistance 
process. The significance or exact role of GST overexpression in these models remains an 
unanswered question. It has been postulated that GST may be involved in a more 
generalised stress response mechanism and that challenging cells with toxic anticancer drugs 
elicits such a response, which may contribute to resistance (Hayes & Wolf, 1988; Lewis et 
al, 1988). 
Whatever the role the GSTs have in drug resistance, it is clear from the work 
presented in this thesis that in the particular model generated during this project the GST 
subunits overexpressed in the CDNBr cell line do not confer resistance to the anticancer 
drugs analysed in Figures 3.23 to 3.26. The overexpressed subunits may however confer 
resistance to CDNB and cumene hydroperoxide showing that these proteins can afford 
protection against certain cytotoxic compounds of dissimilar structure and functon. 
It is evident from the work of others (Manoharan et al, 1987; Puchalski et al, 1989; 
Black et al, 1990) that GSTs do have the potential to confer resistance to certain compounds 
such as adriamycin and chlorambucil. Based on evidence of this nature and further work 
showing that certain anticancer drugs can act as substrates for different GST subunits (Dulik 
et al, 1986; Smith et al, 1989), it would seem that GSTs can confer resistance to a number 
of antineoplastic drugs. It is therefore likely that in many of the models referenced in Table 
1.5, the increased GST activity that is observed is at least partially responsible for the 
resistance to the drugs described. 
As drug resistance can be conferred by a number of mechanisms, it is important that 
future analysis of resistant cell lines is conducted in such a way as to identify as many 
resistance mechanisms as possible in a given cell line. At present this is seldom achieved in 
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the majority of analyses of this nature. 
Another unanswered question in the field of drug resistance is just how the resistant 
population arises. It could be due to a sub population of cells that already expresses the 
factors that confer resistance and which is selected out in the presence of drug concentrations 
that are toxic to the majority of cells in the population. Alternatively, in response to toxic 
drug concentrations, cells may have the capacity to induce the factors which confer 
resistance. 
In the CDNBr model discussed here, it is not possible to say how the cellular 
population arose which overexpressed both elevated pi and alpha class subunits. The 
mechanism by which these subunits were elevated was, however, addressed. 
3.2.9 Molecular Basis for the Alpha Class GST 
Overexpression 
The work of several investigators has shown that GST overexpression in various 
drug resistant models can occur via several routes. For example, the adriamycin resistant 
MCF -7 cell line has been analysed with respect to mechanism of class pi overexpression 
(Cowan et al, 1986; Batist et al, 1986). In this cell line the class pi subunit is elevated at 
least 45 -fold. This change in protein level has been shown to be accompanied by an 
increase in the mRNA coding for this subunit. However, no increase in gene copy 
number has been observed. These results indicate that the elevation seen at the protein level 
occurs either by an increase in transcription rate or by a stabilisation of the pi mRNA. 
In the work by Robson et al (1986; 1987), the Chinese hamster ovary cell line 
resistant to chlorambucil showed a marked increase in the Yc class alpha subunit. Upon 
examination, there was found to be an increase in both the mRNA levels and gene copy 
number as determined by northern and Southern blot analysis respectively (Lewis et al, 
1988). The protein over -expression therefore appears to be a result of an increase in 
transcription due to gene amplification. 
To examine whether the overexpression of alpha and pi class GST is due to 
transcriptional activation, gene amplification or protein stabilisation Southern and northern 
blot analyses were performed on both the WT and CDNBr lines. The Southern blots 
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(Figures 3.27 and 3.28) indicate that the overexpression of both the alpha and pi class 
subunits is not a consequence of gene amplification. 
Northern blot analysis (Figure 3.29) indicate that the increase in the levels of the B 1 
and B2 subunits is not accompanied by a notable elevation of mRNA levels encoding these 
GST. 
It is possible therefore, that the alpha class subunits have been stabilised and so their 
turnover rate is slower than that seen in the WT cell line. Alternatively, there may have been 
an increase in the rate of translation of protein from the mRNA. 
Other workers (McClarty et al, 1988) investigating the protein ribonucleotide 
reductase in a hydroxyurea resistant mouse cell line, have shown overexpression of two 
protein subunits (M1 and M2), which are responsible for the activity of the enzyme. This 
overexpresson at the protein level could be attributed to increases in the levels of mRNA for 
both subunits when the cells were cultured in the presence of hydroxyurea up to a certain 
concentration. However, when concentrations of the drug were increased still further, there 
was a further elevation of the M1 and M2 subunits. This was not accompanied by further 
increases in the mRNA levels. Pulse chase experiments indicated that the half lives of both 
polypeptides were increased approximately two -fold. This could be accounted for by protein 
stabilisation. . 
The information presented in Figures 3.27 to 3.29 taken together with the work 
discussed above (Cowan et al, 1986; Batist et al, 1986; Robson et al, 1986; Robson et al, 
1987; Lewis et al, 1988) illustrate that GST overexpression may occur via a variety of 
routes. The factors that determine which mechanism is operational remain to be elucidated 
and are far from obvious. However, the type of drug to which cells are exposed as well as 
the length of time of exposure are likely to be important determinants. As discussed earlier, 
the tissue of origin of the tumour cells may determine whether transacting factors are present 
or absent and hence influence the ultimate mechanism responsible for GST overexpression. 
Regulation of GST expression has received much attention in recent years (Ding & 
Picket, 1985; Picket, 1987; Daniel et al, 1987; Cowell et al, 1988; Telahowski -Hopkins t 
al, 1988). However, this work has focussed predominantly on regulation of GST 
expression in the rat. Whether parallels can be drawn between regulation of the rat and 
human GST genes remains to be established. 
122 
Figure 3.27 Southern blot analysis of WT and CDNBr cell 
lines probed with a cDNA to a human alpha class subunit. 
DNA was isolated from cells as described in Section 2.6.1 
20µg of DNA was digested with (A) EcoRI, (B) Barn HI and (C) Pst I., separated by 
electrophoresis on a 1% agarose gel, transferred to hy- bondTM membrane and hybridised 
with a nick translated [32P] labelled full length cDNA clone (Board & Webb,1987) 
Liv = control human liver DNA 
WT = DNA from wild type NCI H322 cells. 
CDNBr = DNA from CDNB resistant NCI H322 cells. 
A B C 
LIV WT CDNBr LIV WT CDNBr LIV 
WT CDNBr 
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Figure 3.28 Southern blot analysis of WT and CDNBr cell 
lines probed with a cDNA to the human pi subunit. 
DNA was isolated from cells as described in Section 2.6.1 
20µg of DNA was digested with (A) Eco RI, (B) Barn HI and (c) Pst I, separated by 
electrophoresis on a 1% agarose gel, transferred to hy- bondTM membrane and hybridised 
with a nick translated [32P] labelled full length cDNA clone (Kano et al, 1987) 
Liv = control human liver DNA. 
WT = DNA from wild type NCI H322 cells. 
CDNBr = DNA from CDNB resistant NCI H322 cells. 
A B C 
osi 
ION 
LIV WT CDNBr LIV WT CDNBr LIV WT CDNBr 
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Figure 3.29 Northern blot analysis of WT and CDNBr cell 
lines probed with a cDNA to a human alpha class subunit. 
RNA was isolated from cells as described in Section 2.6.2 
151.1.g (WT and CDNB') and 5, 10 and 15µg (liv) was electrophoresised on a 1.5% agarose 
gel, transferred to hy- bondTM and hybridised with a nick translated [32P] labelled full length 
cDNA clone (Board & Webb, 1987). 
liv = control human liver RNA 
WT = RNA from wild type NCI H322 cells 
CDNBr = RNA from CDNB resistant NCI H322 cells 
0.94 Kb - 
LIV LIV LIV WT CDNBr 
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A model for mechanism of regulation of a rat Ya gene is shown in Figure 1.4. It has 
been shown that planar aromatic compounds such as 3- methylcholanthrene and 
phenobarbital can induce the rat liver Ya subunit (Telakowski- Hopkins 1988). The 
proposed mechanism of induction, as outlined in Figure 1.4 , is that the planar aromatic 
compound binds to the dioxin receptor forming a complex. The ligand receptor complex is 
then translocated to the nucleus. Here it causes transcriptional activation of the Ya gene by 
interacting with a regulatory sequence that is known to be responsive to planar aromatic 
compounds (see Section 1.2.8 (ii)). This is only one of several proposed mechanisms of 
action. 
Whether other compounds, such as antineoplastic drugs cause elevation of GST 
subunits via mechanisms similar to the one outlined above is not known. However, it is an 
area of research which must surely yield exciting results. 
Whether factors that are involved in the control of GST expression are also involved 
in regulation of other resistance mechanisms awaits clarification. It is noteworthy however, 
that oncogenes have been shown to increase expression of both GST pi and P- glycoprotein 
concomitantly (Burt et al, 1988). 
Further evidence is necessary before conclusions regarding coordinated regulation of 
resistance mechanisms can be reached. The data available suggests that certain proteins 
involved in resistance can be co- induced but it depends on the model. 
3.3.0 CONCLUSION 
The data presented and discussed above are in agreement with the results presented 
by a number of workers (Black et al, 1990). In recent years, a growing number of reports 
have appeared in the literature of increases in GST subunit expression in cells challenged 
and made resistant to cytotoxic antitumour agents. 
As more has become known of the GST and their biochemical characteristics, 
attention has focussed on a potential role for the GST in the drug resistance phenomenon. 
Supportive evidence for this role has come from results showing that when cDNAs coding 
for certain GST subunits are transfected into eukaryotic cells, resistance to certain agents is 
conferred (Black et al, 1990). Further to this, results have been presented showing both 
melphalan and BCNU can act as substrates for certain GSTs (Dulik et al, 1986; Smith et al, 
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1989). 
From the available evidence, it seems that the GST may have the potential to confer 
resistance to cytotoxic drugs as a result of the GST catalysed formation of drug -glutathione 
conjugates. However, much of the work in this field has involved derivation of cell lines 
resistant to antitumour agents and measurement of overall GST activity. Changes in 
individual subunits and ability of these subunits to catalyse detoxification of the drug are 
seldom investigated. Many of these cell lines have also exhibited cross resistance to other 
anticancer drugs and GSTs have been speculated to be involved in this phenomenon as a 
result of their broad range of substrate specificities. 
Since the compound used to generate the CDNBr cell line discussed in the preceding 
Chapter, is a known GST substrate, it is very likely that the CDNB resistance demonstrated 
by this line, is a direct result of elevation of the class alpha and pi GST subunits. That 
resistance to cumene hydroperoxide is also observed, suggests that GSTs do indeed have the 




GLUTATHIONE S- TRANSFERASE 
EXPRESSION IN LEUKAEMIA CELLS 
4.1.0 INTRODUCTION 
Although tumour cell models have been used predominantly to investigate the 
possible mechanisms involved in the drug resistance phenomenon, their relevance to the 
clinical situation is uncertain. Work comparing the expression of P- glycoprotein mRNA in 
normal and tumour tissue has sometimes yielded ambiguous results (Bell et al, 1985;Ma et al 
1987) and it has become obvious that P- glycoprotein is not the only factor involved in this 
process. If chemotherapy drug regimens are to prove effective, the underlying mechanisms 
responsible for drug resistance must be elucidated in clinically significant tumour 
populations. 
The information obtained from resected tumours is perhaps questionable. Solid 
tumour masses consist of a heterogenous cell population and the cells in the middle of a 
tumour mass are likely to differ considerably from those cells on the periphery. For 
example, cells within a single tumour will receive markedly different levels of blood supply 
and it is reasonable to assume that the oxygen and nutrient supply are likely to be more 
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accessible to those cells on the periphery of the tumour than those in the centre of the tumour 
mass. 
Much of the work carried out on tumour samples has involved homogenising pieces 
of resected tumour tissues that may consist of cells from various regions of the tumour. The 
results from analyses of homogenised tumour tissue are difficult to interpret if one considers 
that different tumour cell types are mixed during the preparative procedures. 
It may therefore prove that haematological cancers provide a more homogenous 
model with which to work. This kind of malignancy has the advantage that it can be 
separated into different cell populations and these can then be analysed individually. 
4.2.0 RESULTS AND DISCUSSION 
In this study, class pi GST expression in human leucocytes was investigated for a 
series of haemopoietic malignancies and compared with levels found inperipheral leucocytes 
of normal control subjects. Nine patients with myelodysplastic syndrome (MDS), a pre - 
leukemic state, 21 patients with acute myeloblastic leukemia(AML) [5 treated, 5 secondary 
and 11 relapsed or refractory patients] and 32 patients with chronic lymphocytic leukemia 
(CLL)[7 untreated and 25 treated] were analysed. 
The levels of P- glycoprotein mRNA expression had previously been investigated in 
the same samples that were analysed in this study (Holmes et al, 1989; Holmes et al, 
1990b). From these previous results it is apparent that although P- glycoprotein expression 
is elevated in some leukemia samples, it is not in others. This raises questions as to the role 
of P- glycoprotein in the drug resistance process. Although it appears from the work of 
Holmes et al (1989; 1990b) that P- glycoprotein may be involved indrug resistance in some 
instances, it is also obvious that other mechanisms may be operational in other instances. 
For this reason, GST pi expression was examined in the same samples previously analysed 
by Holmes et al (1989; 1990b). 
As described in the Materials and Methods section, RNA slot blot analysis was used 
to investigate mRNA levels of class pi GST in both leukaemic and normal control 
leucocytes. The RNA was quantified using densitometry readings and normalised for any 
loading differences using readings obtained from actin RNA densitometry measurements on 
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the same samples (Holmes et al, 1990a). 
All the measurements obtained from the leukaemia samples were compared to the 
measurements obtained from total peripheral leucocytes collected from ten normal control 
subjects (4 men, 6 women.) ranging in age from 23 to 83 .The lowest densitometry 
measurement from this panel of normal leucocytes was designated as being 1 arbitary unit. 
The level of class pi mRNA expression ranged from one to three in these normal samples 
(Table 4.1). Leukaemia samples showing RNA levels of 4 arbitary units or more were 
classed as having elevated GST pi expression (Table 4.1). Of the patients with MDS, a low 
grade neoplastic proliferation of haemopoietic stem cells which often develops into acute 
myeloblastic leukaemia, 8 out of 9 patients showed increased expression of class pi mRNA, 
the range being 4 -10 arbitary units.These patients were all treated with intermittent or 
continuous low dose chlorambucil. 
Of the 21 patients with acute myelodysplastic leukemia (AML), 12 patients showed 
elevated class pi mRNA expression. Of these, 4 out of 5 were untreated patients (6 -8 units), 
1 out of 5 was a secondary AML (ie. secondary to previous chemotherapy and radiotherapy 
for carcinoma of the breast; 6 units) and 7 out of 11 were patients with relapsed or refractory 
AML (4 -24 units). 
Thirty two patients with chronic lymphocytic leukemia (CLL) were also analysed. 
Of 7 untreated patients, 3 showed elevated class pi GST mRNA levels (5 -27 units) while 21 
out of 25 treated CLL patients showed increased class pi GST mRNA expression (4 -28 
units). Figure 4.1 shows representative examples of MDS, AML and CLL showing elevated 
levels of GST pi mRNA compared to normal control leucocytes. The loadings of the RNA 
on these blots was standardised against actin RNA from the same samples.(results not 
shown) 
The relevance of this data to drug resistance is not known neither are the mechanisms 
whereby GST pi mRNA levels are elevated. This could be attributable to gene 
amplification, mRNA stabilisation, an increase in mRNA transcription or any combination 
of these. 
In addition to the actual mechanism of mRNA overexpression, the cellular events 
leading to induction /overexpression are also unknown. It is possible that some event during 














































































































































































































Figure 4.1 GST pi overexpression in MDS, AML and CLL 
samples 
Representative RNA slot blots from (a) Normal leucocytes and patient with (b) MDS (c) 
AML and (d) CLL. 
One arbitary unit represents the level of GST pi expression demonstrated in normal 
leucocytes. 









has already been shown that some oncogenes can lead to induction of both pi class mRNA 
and P- glycoprotein mRNA in cells which are transfected with the ras oncogene (Li et 
a1,1988) and oncogenes are known to be aberrantly expressed in cancer cells. 
Class pi GST expression has received much attention in recent years since it has 
become evident that it can be used as a marker for preneoplastic lesions in rat liver cells. It 
is hypothesised that exposure to carcinogens results in altered rat liver foci that overexpress 
a range of phase II drug detoxification enzymes including class pi GST (Farber, 1984). 
Since certain cancers are known to result from carcinogen induced changes it is possible that 
cancer cells may already be selected for increased class pi GST expression. This may in 
turn provide further protection from challenge with other cytotoxic compounds such as 
antitumour agents. This is, however, hypothetical and awaits clarification but it is 
interesting to note that the lymphoblastic cell line CEM ( derived from a leukaemia) 
expresses high GST pi (9 units) relative to normal leukocytes (Table 4.1). 
There are also many other examples in the literature where class pi GST is found to 
be overexpressed in tumour tissue relative to normal surrounding tissue and it is possible 
that this is a result of the carcinogenesis process (Soma et al, 1986; Di Ilio et a1, 1988; 
Moscow et a, 1989). 
Other workers looking at haemopoietic malignancies have also shown increases in 
GST pi expression in the leucocytes of leukaemia patients compared to normal control 
leucocytes (McQuaid et al, 1989; Moscow et al, 1989). However, although there are now 
many examples in the literature of increases in class pi GST expression in tumour tissue 
relative to normal surrounding tissue, the relevance of this to drug resistance is unclear and 
the information available largely circumstantial. 
It is necessary to show that class pi GST can lead to resistance by detoxifying the 
anticancer drugs to which resistance is exhibited or by detoxifying metabolites produced by 
the action of the antitumour agents. Until this information is available, the results in this 
field of active research will remain circumstantial. 
There is relatively little information available on haemopoietic malignancies but the 
data emerging from work on other tumour types shows that class pi GST is generally 
elevated in tumours derived from colon (Kodate et al, 1986; Moscow et al, 1989; Howie et 
ál, 1990) stomach (Tsutsume et al, 1987; Howie et al, 1990) and lung (Di Ili° et al, 1988; 
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Moscow et al, 1989; Howie et al, 1990). It is interesting that lung, colon and gastric 
tumours derive from tissues that are associated with increased carcinogen exposure and it is 
possible, as discussed previously, that increases in class pi GST levels may reflect 
carcinogen induced changes similar to those seen in rat hyperplastic nodules. 
As stated earlier, the samples analysed in this study had already been examined with 
respect to their mdr 1 mRNA levels of expression (Holmes et al, 1989; Holmes et al, 
1990b). The results from the mdr 1 mRNA work and the work presented here were 
compared. Little correlation between class pi GST and mdr 1 mRNA levels in these 
leukemia samples was seen. This is shown graphically in Figure 4.2. Using Spearman's 
Rank order correlation, non -significant negative correlation was found between mdr 1 and 
class pi GST expression in both MDS (r = -0.412) and AML specimens (r = -0.314). 
Positive correlation between mRNA expression of these two proteins was seen in the CLL 
samples. However the correlation was weak (r = 0.335, p = 0.05 two tailed test). 
It is also evident in these leukaemia samples, that other mechanisms of resistance 
may also be operational in certain intances as there are those samples which express neither 
protein. Recently, there has been a report of low levels of DNA topoisomerase II in CLL 
(Potmesil et al, 1988). These workers suggested that this may be a clinically significant 
route to a drug resistant state for those tumours with a large population of non -proliferating 
cells. 
The picture with regards to resistance to anticancer agents is becomining increasingly 
complex. That it is a multifactional process is obvious. However, the factors that determine 
which mechanisms operate in a tumour population at a given time are less clear. This is but 
one of the many challenges to workers in this field. 
Although the work discussed above detailing mRNA levels of the class pi GST 
expression in human leukemia samples provides informative data, it is also necessary to 
investigate the protein levels of class pi GST since ultimately it is the proteins that establish 
the phenotype of cells by their ability to catalyse chemical reactions.To this end leucocyte 
samples from leukaemia patients (all AML) of Professor Bob Souhami and normal healthy 
volunteers were compared using the western blot technique. 
At the time the Western blot analysis was carried out, the origin of each sample was 
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results are shown in Figure 4.3. As can be seen, the class pi GST protein is detectable in 
the majority of the samples but it is evidently expressed at higher levels in the leukaemia 
samples. No class alpha or mu protein was detectable in any of the samples analysed 
(results not shown). 
These data are consistent with the results presented above with respect to class pi 
GST mRNA overexpression and the discussion in relation the overexpression of pi mRNA 
in leukaemia samples is also applicable to the results presented in Figure 4.3. However, it 
should be noted that where possible DNA, RNA and protein expression should be examined 
within the same sample so that not only may the mechanism of overexpression be potentially 
assessed but a true picture of the functional unit ie. the protein, be ascertained. 
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Figure 4.3 Expression of the human pi GST subunit in the 
cytosolic fractions of leucocytes from controls and leukaemia 
patients. 
Cell cytosols were prepared as described in section 2.2.1 
25µg of soluble protein was subjected to SDS/PAGE, transferred to nitrocellulose and 
probed with specific antibodies raised against the human class pi subunit (7c). Stds. = 
standards; N = nomal controls; T = leukaemia patients. 
mega r eiositik deo r er-. 
Stds N N T N N N Stds 
t 
T T T T T T T T T 
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CHAPTER 5 
THE ROLE OF THE GLUTATHIONE 
S- TRANSFERASES IN A STRESS 
RESPONSE 
5.1.0 INTRODUCTION 
The work described in Chapter 3 revealed that in a lung tumour cell line made 
resistant to 1- chloro -2,4- dinitrobenzene, both alpha and pi class GST subunits were 
overexpressed. Initialy this cell line was derived in order to examine the role of the GST in 
the phenomenon of drug resistance but the elevated expression of alpha and pi class subunits 
did not appear to confer resistance to any of the antitumour agents analysed in this model 
(see Figures 3.23 to 3.26). The changes with respect to GST expression, that occurred in 
the CDNBr line did however afford protection against cytotoxic insult from cumene 
hydroperoxide Fig. 3.22). 
As well as being implicated in certain drug resistance models, it has also been 
suggested that the GSTs may play a role in the stress response (Lewis,1988; Hayes & Wolf, 
1990). This response describes the process whereby a cellular population can adapt to 
protect itself against a number of physiological stresses. These include heat shock, high 
oxygen concentrations, ultra- violet irradiation, alcohol, osmotic shock, pH changes and 
viral infections (Burdon, 1986; Lindquist, 1986; Pelham, 1986; Subjeck & Thung -Tai, 
1988; Yalkinoglu et al, 1988). 
Besides affording protection against the actual physiological insult endured, it has 
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been shown that the stress response may also result in protection against the toxic effects of 
certain drugs (Li and Hahn, 1978; Li et al, 1982; Li, 1987). The mechanisms whereby 
cellular populations protect themselves from certain physiological stresses are unclear. 
The response to heat shock is the most well studied and understood stress response. 
During this process a transient arrest in cell growth has been noted which is accompanied by 
a block in the synthesis of DNA, RNA and protein. Concomitant with this arrest of 
macromolecule biosynthesis is an increase in transcription of a small number of genes that 
code for the heat shock proteins (hsps) (Welch et al, 1989). It is thought that expression of 
these hsps confer resistance to potentially lethal temperature increases. 
The mechanisms by which the hsps may confer thermotolerance on cells is to a large 
extent unknown as are the exact functions of the majority of these proteins. It is thought that 
members of the hsp 70 family are involved in protein -protein interactions (Welch et al, 
1989). 
The hsps have been shown to interact with p53, which is a protein expressed in the 
nuclei of cancer cells. p53 has also been shown to be induced by carcinogens and 
oncogenes (Pinhasi -Kimhi et al, 1986). The hsp 70 proteins may also be involved in actin 
microfilament reassembly and also recovery of nuclear morphology following exposure to 
abnormally high temperatures (Pelham, 1986; Burdon, 1986). 
Other proteins of higher and lower molecular weight than the hsp 70s have also been 
shown to be induced in response to certain stresses (Burdon, 1986). However, they remain 
poorly characterised. 
The idea that the GSTs may in some way be involved in a stress response has arisen 
from several lines of evidence. Certain enzymes involved in the metabolism of glutathione 
have been implicated in the protection of prokaryotes from oxidative stress and glutathione 
itself has been postulated to participate in the induction of a stress protein (Christman et al, 
1985; Shelton et al, 1986). 
In the work that is described and discussed below, the expression of certain stress 
response proteins was analysed in the CDNBr line. The relationship between expression of 
stress response proteins and the sensitivity of the WT and CDNBr cell lines to elevated 
temperatures was also analysed. 
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5.2.0 RESULTS AND DISCUSSION 
5.1.0 Expression of p53 in WT and CDNBr cell lines 
The expression of hsp 70 and the nuclear protein p53 in both WT and CDNBr cell lines was 
analysed using the technique of immunohistochemistry. These analyses were carried out as 
detailed in the Materials and Methods Section 2.7.0 
The results using monoclonal antibodies to different epitopes on p53 are shown in 
Figures 5.01 and 5.02. It is evident from these results that the expression of this protein is 
elevated in the CDNBr line as judged by the intensity of immunohistochemical staining of 
the nuclei. 
One notable feature in the nuclei of the CDNBr cell line in Figures 5.01 and 5.02 is 
the apparent increase in size of the nuclei. The reason and implication of this is unknown. It 
is possible that DNA replication has occurred, but for some reason the nuclei have failed to 
divict'. 
The elevated expression of p53 in the nuclei of the CDNBr cell line would be 
consistant with the report that hsp 70 can act to stabilise p53 (Pinhasi -Kimhi et al, 1986). It 
is possible that the observed elevation of p53 seen in the CDNBr model is the result of hsp 
70 mediated stabilisation of this protein since hsp 70 is also seen to be elevated in CDNB r 
(See section 5.2.0). 
It is possible that hsp 70 has the capacity to stabilise other proteins and that is one of 
the ways that cells expressing stress response proteins such as hsp 70 can resist abnormally 
high temperatures. It has recently been speculated that hsp functions are concerned with 
refolding and/or removal of denatured proteins when they are damaged by conditions such 
as elevated temperatures and pH changes (Welch et al, 1989). 
140 
Fig 5.01 Immunohistochemistry using a monoclonal 
antibody to p53 (Antibody 240, undiluted) 
Immunohistochemistry was carried out on fixed cells as described in the Materials and 
Methods, section 2.7.0. The stained cells were photographed at a 200x magnification after 







Fig 5.02 Immunohistochemistry using a monoclonal antibody to 
p53 (Antibody 1801, undiluted.) 
Immunohistochemistry was carried out on fixed cells as described in the Materials and 
Methods, section 2.7.0. The stained cells were photographed at a 200x magnification after 
the plates had been developed 
WT CDNBr 
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5.2.0 Expression of hsp 70 in WT and CDNBr cell 
lines 
The results from the immunohistochemical analysis of the WT and CDNBr cell lines 
using a monoclonal antibody to hsp 70 are shown in Figure 5.03. Hsp 70 also seems to be 
overexpressed in the CDNBr line when compared to the WT. Hsp 70 expression as 
mentioned in the introduction to this chapter is switched on in response to a number of 
stresses including heat and high oxygen concentrations. From the information presented in 
Figure 5.03 it appears that 1- chloro,2,4- dinitrobenzene can also be added to the list of 
agents that induce heat shock proteins. 
The family of proteins known as the heat shock proteins (they were first n6ted in 
cells after exposure to abnormally high temperatures) have received much attention in the last 
few years (Eurdon, 1986; Lindquist, 1986; Pelham, 1986; Subjeck & Thung -Thai, 1986). 
Although their function and mode of action have been extensively researched, the emerging 
picture is complex. During heat shock in various organisms a number of proteins of varying 
molecular weight have been shown to be induced. These include proteins of molecular 
weight 110 kD, 95 kD, 84 kD, 70 kD and a range of smaller proteins of around 20 -30 kD 
(Burdon, 1986). Of these proteins, hsp 70 has been shown to be the most readily detectable 
in most of the organisms studied to date. Using immunohistochemical techniques hsp 70 
has been found at low levels in the cytoplasm of cells at normal growth temperatures but 
high levels were observed in the nucleus and nucleolus of cells after heat shock (Welch & 
Feranisco, 1984). 
The fact that hsp 70 appears to be induced in the CDNBr cell line raises some 
interesting questions. Since the hsp(s) are expressed in the CDNB resistant cell line, which 
is cultured in the absence of CDNB,they are actually expressed in the absence of any 
immediate stress, suggesting that their overexpression is not of a transient nature. It is 
possible that the gene(s) encoding the hsp 70 protein have not been "switched off" once 
CDNB has been removed or that some sort of mutational event during the 
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Fig 5.03 Immunohistochemistry using a monoclonal 
antibody to hsp 70. 
Immunohistochemistry was carried out on fixed cells as described in the Materials and 
Methods, section 2.7.0. The stained cells were photographed at a 200x magnification after 
the plates had been developed. 
WT CDNBr 
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derivation of the CDNBr cell line has led to permanent expression of hsp 70. This may 
have been either a mutation in a regulatory sequence of the hsp 70 gene(s) or a mutation in 
gene sequences of factors that regulate hsp 70. 
5 . 2 . 3 Thermotolerance of WT and CDNBr cell lines 
The CDNBr cell line exhibited some degree of resistance to elevated temperatures 
(Figures 5.04 and 5.05). In Figure 5.04, the qualitative changes seen in both WT and 
CDNBr cell lines when incubated at 42 °C for 5 days and then returned to 37 °C, are shown. 
The two cell lines were plated out at equal plating densities in order to rule out, as far as 
possible, tlié'effects of different cell densities on survival rates. What seemed to occur is 
that the CDIÑi$r cells, although showing a certain amount of cell death during incubation at 
42 °C, appeared to recover when they were returned to 37 °C. The WT cells on the other 
hand showed signs of cell death at 42 °C as did the CDNBr cells, but when the WT cells 
were returned to 37 °C they did not recover and after 12 days at 37 °C, no viable cells were 
observed. 
In order to try and quantify this observation, WT and CDNBr cell lines were plated 
out at equal cell densities in 96 -well plates. They were then incubated at 42° for 40 hours 
and then returned to 37 °C for a further 10 day incubation. MTT was then added and the 
plates processed as described in Section 2.1.6. The results are shown in Figure 5.05. The 
optical density readings were used to measure cell viability. It is evident that although there 
were some viable cells after heat shock for 40 hours, comparatively more CDNBr cells 
were observed after heat treatment. 
To summarise the results presented above, the model that has been generated during 
the derivation of the CDNBr cell line is one which overexpresses both alpha and pi class 
GST and is resistant to both CDNB and cumene hydroperoxide. As well as the changes 
with regards to GST expression, the CDNBr cell line also appears to overexpress hsp 70 
and exhibits some degree of resistance to abnormally high temperatures. It is possible that 
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Fig 5.04 Survival of WT and CDNBr cell lines after heat shock at 
42 °C for 5 days followed by 12 days of culture at 37 °C 
Cells were harvested as described in the Materials and Methods, section 2.1.5. WT and 
CDNBr cells were plated out at equal cell densities in 75cm2 culture flasks and allowed to 
attach for 12 hours. The cells were then transferred to an incubator at a temperature of 42 °C. 
Cells were incubated at this temperature for 5 days and were photographed daily during this 
period. The cells were then returned to 37 °C and left for 12 days during which time they 
were photographed on a daily basis. A = 3 days at 42 °C; B = 5 days at 42 °C, 1 day at 















Fig. 5.05. Survival of WT and CDNBr cell lines (as measured by O.D. 
at 540nm following treatment with MTT) after heat shock at 42 °C for 40 
hour followed by ll days of culture at 37 °C . 
Cells were harvested as described in the Materials and Methods, section 2.1.5 WT and 
CDNBr cell lines were plated out at equal cell densities in a 96 -well culture plate and 
incubated for 40 hours at 42 °C followed by 11 days at 37 °C. MTT was then added to 
the plates and after 4 hours these were developed as described in the Materials and 
Methods (section 2.1.6). The optical density of each well was measured at 540nm. 
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certain GSTs can function as stress response proteins in that their expression is either 
"switched -on" or elevated in response to cellular injury. 
One likely function of these proteins in a stressed cell would be the detoxification of 
toxic compounds which may result from stresses such as high oxygen concentrations or 
elevated temperatures. Such resultant toxic compounds produced in response to stresses 
such as these, would possibly include oxygen radicals, lipid peroxides and other 
macromolecule breakdown products. To what extent the GST are involved in a stress 
response, if at all, may be largely dependent upon the stress in question. 
It has already been shown that in response to a number of stresses, proteins of a 
molecular weight of 110 kD, 95 kD, 84 kD, 75 kD and 20 -35 kD may be expressed 
(Burdon, 1986). However, not all these proteins are expressed in response to all stresses. 
For example, the work of Caltabiano et al (1986), demonstrates that in a human 
melanoma cell line, a stress protein of molecular weight 32 kD is induced in response to 
sodium arsenite, zinc, copper, cadmium, iodoacetamide and disulfiram, but is not induced in 
response to physical hyperthermia. Although not all stress response proteins are expressed 
in response to all stresses, hsp 70 does seem to be expressed in response to most stresses. 
In prokaryotes it has been shown that certain glutathione metabolising enzymes may 
be involved in protection from oxidative stress. Christman et al (1985) showed that in S- 
typhimurium there is a coordinated expression of glutathione peroxidase, glutathione 
reductase as well as superoxide dismutase, catalase and at least 30 other proteins, in 
response to hydrogen peroxide and other oxidants such as cumene hydroperoxide and tetra - 
butyl hydroperoxide. 
This work was extended to show that hydrogen peroxide inducible proteins in S- 
typhimurium overlap with certain proteins induced by heat shock, that is, 5 of the 30 or so 
proteins induced in this bacteria by hydrogen peroxide are also induced in response to 
elevated temperatures (Morgan et al, 1986). These workers also showed that other stresses 
such as nalidixic acid and ethanol also induced certain of the 30 or so proteins that were 
induced by hydrogen peroxide. 
It may be that for each type of stress, a specific set of genes are induced that code for 
stress response proteins that protect against specific stresses. It appears from the above 
discussion however, that cellular responses to particular injurous agents are interrelated, as 
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cells appear to express overlapping sets of proteins when subjected to various stresses. 
It is possible that in the CDNBr cell line, in response to cytotoxic insult with 
CDNB, a stress response has been elicited which involves both induction of known stress 
response proteins such as hsp 70 and induction /elevation of proteins that can specifically 
detoxify toxic injurous agents. Whether in the CDNBr model, the GST can also be classed 
as stress response proteins is not known. 
An association between adaptation to stress and acquired resistance to drugs has 
already been established by several workers. It has been shown that the response provoked 
by a number of physiological stresses such as heat, anoxia, ethanol and oxidative stress can 
lead to protection against certain drugs. Li and Hahn (1978) established a link between 
thermotolerance and drug resistance when they showed that ethanol could induce resistance 
to both adriamycin and heat in Chinese hamster ovary cells. Li et al (1982) went on to show 
that other agents capable of inducing heat shock response such as hypoxia, arsenite and 
cadmium also resulted in resistance to adriamycin. 
Subsequent to this work, thermotolerant cells have also been shown to exhibit 
resistance to other antitumour agents such as actinomycin D, bleomycin and VM26 (Wallner 
and Li, 1986; Li, 1987; Hahn et al, 1989). How agents that induce a heat shock response 
also lead to resistance to certain anticancer drugs is far from clear. It could be speculated that 
certain proteins are induced alongside stress response proteins that somehow specifically 
confer resistance to the drugs. 
The expression of stress response proteins in drug resistant cells has rarely been 
investigated. It would be interesting to analyse the expression of stress response proteins in 
drug resistant cells since it is possible that cells challenged with cytotoxic drugs may elicit 
some sort of stress response. It has already been shown that the drugs adriamycin and 
VM26 can both induce hsp 70 transcription in drosophilla and Chinese hamster fibroblast 
cells (Rowe et al, 1986). There has also been a report that BCNU can induce hsp 70 RNA 
in certain cells (Schaefer et al, 1988). 
It has been noted that certain thiol reactive agents, including CDNB induce a stress 
protein of 30 to 35 kD in rat fibroblast cells (Shelton et al, 1986). As mentioned earlier, 
induction of a 32 kDa stress protein by sodium arsenite, heavy metals and thiol reactive 
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agents in a human cell line has also been reported (Caltabiano et al, 1986). Concomitant 
induction of other stress proteins of molecular masses 100, 90 and 72 kDa was also 
observed. 
Although the stress response proteins of molecular weight 70 kDa have received 
much attention in recent years and are by far the best characterised, the same cannot be said 
of the proteins in the 20 -35 kDa range. Their identity, physiochemical properties and 
functions are largely unknown. However, it is interesting that using affinity 
chromatography, unidentified proteins ranging in size from 30 -35 kDa have been shown to 
bind to S -hexyl glutathione columns (Hayes et al, 1987). 
Once the identity of the proteins that are elevated in cells treated with CDNB (Shelton 
et al, 1986) sodium arsenite, heavy metals and thiol reactive agents (Caltabiano et al, 1986) 
has been established, comparisons with other proteins can be made. If these stress induced 
proteins are found to share similarities with the proteins that elute from S -hexyl glutathione 
colums (Hayes, et al, 1987), then it is likely that they are involved in glutathione metabolism 
in some way. The identity of the stress proteins identified by Shelton et al (1986) and 
Caltiabiano et al (1986), however, remains to be elucidated. 
In conclusion, the relationship between GST and hsp 70 overexpression in the 
CDNBr model remains to be established. Also information regarding stress protein 
expression in cell lines resistant to anticancer drugs is eagerly awaited. As discussed earlier, 
it seems likely that induction of subsets of stress proteins may be dependent upon the stress 
in question, although there seems to be an overlap in the proteins expressed during differnt 
types of stress. 
The implications of the apparent link between stress response and drug resistance 
are unknown. Stress response protein expression in drug resistant cells, (if indeed, this 
occurs) may be part of a general protection mechanism that is elicited in response to cellular 
damage. Other proteins that provide specific protection against toxic species may be 
coinduced with stress proteins and as such may also be regarded as stress response proteins. 




It has been shown during the course of the work presented above, that directed 
overexpression of alpha and pi class subunits can be achieved in cell lines made resistant 
to the cytotoxic GST substrates,ethacrynic acid and CDNB. In the CDNB resistant lung 
tumuor subline that was derived, resistance to cumene hydroperoxide was also shown. That 
these compounds are known to be metabolised by certain GST isoenzymes, is indicative that 
the elevated GST subunits are responsible, at least partially, for the development of 
resistance to CDNB and cumene hydroperoxide. It is likely that resistance to the two 
cytotoxic GST substates has resulted from increased GST catalysed conjugation of CDNB 
and cumene hydroperoxide to glutathione.That CDNB and cumene hydroperoxide differ in 
their structure and mechanism of action is in itself interesting since it shows that resistance to 
diverse cytotoxic compounds may occur via potentially one mechanism. In the work 
described above, it is proposed that this mechanism is increased drug deotoxification, 
catalysed by the GSTs. 
There are many reports of increased GST activity in tumour cell lines resistant to a 
range of structurally and functionally unrelated anticancer drugs.(Table 1.5) and also data 
has been presented that certain anticancer drugs can act as GST substrates (Dulik et al, 1989; 
Smith et al, 1989). Further work has shown that when cDNAs encoding GST subunits are 
transfected into eukaryotic cells, they confer resistance to a number of anticancer drugs 
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(Black et al, 1990). The data described above, taken together with the results presented in 
this thesis, indicate that the GSTs may play an important role in drug resistance. The wide 
ranging substrate specificity of the GSTs mean they probably have the potential to detoxify 
and so confer resistance to, a number of different anticancer drugs. However, infomation 
regarding the ability of anticancer drugs to act as GST substrates is necessary, in order to 
substantiate this. 
The sensitvity of the derived CDNB resistant lung tumour cell line to a number of 
antitumour agents was investigated but there were no observable cross resistance patterns to 
any of the compounds analysed. In the light of these data, the possible involvement of the 
GSTs in a stress response was studied since challenging cells with cytotoxic compounds 
may possibly be regarded as a physiological stress.The CDNB resistant cell line was found 
to be overexpressing a hsp70 and also exhibited a degree of tolerance to elevated 
temperatures. It was concluded from this work that GSTs may play a role in stress response 
by possibly detoxifying harmful products resulting from the stress in question. In the work 
presented in this thesis, the stress in question is cytotoxic insult. 
GST pi expression was investigated in leukaemia samples from a number of treated 
and untreated patients.The former group had been treated with a variety of anticancer drugs 
and had either relapsed or were unresponsive to treatment. Like much of the work in this 
field, the results were ambiguous, with overexpression of GST pi seen in some 
unresponsive tumours but not in others. Of the 32 chronic lymphocytic leukaemias 
analysed, 21 out of 25 chlorambucil treated patients showed increases in expression of pi 
GST suggesting that in this group of patients, GST pi overexpression may be one of the 
ways that leukaemia cells overcome cytotoxic drug concentrations. 
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